Women’s Health Initiative
2021 Annual Progress Report

Data as of: March 6, 2021

The data, if any, contained in this report/deliverable are preliminary and may contain unvalidated findings. These data are not intended for public use. Public use of these data could create erroneous conclusions which, if acted upon, could threaten public health or safety.
# Table of Contents

<table>
<thead>
<tr>
<th>Tables</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Overview</strong></td>
<td></td>
</tr>
<tr>
<td>Table 1.1 WHI Centers and Principal Investigators</td>
<td>1-1</td>
</tr>
<tr>
<td>Table 1.2 Consent Status by Study Component and Arm</td>
<td>1-6</td>
</tr>
<tr>
<td>Table 1.3 Consent Status by Age at Enrollment and Race/Ethnicity</td>
<td>1-7</td>
</tr>
<tr>
<td>Table 1.4 Counts of Participants with Active Participation by Current Age, Race/Ethnicity and Cohort</td>
<td>1-8</td>
</tr>
<tr>
<td>Table 1.5 Composition of WHI Cohort Over Time</td>
<td>1-10</td>
</tr>
<tr>
<td>Table 1.6 Response Rates to CCC Annual Mailings, Extension Study 2010-2025, Years 2019-2020,</td>
<td>1-11</td>
</tr>
<tr>
<td>By Cohort and Regional Center</td>
<td></td>
</tr>
<tr>
<td>Table 1.7 Response Rates to Regional Center Follow-up and Cumulative Response,</td>
<td></td>
</tr>
<tr>
<td>Extension Study 2010-2025, Years 2019-2020, by Cohort and Regional Center</td>
<td>1-14</td>
</tr>
<tr>
<td>Table 1.8 Form 2 vs. Imputed Form 41 Race/Ethnicity,</td>
<td>1-17</td>
</tr>
<tr>
<td><strong>2. Vital Status</strong></td>
<td></td>
</tr>
<tr>
<td>Table 2.1 Participation and Vital Status: WHI Participants by Extension Study Participation and Cohort</td>
<td>2-1</td>
</tr>
<tr>
<td>Table 2.2 Participation and Vital Status: WHI Extension Study 2010-2025 Participation by MRC vs. SRC Cohort</td>
<td>2-2</td>
</tr>
<tr>
<td>Table 2.3 Proxy Follow-up Status: WHI Extension Study 2010-2025 Participants by Cohort, Current Age, and Race/Ethnicity</td>
<td>2-3</td>
</tr>
<tr>
<td>Table 2.4 Participation and Vital Status: CT and OS Participants</td>
<td>2-4</td>
</tr>
<tr>
<td>Table 2.5 Participation and Vital Status: WHI Extension Study 2010-2025 Participation by CT vs. OS Cohort</td>
<td>2-5</td>
</tr>
<tr>
<td>Table 2.6 Cause of Death (Annualized Percentages): MRC and SRC Super Cohort Participants</td>
<td>2-6</td>
</tr>
<tr>
<td>Table 2.7 Cause of Death (Annualized Percentages): CT and OS Participants</td>
<td>2-8</td>
</tr>
<tr>
<td>Table 2.8 Cause of Death Excluding Discovered Deaths Among Non-Extension Study Participants (Annualized Percentages): CT and OS Participants</td>
<td>2-9</td>
</tr>
<tr>
<td><strong>3. Adjudicated Outcomes</strong></td>
<td></td>
</tr>
<tr>
<td>Table 3.1 Verified Outcomes (Annualized Percentages) by Age at Enrollment For MRC Super Cohort Participants</td>
<td>3-1</td>
</tr>
<tr>
<td>Table 3.2 Verified Outcomes (Annualized Percentages) by Race/Ethnicity For MRC Super Cohort Participants</td>
<td>3-2</td>
</tr>
<tr>
<td>Table 3.3 Verified Outcomes (Annualized Percentages) by Age at Diagnosis For MRC Super Cohort Participants</td>
<td>3-4</td>
</tr>
<tr>
<td>Table 3.4 Verified Outcomes (Annualized Percentages) by Age at Enrollment For SRC Super Cohort Participants</td>
<td>3-5</td>
</tr>
<tr>
<td>Table 3.5 Verified Outcomes (Annualized Percentages) by Race/Ethnicity For SRC Super Cohort Participants</td>
<td>3-6</td>
</tr>
<tr>
<td>Table 3.6 Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants</td>
<td>3-8</td>
</tr>
<tr>
<td>Table 3.7 Verified Outcomes (Annualized Percentages) by Age at Diagnosis for CT and OS Participants</td>
<td>3-10</td>
</tr>
<tr>
<td>Table 3.8 Verified Primary and Other Cancers (Annualized Percentages): CT and OS Participants</td>
<td>3-11</td>
</tr>
<tr>
<td>Table 3.9 Verified Primary and Other Cancers (Annualized Percentages) by Race/Ethnicity For CT and OS Participants</td>
<td>3-13</td>
</tr>
<tr>
<td><strong>4. Self-Reported Outcomes</strong></td>
<td></td>
</tr>
<tr>
<td>Table 4.1 Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment for MRC Super Cohort Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>4-1</td>
</tr>
<tr>
<td>Table 4.2 Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for MRC Super Cohort Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>4-2</td>
</tr>
<tr>
<td>Table 4.3 Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment for SRC Super Cohort Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>4-3</td>
</tr>
</tbody>
</table>
### Tables of Contents

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 4.4</td>
<td>Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for SRC Super Cohort Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>4-4</td>
</tr>
<tr>
<td>Table 4.5</td>
<td>Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment for CT Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>4-5</td>
</tr>
<tr>
<td>Table 4.6</td>
<td>Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for CT Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>4-6</td>
</tr>
<tr>
<td>Table 4.7</td>
<td>Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment for OS Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>4-7</td>
</tr>
<tr>
<td>Table 4.8</td>
<td>Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for OS Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>4-8</td>
</tr>
<tr>
<td>Table 4.9</td>
<td>Self-Reported Fractures (Annualized Percentages): MRC and SRC Super Cohort Participants</td>
<td>4-9</td>
</tr>
<tr>
<td>Table 4.10</td>
<td>Self-Reported Fractures (Annualized Percentages): CT and OS Participants</td>
<td>4-10</td>
</tr>
</tbody>
</table>

#### 5. Outcomes Adjudication Agreement

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 5.1</td>
<td>Agreement of the Central Adjudications with Self-Reports for Outcomes Reported in Extension Study 2010-2025</td>
<td>5-1</td>
</tr>
<tr>
<td>Table 5.2</td>
<td>Agreement of the UNC Heart Failure (HF) Adjudications with Self-Reports among MRC Super Cohort Participants</td>
<td>5-3</td>
</tr>
<tr>
<td>Table 5.3</td>
<td>Source of Outcomes Confirmed by Central Adjudication for Self-Reported Outcomes in Extension Study 2010-2025</td>
<td>5-4</td>
</tr>
</tbody>
</table>

#### 6. Long Life Study

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 6.1</td>
<td>Consent Status and Participant Characteristics for Long Life Study Participants by Race/Ethnicity</td>
<td>6-1</td>
</tr>
<tr>
<td>Table 6.2</td>
<td>Participation and Vital Status: Long Life Study (LLS) Participants</td>
<td>6-3</td>
</tr>
<tr>
<td>Table 6.3</td>
<td>Verified Outcomes (Annualized Percentages) After Long Life Study (LLS) Visit by Age at Visit for LLS Participants</td>
<td>6-4</td>
</tr>
<tr>
<td>Table 6.4</td>
<td>Verified Outcomes (Annualized Percentages) After Long Life Study (LLS) Visit by Race/Ethnicity for LLS Participants</td>
<td>6-5</td>
</tr>
<tr>
<td>Table 6.5</td>
<td>Self-Reported Outcomes (Annualized Percentages) After Long Life Study (LLS) Visit by Age at Visit and Race/Ethnicity for LLS Participants Who Did Not Report a Prevalent Condition at Baseline</td>
<td>6-6</td>
</tr>
</tbody>
</table>

#### 7. Falls During Extension Study 2010-2025

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 7.1</td>
<td>Number of Falls per Participant During Extension Study 2010-2025 by Visit Year</td>
<td>7-1</td>
</tr>
<tr>
<td>Table 7.2</td>
<td>Percent of Participants with Falls During Extension Study 2010-2025 by Visit Year and Age at the Start of Extension Study 2010-2025</td>
<td>7-2</td>
</tr>
<tr>
<td>Table 7.3</td>
<td>Age-Adjusted Percent of Participants with Falls During Extension Study 2010-2025 by Visit Year and Race/Ethnicity</td>
<td>7-3</td>
</tr>
</tbody>
</table>

#### 8. Publications

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 8.1</td>
<td>WHI Manuscript Stages</td>
<td>8-1</td>
</tr>
<tr>
<td>Table 8.2</td>
<td>Publications April 2020 – February 2021</td>
<td>8-2</td>
</tr>
</tbody>
</table>

#### 9. COVID-19 Survey Data

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 9.1</td>
<td>WHI COVID-19 Survey Response Rates by Collection Mechanism</td>
<td>9-1</td>
</tr>
<tr>
<td>Table 9.2</td>
<td>Responses to First WHI COVID-19 Survey Overall and by Age at Survey Completion</td>
<td>9-2</td>
</tr>
</tbody>
</table>
1. Overview

1.0 Background
In the mid-1990s, WHI investigators at 40 Clinical Centers recruited 161,808 women into the program. 68,132 women were randomized into the clinical trial component (CT) and 93,676 were enrolled into the observational study (OS) (Figure 1). During 2004-2005, the original close-out period, 115,407 women consented to five additional years of follow-up, representing 76.9% of the 150,076 participants who were alive in active follow-up at that time. In 2010, participants were offered the opportunity to continue, and 87% of the 107,706 eligible women agreed (n=93,567). Active follow-up, and passive follow-up through administrative data sources, continues unless participants withdraw consent.

1.1 The 2010-2025 Extension Study
The follow-up protocol for 2015-2025 is similar to follow-up starting in 2010. Participants are contacted annually, by mail or email (forms via RedCAP), for health and selected exposure updates. For reports of designated health events, we obtain medical records documentation for a subset. Cardiovascular events and hip fractures are documented only in the subset of participants referred to as the Medical Records Cohort (MRC), comprising all former hormone trial (HT) participants and all non-Hispanic Black/African American and Hispanic/Latina participants regardless of their previous enrollment status (Figure 2). Active outcome data collection for the remaining participants (the Self-Report Cohort or SRC) is primarily limited to self-report. However, NCI supports documentation and coding of incident primary cancers, and NINDS is supporting documentation of incident stroke events. In addition, several active ancillary studies augment the endpoints documentation, and passive follow-up is available through linkage to Medicare, including HMO covered (part C) participants starting in 2015 and the National Death Index. Both of these sources are queried annually and we continue to work with NAACCR to develop an efficient link with the national Virtual Pooled Registry for cancer cases.
The Clinical Coordinating Center (CCC) conducts annual mailings of follow-up questionnaires to all eligible participants. The Regional Centers (RC) and their collaborating centers contact non-responders, collect and submit medical records for all of the designated outcomes to the CCC, and participate in a range of scientific endeavors. The CCC fulfills the RC role for three former Field Centers (Seattle, LaJolla, and Gainesville).

As of March 6, 2021, 59,107 women remain in active follow-up (Table 1.4), 21% of whom are 90 or older. Table 1.5 shows how characteristics of currently active participants compare to those originally recruited. As the size of the cohort decreases, the infrastructure has been reconfigured to maximize efficiency. Participants are now being followed by four RCs and one satellite (Boston). Gainesville participants are now followed by the CCC and those from Tucson are followed by the Stanford RC.

1.2 Progress on Primary Study Objectives

Follow-up rates through March 2021 have remained strong, although there has been gradual decline. The response to mailings after two attempts was 81.5% for 2019. Participant age and health are both factors in this gradual decline and we assume that the COVID-19 pandemic and many of the restrictions imposed on our participants led to a lesser response in 2020. WHI administered detailed questionnaires and received a high response. This has contributed to the WHI program’s ability to study how the pandemic has affected women in an age-range that has been overwhelmingly impacted by the pandemic.

WHI investigators have been interested in providing better information on race/ethnicity in support of studies of health disparities. Information from the baseline questionnaire (Form 2, administered in 1993-1998) has been used to supplement the more detailed Form 41 questionnaire (administered in 2003) to create an imputed race/ethnicity (Table 1.8). This new coding system preserves more detail of a woman’s self-report as available.

For the designated WHI outcomes, annualized clinical event rates based on fully adjudicated outcomes through March 6, 2021 are presented by original study component, age and race (Sections 2-4). We present data for the MRC and SRC Supercohorts, including data for women from these subgroups from the beginning of WHI. Fully adjudicated events available through March 6, 2021 are provided for the MRC Supercohort. For the SRC Supercohort, fully adjudicated events are provided for the interval from enrollment to September 2010 or March 2021 as appropriate.

Nearly a third of the cohort enrolled in the extension studies is deceased (Table 2.1). Unfortunately at this point, the annualized death rate within the cohort is 5.5%. The women in the cohort are an average age of 84.8 years. It is critical to continue to do research within this cohort to examine the health and quality of life issues in this very understudied age group.

Section 5 provides a current summary of the agreement rates between self-reported events and centrally adjudicated events among MRC participants. In general, 50% to 70% of self-reported cardiovascular outcomes are confirmed as the reported diagnosis (Table 5.1). Often, however, a related diagnosis is found. For example, of the confirmed clinical myocardial infarctions, only 52% were based on a self-report of that condition, and the remainder were discovered when investigating a self-report of a different outcome (Table 5.3). Similarly, only 54% of confirmed heart failure cases were found based on a self-report of that condition (Table 5.2). In contrast, the vast majority of self-reported cancer types are confirmed (Table 5.3).

The WHI Long Life Study (LLS) enrolled 7,875 women in the MRC, and collected a blood sample and physical frailty measures. The LLS visit will be repeated in surviving members in 2022-2023. Of the participants who were in the LLS, 65% (n=5122) continue to be actively followed (Table 6.2). Verified
and self-reported outcomes occurring after the LLS visit are presented by age at LLS study visit (Table 6.3) and race (Table 6.4). So far, 1170 LLS participants have had verified cardiovascular outcomes, 681 have had a verified cancer, and 2,252 have died after the LLS visit. The most frequent self-reported outcomes after the visit are: macular degeneration (N=1168), dementia (N=1116), osteoarthritis (N=903) and COPD (N=793) (Table 6.5).

In 2021, WHI began adjudicating strokes in the SRC cohort. NINDS funded efforts to expand stroke adjudication to the end of being able to have a rich resource for examining the role between cognition and stroke. We have started investigations of both retrospective (back to strokes reported in 2010) and current reports. These are scientifically important events to document, though we expect this will change our approach to event rates in the overall cohort. As these adjudications have only been underway recently, these strokes are not included in this year’s report, however they will be next year.

1.3 Engaging Investigators to Continue to Enhance WHI’s Contributions to Science

The WHI program leadership recognizes the importance of drawing in new investigators to use the rich WHI resources, and also providing leadership and growth opportunities. The WHI Scientific Interest Groups (SIGs) are an active opportunity to provide an entryway into understanding WHI resources and proposing ancillary studies and manuscripts. These efforts have yielded several new initiatives.

Section 8 addresses manuscripts published in the last year. A full listing and status of all proposed ancillary studies and manuscripts is available on the WHI website (www.whi.org). In total, 3,863 manuscript proposals have been approved and 2,089 manuscripts published or in press (Table 8.1), including 110 publications since last year’s report. Investigators using WHI data continue to present high-quality science of broad interest, with publications in the last year in many high-impact journals such as JAMA, American Journal of Epidemiology, Cancer and Circulation. In addition to manuscripts addressing cardiovascular disease and cancer among WHI participants, a substantial number examine diabetes, genetics, and aging. WHI also participates in a number of consortia, reflecting the collaborative nature of the WHI investigators and the value of WHI data, particularly for rarer exposures and outcomes.

The cohort serves as the backbone for ancillary studies. The COcoa Supplement and Multivitamin Outcomes Study (COSMOS) trial (PIs: JoAnn Manson and Howard Sesso), the WHI Strong and Healthy (WHISH) trial (PIs: Marcia Stefanick, Charles Kooperberg, Andrea LaCroix), and many related ancillary trials exploring cognition, eye health, cardiovascular conditions, and more related to the benefits of the interventions are ongoing. The COSMOS trial (PIs: JoAnn Manson, Howard Sesso, Garnet Anderson) will be presenting results the Fall of 2021 at both the AHA conference and in multiple peer-reviewed manuscripts.

We anticipate supporting the Long Life Study 2 in the coming year. Several ancillary studies, including the WHISH trial and the LILAC cancer survivorship cohort will leverage the in-person visits to advance aims of those projects. Additional projects, proposed primarily by young investigators, plan to use the in-person visit to collect data, biospecimens, or use the data collection point as an anchor for independent data collection to tie to the functional measures collected by the LLS.

Genetic data are available in dbGaP for over 30,000 WHI participants using a number of approaches, including our participation in the TOPMed program that can be linked to CVD biomarker data, providing an opportunity for outside investigators to use these resources independent of the WHI program. WHI data, including cancer survivorship data, has been submitted to the NHLBI’s BIOLINCC data repository.
The CCC, with assistance from the RCs, developed and implemented a survey of all WHI participants in the summer of 2020, designed to assess the impact of the COVID-19 pandemic and the associated prevention measures on their health and well-being. In total, 64,185 participants were contacted and 50,273 (78.3%) responded (Table 9.1). At the time of the survey, 18.9% reported being tested for COVID-19 and 311 reported having a positive test. Analyses of these data are being prioritized for publication, with a Journal of Gerontology supplemental issue to include the manuscripts. A subsequent survey is in progress, thanks to a collaborative effort of the Regional Centers and the CCC to send surveys to all participants who completed the first survey related to their experience during the COVID-19 pandemic.

The May 2020 celebratory WHI Investigator Meeting was not held in person. Instead a series of webinars were held over an 8 week period, allowing investigators to be updated and to engage on multiple study topics according to their interest. We look forward to meeting again in person in 2022.
## Clinical Coordinating Center

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garnet Anderson, PhD</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Seattle, WA</td>
</tr>
</tbody>
</table>

## Field Centers

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rebecca Jackson, MD</td>
<td>Ohio State University</td>
<td>Columbus, OH</td>
</tr>
<tr>
<td>Mara Vitolins, DrPH</td>
<td>Wake Forest University</td>
<td>Winston-Salem/Greensboro, NC</td>
</tr>
<tr>
<td>Marcia Stefanick, PhD</td>
<td>Stanford University</td>
<td>Palo Alto, CA</td>
</tr>
<tr>
<td>Jean Wactawski-Wende, PhD</td>
<td>University at Buffalo</td>
<td>Buffalo, NY</td>
</tr>
</tbody>
</table>

## Associated Centers

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marian Limacher, MD</td>
<td>University of Florida</td>
<td>Gainesville, FL (FC closed Apr 2019)</td>
</tr>
<tr>
<td>JoAnn Manson, MD DrPH</td>
<td>Brigham and Women’s Hospital</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Cynthia Thomson, PhD RD</td>
<td>University of Arizona</td>
<td>Tucson, AZ (Satellite closed Oct 2020)</td>
</tr>
<tr>
<td>Jennifer Robinson, MD MPH</td>
<td>University of Iowa</td>
<td>Iowa City/ Bettendorf, IA (FC closed Feb 2020)</td>
</tr>
</tbody>
</table>

## Current WHI Committee Chairs

<table>
<thead>
<tr>
<th>Investigator</th>
<th>Institution</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marian Neuhouse, PhD</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Ancillary Studies (ASC)</td>
</tr>
<tr>
<td>Marian Limacher, MD</td>
<td>University of Florida</td>
<td>Outcomes Adjudications (OAC)</td>
</tr>
<tr>
<td>Charles Kooperberg, PhD</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Performance Monitoring (PMC)</td>
</tr>
<tr>
<td>Cynthia Thomson, PhD RD</td>
<td>University of Arizona</td>
<td>Publications and Presentations (P&amp;P)</td>
</tr>
<tr>
<td>Linda Van Horn, PhD RD</td>
<td>Northwestern University</td>
<td>Publications and Presentations (P&amp;P)</td>
</tr>
<tr>
<td>Rebecca Jackson, MD</td>
<td>Ohio State University</td>
<td>Scientific Resources Working Group</td>
</tr>
<tr>
<td>Sally Shumaker, PhD</td>
<td>Wake Forest University</td>
<td>Steering Committee (SC)</td>
</tr>
</tbody>
</table>
Table 1.2
Consent Status by Study Component and Arm

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>WHI Enrollment</th>
<th>Enrolled in WHI</th>
<th>Eligible for Extension 2005-2010</th>
<th>Consented N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormone Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With Uterus</td>
<td>27347</td>
<td>25194</td>
<td>20433</td>
<td>81.1</td>
</tr>
<tr>
<td>E+P</td>
<td>16608</td>
<td>15408</td>
<td>12788</td>
<td>83.0</td>
</tr>
<tr>
<td>Placebo</td>
<td>8506</td>
<td>7878</td>
<td>6545</td>
<td>83.1</td>
</tr>
<tr>
<td>Without Uterus</td>
<td>8102</td>
<td>7530</td>
<td>6243</td>
<td>82.9</td>
</tr>
<tr>
<td>E-alone</td>
<td>10739</td>
<td>9786</td>
<td>7645</td>
<td>78.1</td>
</tr>
<tr>
<td>Placebo</td>
<td>5310</td>
<td>4851</td>
<td>3778</td>
<td>77.9</td>
</tr>
<tr>
<td>Dietary Modification</td>
<td>5429</td>
<td>4935</td>
<td>3867</td>
<td>78.4</td>
</tr>
<tr>
<td>Intervention</td>
<td>48835</td>
<td>45560</td>
<td>37858</td>
<td>83.1</td>
</tr>
<tr>
<td>Comparison</td>
<td>19541</td>
<td>18207</td>
<td>14769</td>
<td>81.1</td>
</tr>
<tr>
<td>Comparison</td>
<td>29294</td>
<td>27353</td>
<td>23089</td>
<td>84.4</td>
</tr>
<tr>
<td>Calcium and Vitamin D</td>
<td>36282</td>
<td>34447</td>
<td>29862</td>
<td>86.7</td>
</tr>
<tr>
<td>Active</td>
<td>18176</td>
<td>17280</td>
<td>15025</td>
<td>87.0</td>
</tr>
<tr>
<td>Placebo</td>
<td>18106</td>
<td>17167</td>
<td>14837</td>
<td>86.4</td>
</tr>
<tr>
<td>Clinical Trial Total</td>
<td>68132</td>
<td>63332</td>
<td>52176</td>
<td>82.4</td>
</tr>
<tr>
<td>Observational Study</td>
<td>93676</td>
<td>86744</td>
<td>63231</td>
<td>72.9</td>
</tr>
<tr>
<td>Total</td>
<td>161808</td>
<td>150076</td>
<td>115407</td>
<td>76.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WHI Enrollment</th>
<th>Enrolled in Extension 2005-2010</th>
<th>Eligible for Extension 2010-2025</th>
<th>Consented N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormone Therapy</td>
<td>20433</td>
<td>18794</td>
<td>15584</td>
<td>82.9</td>
</tr>
<tr>
<td>With Uterus</td>
<td>12788</td>
<td>11789</td>
<td>9891</td>
<td>83.9</td>
</tr>
<tr>
<td>E+P</td>
<td>6545</td>
<td>6048</td>
<td>5047</td>
<td>83.4</td>
</tr>
<tr>
<td>Placebo</td>
<td>6243</td>
<td>5741</td>
<td>4844</td>
<td>84.4</td>
</tr>
<tr>
<td>Without Uterus</td>
<td>7645</td>
<td>7005</td>
<td>5693</td>
<td>81.3</td>
</tr>
<tr>
<td>E-alone</td>
<td>3778</td>
<td>3479</td>
<td>2834</td>
<td>81.5</td>
</tr>
<tr>
<td>Placebo</td>
<td>3867</td>
<td>3526</td>
<td>2859</td>
<td>81.1</td>
</tr>
<tr>
<td>Dietary Modification</td>
<td>37858</td>
<td>35594</td>
<td>30690</td>
<td>86.2</td>
</tr>
<tr>
<td>Intervention</td>
<td>14769</td>
<td>13922</td>
<td>12014</td>
<td>86.3</td>
</tr>
<tr>
<td>Comparison</td>
<td>23089</td>
<td>21672</td>
<td>18676</td>
<td>86.2</td>
</tr>
<tr>
<td>Calcium and Vitamin D</td>
<td>29862</td>
<td>27975</td>
<td>24231</td>
<td>86.6</td>
</tr>
<tr>
<td>Active</td>
<td>15025</td>
<td>14083</td>
<td>12242</td>
<td>86.9</td>
</tr>
<tr>
<td>Placebo</td>
<td>14837</td>
<td>13892</td>
<td>11989</td>
<td>86.3</td>
</tr>
<tr>
<td>Clinical Trial Total</td>
<td>52176</td>
<td>48697</td>
<td>41499</td>
<td>85.2</td>
</tr>
<tr>
<td>Observational Study</td>
<td>63231</td>
<td>59009</td>
<td>52068</td>
<td>88.2</td>
</tr>
<tr>
<td>Total</td>
<td>115407</td>
<td>107706</td>
<td>93567</td>
<td>86.9</td>
</tr>
</tbody>
</table>

1 Eligibility defined as alive at the beginning of consent and willing to be contacted.
## Table 1.3
Consent Status by Age at Enrollment and Race/Ethnicity¹

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>WHI Enrollment</th>
<th>Clinical Trial</th>
<th>Obsitational Study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Enrolled in WHI</td>
<td>Eligible for Extension 2005-2010</td>
</tr>
<tr>
<td>Total</td>
<td>68132</td>
<td>63332</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50-54</td>
<td>9188</td>
<td>8754</td>
</tr>
<tr>
<td>55-59</td>
<td>14661</td>
<td>13940</td>
</tr>
<tr>
<td>60-69</td>
<td>31389</td>
<td>29290</td>
</tr>
<tr>
<td>70-79</td>
<td>12894</td>
<td>11348</td>
</tr>
<tr>
<td>Race/Ethnicity¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>292</td>
<td>260</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1519</td>
<td>1414</td>
</tr>
<tr>
<td>Non-Hispanic Black/African American</td>
<td>6983</td>
<td>6423</td>
</tr>
<tr>
<td>Hispanic/Latina</td>
<td>2875</td>
<td>2686</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>55525</td>
<td>51682</td>
</tr>
<tr>
<td>Unknown</td>
<td>938</td>
<td>867</td>
</tr>
</tbody>
</table>

¹ Race/ethnicity as identified on Form 2 at baseline.
² Eligibility defined as alive at the beginning of consent and willing to be contacted.
### Table 1.4
Counts of Participants with Active\(^1\) Participation by Current Age\(^2\), Race/Ethnicity and Cohort
Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Age on 3/06/2021</th>
<th>Clinical Trial (N=26,395)</th>
<th>Observational Study (N=32,712)</th>
<th>MRC Cohort(^3) (N=13,649)</th>
<th>SRC Cohort(^4) (N=45,458)</th>
<th>Total (N=59,107)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>&lt;75</td>
<td>124</td>
<td>0.5</td>
<td>416</td>
<td>1.3</td>
<td>183</td>
</tr>
<tr>
<td>75-79</td>
<td>5148</td>
<td>19.5</td>
<td>6987</td>
<td>21.4</td>
<td>2990</td>
</tr>
<tr>
<td>80-84</td>
<td>8620</td>
<td>32.7</td>
<td>10007</td>
<td>30.6</td>
<td>4273</td>
</tr>
<tr>
<td>85-89</td>
<td>7178</td>
<td>27.2</td>
<td>8250</td>
<td>25.2</td>
<td>3458</td>
</tr>
<tr>
<td>90-94</td>
<td>4093</td>
<td>15.5</td>
<td>5279</td>
<td>16.1</td>
<td>2069</td>
</tr>
<tr>
<td>95+</td>
<td>1232</td>
<td>4.7</td>
<td>1773</td>
<td>5.4</td>
<td>676</td>
</tr>
<tr>
<td><strong>Ethnicity(^5)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Hispanic/Latina</td>
<td>25322</td>
<td>95.9</td>
<td>31602</td>
<td>96.6</td>
<td>11900</td>
</tr>
<tr>
<td>Hispanic/Latina</td>
<td>1025</td>
<td>3.9</td>
<td>1032</td>
<td>3.2</td>
<td>1739</td>
</tr>
<tr>
<td>Other/Not Reported</td>
<td>48</td>
<td>0.2</td>
<td>78</td>
<td>0.2</td>
<td>10</td>
</tr>
<tr>
<td><strong>Race(^6)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>59</td>
<td>0.2</td>
<td>72</td>
<td>0.2</td>
<td>42</td>
</tr>
<tr>
<td>Asian</td>
<td>589</td>
<td>2.2</td>
<td>700</td>
<td>2.1</td>
<td>151</td>
</tr>
<tr>
<td>Native Hawaiian/Other Pacific Islander</td>
<td>30</td>
<td>0.1</td>
<td>17</td>
<td>0.1</td>
<td>19</td>
</tr>
<tr>
<td>Black/African American</td>
<td>2117</td>
<td>8.0</td>
<td>1701</td>
<td>5.2</td>
<td>3767</td>
</tr>
<tr>
<td>White</td>
<td>22953</td>
<td>87.0</td>
<td>29552</td>
<td>90.3</td>
<td>8955</td>
</tr>
<tr>
<td>More than one Race</td>
<td>398</td>
<td>1.5</td>
<td>335</td>
<td>1.0</td>
<td>257</td>
</tr>
<tr>
<td>Other/Not Reported</td>
<td>249</td>
<td>0.9</td>
<td>335</td>
<td>1.0</td>
<td>458</td>
</tr>
</tbody>
</table>

---

\(^1\) Active participation is defined as current (Form 33 within last 15 months) or recent (Form 33 between 15 and 24 months ago) follow-up.

\(^2\) Age on March 06, 2021.

\(^3\) The MRC Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS who consented to WHI Extension Study 2010-2025.

\(^4\) The SRC Cohort includes all Non-Hispanic White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study who consented to WHI Extension Study 2010-2025.

\(^5\) Ethnicity and race are presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.
## Table 1.4 (continued)

Current Age\(^1\) Distribution by Race/Ethnicity for Active\(^2\) WHI Extension Study 2010-2025 Participants

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Age on March 6, 2021</th>
<th>Total (N = 59,107)</th>
<th>American Indian/Alaska Native (N = 115)</th>
<th>Asian or Native Hawaiian/Other Pacific Islander(^3) (N = 1,308)</th>
<th>Hispanic/Latina (N = 2,057)</th>
<th>Non-Hispanic Black/African American (N = 3,777)</th>
<th>Non-Hispanic White (N = 51,041)</th>
<th>More than one Race (N = 649)</th>
<th>Other/Not Reported (N = 160)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;75</td>
<td>540 0.9</td>
<td>2 1.7</td>
<td>26 2.0</td>
<td>66 3.2</td>
<td>94 2.5</td>
<td>336 0.7</td>
<td>12 1.8</td>
<td>4 2.5</td>
</tr>
<tr>
<td>75-79</td>
<td>12135 20.5</td>
<td>35 30.4</td>
<td>333 25.5</td>
<td>595 28.9</td>
<td>986 26.1</td>
<td>9984 19.6</td>
<td>165 25.4</td>
<td>37 23.1</td>
</tr>
<tr>
<td>80-84</td>
<td>18627 31.5</td>
<td>39 33.9</td>
<td>381 29.1</td>
<td>651 31.6</td>
<td>1227 32.5</td>
<td>16083 31.5</td>
<td>198 30.5</td>
<td>48 30.0</td>
</tr>
<tr>
<td>85-89</td>
<td>15428 26.1</td>
<td>23 20.0</td>
<td>313 23.9</td>
<td>441 21.4</td>
<td>903 23.9</td>
<td>13532 26.5</td>
<td>172 26.5</td>
<td>44 27.5</td>
</tr>
<tr>
<td>90-94</td>
<td>9372 15.9</td>
<td>13 11.3</td>
<td>198 15.1</td>
<td>240 11.7</td>
<td>437 11.6</td>
<td>8378 16.4</td>
<td>84 12.9</td>
<td>22 13.8</td>
</tr>
<tr>
<td>95+</td>
<td>3005 5.1</td>
<td>3 2.6</td>
<td>57 4.4</td>
<td>64 3.1</td>
<td>130 3.4</td>
<td>2728 5.3</td>
<td>18 2.8</td>
<td>5 3.1</td>
</tr>
</tbody>
</table>

\(^1\) Age on March 6, 2021.
\(^2\) Active participation is defined as current (Form 33 within last 15 months) or recent (Form 33 between 15 and 24 months ago) follow-up.
\(^3\) Native Hawaiian/Other Pacific Islander participants (n=47) are combined with Asian participants for reporting purposes due to small numbers.
### Table 1.5
Composition of WHI Cohort Over Time
Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Age</th>
<th>Enrolled in WHI (N=161,808)</th>
<th>Active Participation at End of Extension 1 (9/30/2010) (N=104,888)</th>
<th>Active Participation as of 3/06/2021 (N=59,107)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>50-54</td>
<td>21569</td>
<td>13.3</td>
<td>1137</td>
</tr>
<tr>
<td>55-59</td>
<td>31990</td>
<td>19.8</td>
<td>16490</td>
</tr>
<tr>
<td>60-64</td>
<td>37210</td>
<td>23.0</td>
<td>25587</td>
</tr>
<tr>
<td>65-69</td>
<td>35379</td>
<td>21.9</td>
<td>25353</td>
</tr>
<tr>
<td>70-74</td>
<td>24906</td>
<td>15.4</td>
<td>11379</td>
</tr>
<tr>
<td>75-79</td>
<td>10754</td>
<td>6.6</td>
<td>59107</td>
</tr>
<tr>
<td>80-84</td>
<td>11636</td>
<td>7.2</td>
<td>56897</td>
</tr>
<tr>
<td>85-89</td>
<td>2839</td>
<td>1.7</td>
<td>11379</td>
</tr>
<tr>
<td>90-94</td>
<td>35379</td>
<td>21.9</td>
<td>16490</td>
</tr>
<tr>
<td>95+</td>
<td>38</td>
<td>&lt;0.1</td>
<td>2029</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Enrolled in WHI (N=161,808)</td>
<td>Active Participation at End of Extension 1 (9/30/2010) (N=104,888)</td>
<td>Active Participation as of 3/06/2021 (N=59,107)</td>
</tr>
<tr>
<td>Not Hispanic/Latina</td>
<td>153117</td>
<td>94.6</td>
<td>100996</td>
</tr>
<tr>
<td>Hispanic/Latina</td>
<td>7312</td>
<td>4.5</td>
<td>3653</td>
</tr>
<tr>
<td>Other/Not Reported</td>
<td>1379</td>
<td>0.9</td>
<td>239</td>
</tr>
<tr>
<td>Race</td>
<td>Enrolled in WHI (N=161,808)</td>
<td>Active Participation at End of Extension 1 (9/30/2010) (N=104,888)</td>
<td>Active Participation as of 3/06/2021 (N=59,107)</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>540</td>
<td>0.3</td>
<td>242</td>
</tr>
<tr>
<td>Asian</td>
<td>4025</td>
<td>2.5</td>
<td>2108</td>
</tr>
<tr>
<td>Native Hawaiian/Pacific Islander</td>
<td>137</td>
<td>0.1</td>
<td>82</td>
</tr>
<tr>
<td>Black/African American</td>
<td>14327</td>
<td>8.9</td>
<td>7285</td>
</tr>
<tr>
<td>White</td>
<td>137628</td>
<td>85.1</td>
<td>92810</td>
</tr>
<tr>
<td>More than one Race</td>
<td>1880</td>
<td>1.2</td>
<td>1305</td>
</tr>
<tr>
<td>Other/Not Reported</td>
<td>3271</td>
<td>2.0</td>
<td>1056</td>
</tr>
<tr>
<td>Education1</td>
<td>Enrolled in WHI (N=161,808)</td>
<td>Active Participation at End of Extension 1 (9/30/2010) (N=104,888)</td>
<td>Active Participation as of 3/06/2021 (N=59,107)</td>
</tr>
<tr>
<td>0-8 years</td>
<td>2665</td>
<td>1.7</td>
<td>869</td>
</tr>
<tr>
<td>Some high school</td>
<td>5979</td>
<td>3.7</td>
<td>2818</td>
</tr>
<tr>
<td>High school diploma/GED</td>
<td>27624</td>
<td>17.2</td>
<td>16760</td>
</tr>
<tr>
<td>School after high school</td>
<td>60909</td>
<td>37.9</td>
<td>38435</td>
</tr>
<tr>
<td>College degree or higher</td>
<td>63415</td>
<td>39.5</td>
<td>45297</td>
</tr>
<tr>
<td>Income2</td>
<td>Enrolled in WHI (N=161,808)</td>
<td>Active Participation at End of Extension 1 (9/30/2010) (N=104,888)</td>
<td>Active Participation as of 3/06/2021 (N=59,107)</td>
</tr>
<tr>
<td>&lt; $10,000</td>
<td>6937</td>
<td>4.6</td>
<td>2870</td>
</tr>
<tr>
<td>$10,000 – $19,999</td>
<td>18499</td>
<td>12.3</td>
<td>9543</td>
</tr>
<tr>
<td>$20,000 – $34,999</td>
<td>36665</td>
<td>23.4</td>
<td>22385</td>
</tr>
<tr>
<td>$35,000 – $49,999</td>
<td>30912</td>
<td>20.5</td>
<td>21008</td>
</tr>
<tr>
<td>$50,000 – $74,999</td>
<td>29948</td>
<td>19.8</td>
<td>21611</td>
</tr>
<tr>
<td>$75,000 +</td>
<td>27973</td>
<td>18.5</td>
<td>21564</td>
</tr>
<tr>
<td>Study Component</td>
<td>Enrolled in WHI (N=161,808)</td>
<td>Active Participation at End of Extension 1 (9/30/2010) (N=104,888)</td>
<td>Active Participation as of 3/06/2021 (N=59,107)</td>
</tr>
<tr>
<td>Clinical Trial</td>
<td>68132</td>
<td>42.1</td>
<td>47325</td>
</tr>
<tr>
<td>Observational Study</td>
<td>93676</td>
<td>57.9</td>
<td>57563</td>
</tr>
</tbody>
</table>

1 Active participation is defined as current (Form 33 within the last 15 months) or recent (Form 33 between 15 and 24 months ago) follow-up.
2 Age at WHI Enrollment, End of Extension 1 (9/30/2010), and on 03/06/2021.
3 Education and income reported at baseline.
## SECTION 1: OVERVIEW

### Table 1.6
Response Rates to CCC Annual Mailings, Extension Study 2010-2025
Year 2019 by Cohort and Regional Center

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Cohort</th>
<th>1st Mailing Period</th>
<th>2nd Mailing Period</th>
<th>Cumulative Response</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sent</td>
<td>Response</td>
<td>%</td>
</tr>
<tr>
<td></td>
<td>Form</td>
<td>Mail 1</td>
<td>N</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>63661</td>
<td>47130</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>62536</td>
<td>46100</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>542</td>
<td>195</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>5148</td>
<td>3632</td>
</tr>
<tr>
<td>Medical Record</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohort 2</td>
<td>33</td>
<td>14501</td>
<td>9814</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>14230</td>
<td>9672</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>177</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>1189</td>
<td>793</td>
</tr>
<tr>
<td>Self Report</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohort 3</td>
<td>33</td>
<td>49160</td>
<td>37316</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>48306</td>
<td>36428</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>365</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>3959</td>
<td>2839</td>
</tr>
<tr>
<td>Regional Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston</td>
<td>33</td>
<td>6938</td>
<td>5072</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>6863</td>
<td>5004</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>51</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>572</td>
<td>391</td>
</tr>
<tr>
<td>Buffalo</td>
<td>33</td>
<td>10179</td>
<td>7445</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>10087</td>
<td>7374</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>55</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>808</td>
<td>581</td>
</tr>
<tr>
<td>Columbus</td>
<td>33</td>
<td>10329</td>
<td>7652</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>10175</td>
<td>7482</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>49</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>848</td>
<td>603</td>
</tr>
<tr>
<td>Gainesville</td>
<td>33</td>
<td>2311</td>
<td>1613</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>2311</td>
<td>1608</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>546</td>
<td>366</td>
</tr>
<tr>
<td>Iowa</td>
<td>33</td>
<td>6042</td>
<td>4692</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>5933</td>
<td>4586</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>51</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>507</td>
<td>370</td>
</tr>
<tr>
<td>Seattle</td>
<td>33</td>
<td>2932</td>
<td>2254</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>2845</td>
<td>2176</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>36</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>262</td>
<td>192</td>
</tr>
<tr>
<td>Stanford</td>
<td>33</td>
<td>10833</td>
<td>8415</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>10573</td>
<td>8158</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>106</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>733</td>
<td>538</td>
</tr>
</tbody>
</table>

---

1. Form 33 = Medical History Update; Form 151 = Activities of Daily Life; Form 151B = Activities of Daily Life; Form 159 = Supplemental Questionnaire 2019.
2. The MRC Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS who consented to WHI Extension Study 2010-2025.
3. The SRC Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study who consented to WHI Extension Study 2010-2025.
4. Regional Center is determined based on the participant’s responsible clinic at the start of the mailing window (2 months prior to the participant’s mailing anniversary).
5. The Gainesville Regional Center closed in April 2019.
Table 1.6 (continued)
Response Rates to CCC Annual Mailings, Extension Study 2010-2025
Year 2019 by Cohort and Regional Center

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Regional Center¹</th>
<th>1st Mailing Period</th>
<th>2nd Mailing Period</th>
<th>Cumulative Response</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sent Mail 1</td>
<td>Response N %</td>
<td>Past 2nd mailing period</td>
</tr>
<tr>
<td>Tucson</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>4123</td>
<td>2961 71.8 %</td>
<td>4123 1021 24.8 %</td>
</tr>
<tr>
<td>151</td>
<td>4030</td>
<td>2893 71.8 %</td>
<td>4030 844 20.9 %</td>
</tr>
<tr>
<td>151B</td>
<td>59</td>
<td>19 32.2 %</td>
<td>59 4 6.8 %</td>
</tr>
<tr>
<td>159</td>
<td>352</td>
<td>238 67.6 %</td>
<td>352 110 31.3 %</td>
</tr>
<tr>
<td>Wake Forest</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>9974</td>
<td>7026 70.4 %</td>
<td>9974 2418 24.2 %</td>
</tr>
<tr>
<td>151</td>
<td>9719</td>
<td>6819 70.2 %</td>
<td>9719 2041 21.0 %</td>
</tr>
<tr>
<td>151B</td>
<td>135</td>
<td>43 31.9 %</td>
<td>135 0 0.0 %</td>
</tr>
<tr>
<td>159</td>
<td>520</td>
<td>353 67.9 %</td>
<td>520 147 28.3 %</td>
</tr>
</tbody>
</table>

¹ Regional Center is determined based on the participant’s responsible clinic at the start of the mailing window (2 months prior to the participant’s mailing anniversary).
² Form 33 = Medical History Update; Form 151 = Activities of Daily Life; Form 151B = Activities of Daily Life; Form 159 = Supplemental Questionnaire 2019.
### Table 1.6 (continued)

**Response Rates to CCC Annual Mailings, Extension Study 2010-2025**  
*Year 2020 by Cohort and Regional Center*

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Cohort</th>
<th>1st Mailing Period</th>
<th>2nd Mailing Period</th>
<th>2nd Mailing Period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Form</td>
<td>Sent</td>
<td>Response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mail 1</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>33</td>
<td>60406</td>
<td>40471</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>2250</td>
<td>1451</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>55548</td>
<td>36169</td>
</tr>
<tr>
<td>Medical Record</td>
<td>33</td>
<td>13861</td>
<td>8590</td>
</tr>
<tr>
<td>Cohort</td>
<td>151</td>
<td>561</td>
<td>324</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>12861</td>
<td>7786</td>
</tr>
<tr>
<td>Self-Report Cohort</td>
<td>33</td>
<td>46545</td>
<td>31881</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>1689</td>
<td>1127</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>42687</td>
<td>28383</td>
</tr>
<tr>
<td>Regional Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston</td>
<td>33</td>
<td>6346</td>
<td>4285</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>328</td>
<td>218</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>5742</td>
<td>3790</td>
</tr>
<tr>
<td>Buffalo</td>
<td>33</td>
<td>9913</td>
<td>6454</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>494</td>
<td>299</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>8988</td>
<td>5665</td>
</tr>
<tr>
<td>Columbus</td>
<td>33</td>
<td>14485</td>
<td>9961</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>444</td>
<td>280</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>13654</td>
<td>9160</td>
</tr>
<tr>
<td>Iowa</td>
<td>33</td>
<td>901</td>
<td>649</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>261</td>
<td>202</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>402</td>
<td>293</td>
</tr>
<tr>
<td>Seattle</td>
<td>33</td>
<td>4237</td>
<td>2617</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>84</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>3994</td>
<td>2385</td>
</tr>
<tr>
<td>Stanford</td>
<td>33</td>
<td>11139</td>
<td>7725</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>62</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>10532</td>
<td>7073</td>
</tr>
<tr>
<td>Tucson</td>
<td>33</td>
<td>3119</td>
<td>2112</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>10</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>2957</td>
<td>1961</td>
</tr>
<tr>
<td>Wake Forest</td>
<td>33</td>
<td>10266</td>
<td>6668</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>567</td>
<td>381</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>9279</td>
<td>5842</td>
</tr>
</tbody>
</table>

---

1. Form 33 = Medical History Update; Form 151 = Activities of Daily Life; Form 151B = Activities of Daily Life; Form 159 = Supplemental Questionnaire 2019.
2. The MRC Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS who consented to WHI Extension Study 2010-2025.
3. The SRC Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study who consented to WHI Extension Study 2010-2025.
4. Regional Center is determined based on the participant’s responsible clinic at the start of the mailing window (2 months prior to the participant’s mailing anniversary).
## Table 1.7
**Response Rates to Regional Center Follow-up and Cumulative Response Extension Study 2010-2025, Year 2019 by Cohort and Regional Center**

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Eligible for RC Follow-up</th>
<th>Respondents</th>
<th>Total Estimated Response Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Form¹</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>16049</td>
<td>9970</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>17380</td>
<td>2136</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>591</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>1485</td>
<td>42</td>
</tr>
<tr>
<td><strong>Medical Record Cohort²</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>4944</td>
<td>3274</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>5340</td>
<td>781</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>201</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>430</td>
<td>16</td>
</tr>
<tr>
<td><strong>Self Report Cohort³</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>11105</td>
<td>6696</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>12040</td>
<td>1355</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>390</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>1055</td>
<td>26</td>
</tr>
<tr>
<td><strong>Regional Center⁴</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston</td>
<td>33</td>
<td>1742</td>
<td>953</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>1921</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>72</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>156</td>
<td>1</td>
</tr>
<tr>
<td>Buffalo</td>
<td>33</td>
<td>2713</td>
<td>1848</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>2933</td>
<td>1043</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>90</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>256</td>
<td>38</td>
</tr>
<tr>
<td>Columbus</td>
<td>33</td>
<td>2470</td>
<td>1432</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>2625</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>219</td>
<td>1</td>
</tr>
<tr>
<td>Gainesville⁵</td>
<td>33</td>
<td>694</td>
<td>450</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>729</td>
<td>152</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>178</td>
<td>1</td>
</tr>
<tr>
<td>Iowa</td>
<td>33</td>
<td>1023</td>
<td>537</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>1133</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>60</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>104</td>
<td>0</td>
</tr>
<tr>
<td>Seattle</td>
<td>33</td>
<td>761</td>
<td>500</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>813</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>32</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>82</td>
<td>0</td>
</tr>
<tr>
<td>Stanford</td>
<td>33</td>
<td>2487</td>
<td>1677</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>2680</td>
<td>202</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>87</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>205</td>
<td>1</td>
</tr>
</tbody>
</table>

---

¹ Form 33 = Medical History Update; Form 151 = Activities of Daily Life; Form 151B = Activities of Daily Life; Form 159 = Supplemental Questionnaire 2019.
² The MRC Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS who consented to WHI Extension Study 2010-2025.
³ The SRC Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study who consented to WHI Extension Study 2010-2025.
⁴ Regional Center is determined based on the participant’s responsible clinic at the start of the mailing window (2 months prior to the participant’s mailing anniversary).
⁵ The Gainesville Regional Center closed in April 2019.
## Table 1.7 (continued)

Response Rates to Regional Center Follow-up and Cumulative Response Extension Study 2010-2025, Year 2019 by Cohort and Regional Center

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Regional Center¹</th>
<th>Form²</th>
<th>Eligible for RC Follow-up</th>
<th>Respondents</th>
<th>Total Estimated Response Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Tucson</td>
<td>33</td>
<td>1158</td>
<td>652</td>
<td>56.3</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>1260</td>
<td>49</td>
<td>3.9</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>49</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>101</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Wake Forest</td>
<td>33</td>
<td>3001</td>
<td>1921</td>
<td>64.0</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>3286</td>
<td>596</td>
<td>18.1</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>151</td>
<td>1</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>159</td>
<td>184</td>
<td>0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

¹ Regional Center is determined based on the participant’s responsible clinic at the start of the mailing window (2 months prior to the participant’s mailing anniversary).
² Form 33 = Medical History Update; Form 151 = Activities of Daily Life; Form 151B = Activities of Daily Life; Form 159 = Supplemental Questionnaire 2019.
### Table 1.7 (continued)
Response Rates to Regional Center Follow-up and Cumulative Response Extension Study 2010-2025, Year 2020 by Cohort and Regional Center

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Eligible for RC Follow-up</th>
<th>Respondents</th>
<th>Total Estimated Response Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Form</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Total</td>
<td>33</td>
<td>19917</td>
<td>7816</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>1572</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>20188</td>
<td>1318</td>
</tr>
<tr>
<td>Medical Record Cohort3</td>
<td>33</td>
<td>5628</td>
<td>2341</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>481</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>5726</td>
<td>354</td>
</tr>
<tr>
<td>Self Report Cohort3</td>
<td>33</td>
<td>14289</td>
<td>5475</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>1091</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>14462</td>
<td>964</td>
</tr>
<tr>
<td>Regional Center4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston</td>
<td>33</td>
<td>2047</td>
<td>759</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>204</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>2050</td>
<td>129</td>
</tr>
<tr>
<td>Buffalo</td>
<td>33</td>
<td>3439</td>
<td>1535</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>377</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>3481</td>
<td>613</td>
</tr>
<tr>
<td>Columbus</td>
<td>33</td>
<td>4356</td>
<td>1453</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>304</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>4474</td>
<td>170</td>
</tr>
<tr>
<td>Iowa</td>
<td>33</td>
<td>163</td>
<td>144</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>101</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>103</td>
<td>0</td>
</tr>
<tr>
<td>Seattle</td>
<td>33</td>
<td>1746</td>
<td>571</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>86</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>1791</td>
<td>57</td>
</tr>
<tr>
<td>Stanford</td>
<td>33</td>
<td>3548</td>
<td>1195</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>107</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>3623</td>
<td>169</td>
</tr>
<tr>
<td>Tucson</td>
<td>33</td>
<td>982</td>
<td>413</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>1006</td>
<td>44</td>
</tr>
<tr>
<td>Wake Forest</td>
<td>33</td>
<td>3636</td>
<td>1746</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>383</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>151B</td>
<td>3660</td>
<td>136</td>
</tr>
</tbody>
</table>

---

1 Form 33 = Medical History Update; Form 151 = Activities of Daily Life; Form 151B = Activities of Daily Life; Form 159 = Supplemental Questionnaire 2019.
2 The MRC Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS who consented to WHI Extension Study 2010-2025.
3 The SRC Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study who consented to WHI Extension Study 2010-2025.
4 Regional Center is determined based on the participant’s responsible clinic at the start of the mailing window (2 months prior to the participant’s mailing anniversary).
Table 1.8
Form 2 vs. Imputed Form 41 Race/ Ethnicity

Data as of: March 06, 2021

<table>
<thead>
<tr>
<th></th>
<th>Imputed F41 Race/ Ethnicity¹</th>
<th>Form 2 Race/Ethnicity¹</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>American Indian/Alaska Native</td>
<td>Asian or Native Hawaiian/ Other Pacific Islander²</td>
</tr>
<tr>
<td>N</td>
<td>%</td>
<td>N %</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>397 81.5</td>
<td>2 &lt;0.1</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>0 0.0</td>
<td>3901 95.5</td>
</tr>
<tr>
<td>Non-Hispanic Black/African American</td>
<td>28 5.7</td>
<td>2 &lt;0.1</td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>2 0.4</td>
<td>2 &lt;0.1</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>47 9.7</td>
<td>11 0.3</td>
</tr>
<tr>
<td>Other/Unspecified</td>
<td>13 2.7</td>
<td>166 4.1</td>
</tr>
</tbody>
</table>

¹ Race/ethnicity as identified on Form 2 at baseline.
² Native Hawaiian/Other Pacific Islander participants (n=119) are combined with Asian participants for reporting purposes due to small numbers.
Table 2.1
Participation and Vital Status: WHI Participants by Extension Study Participation and Cohort

Data as of: March 6, 2021

WHI Extension Study 2010-2025 Participants

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>MRC Cohort(^1) (N = 22,316)</th>
<th>SRC Cohort(^2) (N = 71,251)</th>
<th>Total Participants (N = 93,567)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Deceased</td>
<td>6916</td>
<td>31.0</td>
<td>22184</td>
</tr>
<tr>
<td>Alive: Current Participation(^3)</td>
<td>12552</td>
<td>56.2</td>
<td>42300</td>
</tr>
<tr>
<td>Alive: Recent Participation(^4)</td>
<td>1097</td>
<td>4.9</td>
<td>3158</td>
</tr>
<tr>
<td>Stopped Follow-Up(^5)</td>
<td>858</td>
<td>3.8</td>
<td>2113</td>
</tr>
<tr>
<td>Lost to Follow-Up(^6)</td>
<td>893</td>
<td>4.0</td>
<td>1496</td>
</tr>
</tbody>
</table>

Data as of: March 6, 2021; Status as of September 30, 2010

WHI Extension Study 2005-2010 Participants

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>MRC Super Cohort(^7) (N = 29,368)</th>
<th>SRC Super Cohort(^8) (N = 86,039)</th>
<th>Total Participants (N = 115,407)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Deceased</td>
<td>2360</td>
<td>8.0</td>
<td>6211</td>
</tr>
<tr>
<td>Alive: Current Participation(^3)</td>
<td>25884</td>
<td>88.1</td>
<td>78194</td>
</tr>
<tr>
<td>Alive: Recent Participation(^4)</td>
<td>321</td>
<td>1.1</td>
<td>489</td>
</tr>
<tr>
<td>Alive: Past/Unknown Participation(^9)</td>
<td>32</td>
<td>0.1</td>
<td>39</td>
</tr>
<tr>
<td>Stopped Follow-Up(^5)</td>
<td>459</td>
<td>1.6</td>
<td>794</td>
</tr>
<tr>
<td>Lost to Follow-Up(^6)</td>
<td>312</td>
<td>1.1</td>
<td>312</td>
</tr>
</tbody>
</table>

Data as of: March 6, 2021; Status as of April 8, 2005

WHI Participants

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>MRC Super Cohort(^7) (N = 44,174)</th>
<th>SRC Super Cohort(^8) (N = 117,634)</th>
<th>Total Participants (N = 161,808)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Deceased</td>
<td>2820</td>
<td>6.4</td>
<td>7232</td>
</tr>
<tr>
<td>Alive: Current Participation(^10)</td>
<td>38165</td>
<td>86.4</td>
<td>105585</td>
</tr>
<tr>
<td>Alive: Recent Participation(^11)</td>
<td>342</td>
<td>0.8</td>
<td>419</td>
</tr>
<tr>
<td>Alive: Past/Unknown Participation(^12)</td>
<td>21</td>
<td>&lt;0.1</td>
<td>41</td>
</tr>
<tr>
<td>Stopped Follow-Up(^5)</td>
<td>1699</td>
<td>3.8</td>
<td>2757</td>
</tr>
<tr>
<td>Lost to Follow-Up(^6)</td>
<td>1127</td>
<td>2.6</td>
<td>1600</td>
</tr>
</tbody>
</table>

\(^1\) The MRC Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS who consented to WHI Extension Study 2010-2025.
\(^2\) The SRC Cohort includes all Non-Hispanic White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study who consented to WHI Extension Study 2010-2025.
\(^3\) Participants who have filled in a Form 33 within the last 15 months.
\(^4\) Participants who last filled in a Form 33 between 15 and 24 months ago.
\(^5\) Participants with codes 5 (no follow-up) or 8 (absolutely no follow-up) on Form 7 or 9.
\(^6\) Participants not in any of the above categories.
\(^7\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.
\(^8\) The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.
\(^9\) Participants without a Form 33 within the last 24 months, who have been located (as indicated on Form 23) within the last 6 months.
\(^10\) CT participants who have filled in a Form 33 within the last 9 months; and OS participants who have filled in a Form 33 within the last 15 months.
\(^11\) CT participants who last filled in a Form 33 between 9 and 18 months ago; and OS participants who last filled in a Form 33 between 15 and 24 months ago.
\(^12\) CT participants without a Form 33 within the last 18 months, who have been located (as indicated on Form 23) within the last 6 months; and OS participants without a Form 33 within the last 24 months, who have been located (as indicated on Form 23) within the last 6 months.
### Table 2.2
Participation and Vital Status: WHI Extension Study 2010-2025 Participation by MRC vs. SRC Cohort

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>MRC Cohort(^1) (N = 44,174)</th>
<th>SRC Cohort(^2) (N = 117,634)</th>
<th>Total Participants (N = 161,808)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Deceased</td>
<td>12096</td>
<td>27.4</td>
<td>35627</td>
</tr>
<tr>
<td>Alive: Current Participation(^3)</td>
<td>12552</td>
<td>28.4</td>
<td>42300</td>
</tr>
<tr>
<td>Alive: Recent Participation(^4)</td>
<td>1097</td>
<td>2.5</td>
<td>3158</td>
</tr>
<tr>
<td>Stopped Follow-Up(^5)</td>
<td>17536</td>
<td>39.7</td>
<td>35053</td>
</tr>
<tr>
<td>Lost to Follow-Up(^6)</td>
<td>893</td>
<td>2.0</td>
<td>1496</td>
</tr>
</tbody>
</table>

---

\(^1\) The MRC Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS who consented to WHI Extension Study 2010-2025.

\(^2\) The SRC Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study who consented to WHI Extension Study 2010-2025.

\(^3\) Participants who have filled in a Form 33 within the last 15 months.

\(^4\) Participants who last filled in a Form 33 between 15 and 24 months ago.

\(^5\) Participants with codes 5 (no follow-up) or 8 (absolutely no follow-up) on Form 7 or 9, or who did not consent to WHI Extension Study 2010-2025.

\(^6\) Participants not in any of the above categories.
Table 2.3
Proxy Follow-up Status¹:
WHI Extension Study 2010-2025 Participants by Cohort, Current Age², and Race/Ethnicity

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Current Age²</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>69-79</td>
<td>80-84</td>
<td>85-89</td>
</tr>
<tr>
<td>MRC Cohort³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proxy follow-up</td>
<td>675</td>
<td>4.9</td>
<td>30</td>
<td>102</td>
<td>191</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.9</td>
<td>2.4</td>
<td>5.5</td>
</tr>
<tr>
<td>SRC Cohort⁴</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proxy follow-up</td>
<td>2049</td>
<td>4.5</td>
<td>85</td>
<td>259</td>
<td>605</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.9</td>
<td>1.8</td>
<td>5.1</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proxy follow-up</td>
<td>2724</td>
<td>4.6</td>
<td>115</td>
<td>361</td>
<td>796</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.9</td>
<td>1.9</td>
<td>5.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander⁵</th>
<th>Non-Hispanic Black/African American</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>MRC Cohort³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proxy follow-up</td>
<td>3</td>
<td>10.0</td>
<td>10</td>
<td>6.2</td>
<td>150</td>
<td>4.0</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRC Cohort⁴</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proxy follow-up</td>
<td>4</td>
<td>4.7</td>
<td>49</td>
<td>4.3</td>
<td>5</td>
<td>10.0</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proxy follow-up</td>
<td>7</td>
<td>6.1</td>
<td>59</td>
<td>4.5</td>
<td>155</td>
<td>4.1</td>
<td>85</td>
</tr>
</tbody>
</table>

¹ For participants alive as of March 6, 2021 and with current, recent or past/unknown participation.
² Age on March 6, 2021.
³ The MRC Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants from the CT and OS who consented to WHI Extension Study 2010-2025.
⁴ The SRC Cohort includes all Non-Hispanic White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study who consented to WHI Extension Study 2010-2020.
⁵ Native Hawaiian/Other Pacific Islander participants (n=47) are combined with Asian participants for reporting purposes due to small numbers.
### Table 2.4
Participation and Vital Status: CT and OS Participants

Data as of: March 6, 2021

**WHI Extension Study 2010-2025 Participants**

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>CT Participants (N = 41,499)</th>
<th>OS Participants (N = 52,068)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deceased</td>
<td>12613 30.4</td>
<td>16487 31.7</td>
</tr>
<tr>
<td>Alive: Current Participation(^1)</td>
<td>24421 58.8</td>
<td>30431 58.4</td>
</tr>
<tr>
<td>Alive: Recent Participation(^2)</td>
<td>1974 4.8</td>
<td>2281 4.4</td>
</tr>
<tr>
<td>Stopped Follow-Up(^3)</td>
<td>1337 3.2</td>
<td>1634 3.1</td>
</tr>
<tr>
<td>Lost to Follow-Up(^4)</td>
<td>1154 2.8</td>
<td>1235 2.4</td>
</tr>
</tbody>
</table>

Data as of: March 6, 2021; Status as of September 30, 2010

**WHI Extension Study 2005-2010 Participants**

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>CT Participants (N = 52,176)</th>
<th>OS Participants (N = 63,231)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deceased</td>
<td>3812 7.3</td>
<td>4759 7.5</td>
</tr>
<tr>
<td>Alive: Current Participation(^1)</td>
<td>46883 89.9</td>
<td>57195 90.5</td>
</tr>
<tr>
<td>Alive: Recent Participation(^2)</td>
<td>442 0.8</td>
<td>368 0.6</td>
</tr>
<tr>
<td>Alive: Past/Unknown Participation(^5)</td>
<td>37 0.1</td>
<td>34 0.1</td>
</tr>
<tr>
<td>Stopped Follow-Up(^3)</td>
<td>649 1.2</td>
<td>604 1.0</td>
</tr>
<tr>
<td>Lost to Follow-Up(^4)</td>
<td>353 0.7</td>
<td>271 0.4</td>
</tr>
</tbody>
</table>

Data as of: March 6, 2021; Status as of April 8, 2005

**WHI Participants**

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>CT Participants (N = 68,132)</th>
<th>OS Participants (N = 93,676)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deceased</td>
<td>3701 5.4</td>
<td>6351 6.8</td>
</tr>
<tr>
<td>Alive: Current Participation(^6)</td>
<td>61160 89.8</td>
<td>82590 88.2</td>
</tr>
<tr>
<td>Alive: Recent Participation(^7)</td>
<td>339 0.5</td>
<td>422 0.5</td>
</tr>
<tr>
<td>Alive: Past/Unknown Participation(^8)</td>
<td>10 &lt;0.1</td>
<td>52 0.1</td>
</tr>
<tr>
<td>Stopped Follow-Up(^3)</td>
<td>2194 3.2</td>
<td>2262 2.4</td>
</tr>
<tr>
<td>Lost to Follow-Up(^4)</td>
<td>728 1.1</td>
<td>1999 2.1</td>
</tr>
</tbody>
</table>

\(^1\) Participants who have filled in a Form 33 within the last 15 months.
\(^2\) Participants who last filled in a Form 33 between 15 and 24 months ago.
\(^3\) Participants with codes 5 (no follow-up) or 8 (absolutely no follow-up) on Form 7 or 9.
\(^4\) Participants not in any of the above categories.
\(^5\) Participants who last filled in a Form 33 between 18 and 24 months ago.
\(^6\) CT participants who have filled in a Form 33 within the last 9 months; OS participants who have filled in a Form 33 within the last 15 months.
\(^7\) CT participants who last filled in a Form 33 between 9 and 18 months ago; OS participants who last filled in a Form 33 between 15 and 24 months ago.
\(^8\) CT participants without a Form 33 within the last 18 months, who have been located (as indicated on Form 23) within the last 6 months; OS participants without a Form 33 within the last 24 months, who have been located (as indicated on Form 23) within the last 6 months.
### Table 2.5
**Participation and Vital Status: WHI Extension Study 2010-2025 Participation by CT vs. OS Cohort**

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>CT Participants (N = 68,132)</th>
<th></th>
<th>OS Participants (N = 93,676)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Deceased</td>
<td>20126</td>
<td>29.5</td>
<td>27597</td>
<td>29.5</td>
</tr>
<tr>
<td>Alive: Current Participation(^1)</td>
<td>24421</td>
<td>35.8</td>
<td>30431</td>
<td>32.5</td>
</tr>
<tr>
<td>Alive: Recent Participation(^2)</td>
<td>1974</td>
<td>2.9</td>
<td>2281</td>
<td>2.4</td>
</tr>
<tr>
<td>Stopped Follow-Up(^3)</td>
<td>20457</td>
<td>30.0</td>
<td>32132</td>
<td>34.3</td>
</tr>
<tr>
<td>Lost to Follow-Up(^4)</td>
<td>1154</td>
<td>1.7</td>
<td>1235</td>
<td>1.3</td>
</tr>
</tbody>
</table>

\(^1\) Participants who have filled in a Form 33 within the last 15 months.

\(^2\) Participants who last filled in a Form 33 between 15 and 24 months ago.

\(^3\) Participants with codes 5 (no follow-up) or 8 (absolutely no follow-up) on Form 7 or 9, or who did not consent to WHI Extension Study 2010-2025.

\(^4\) Participants not in any of the above categories.
Table 2.6

Cause of Death\(^1\) (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Number of participants</th>
<th>MRC Super Cohort(^2)</th>
<th>SRC Super Cohort(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean follow-up (months)</td>
<td>239.4</td>
<td>241.2</td>
</tr>
<tr>
<td>Total death</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjudicated death</td>
<td>19430 (2.21%)</td>
<td>52547 (2.22%)</td>
</tr>
<tr>
<td>Centrally adjudicated death</td>
<td>19009 (2.16%)</td>
<td>49553 (2.10%)</td>
</tr>
<tr>
<td>Locally adjudicated death</td>
<td>9141 (1.04%)</td>
<td>7413 (0.31%)</td>
</tr>
<tr>
<td>Identified by NDI search</td>
<td>679 (0.08%)</td>
<td>4681 (0.20%)</td>
</tr>
<tr>
<td>Not yet adjudicated</td>
<td>413 (0.05%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Form 120 death(^4)</td>
<td>8 (&lt;0.01%)</td>
<td>2994 (0.13%)</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atherosclerotic cardiac</td>
<td>2755 (0.31%)</td>
<td>6224 (0.26%)</td>
</tr>
<tr>
<td>Definite CHD deaths after 10/99</td>
<td>1045 (0.12%)</td>
<td>1955 (0.08%)</td>
</tr>
<tr>
<td>Possible CHD deaths after 10/99</td>
<td>1710 (0.19%)</td>
<td>4224 (0.18%)</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>112 (0.01%)</td>
<td>210 (0.01%)</td>
</tr>
<tr>
<td>Other cardiovascular</td>
<td>2037 (0.23%)</td>
<td>5695 (0.24%)</td>
</tr>
<tr>
<td>Total cardiovascular deaths</td>
<td>6510 (0.74%)</td>
<td>16028 (0.68%)</td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>483 (0.05%)</td>
<td>1533 (0.06%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>235 (0.03%)</td>
<td>852 (0.04%)</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>54 (0.01%)</td>
<td>224 (0.01%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>426 (0.05%)</td>
<td>985 (0.04%)</td>
</tr>
<tr>
<td>Uterus cancer</td>
<td>55 (0.01%)</td>
<td>135 (0.01%)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>1144 (0.13%)</td>
<td>2648 (0.11%)</td>
</tr>
<tr>
<td>Pancreas cancer</td>
<td>432 (0.05%)</td>
<td>1125 (0.05%)</td>
</tr>
<tr>
<td>Lymphoma (NHL only)</td>
<td>189 (0.02%)</td>
<td>635 (0.03%)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>184 (0.02%)</td>
<td>593 (0.03%)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>50 (0.01%)</td>
<td>161 (0.01%)</td>
</tr>
<tr>
<td>Brain cancer</td>
<td>86 (0.01%)</td>
<td>349 (0.01%)</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>170 (0.02%)</td>
<td>360 (0.02%)</td>
</tr>
<tr>
<td>Other cancer</td>
<td>882 (0.10%)</td>
<td>2386 (0.10%)</td>
</tr>
<tr>
<td>Unknown cancer site</td>
<td>183 (0.02%)</td>
<td>568 (0.02%)</td>
</tr>
<tr>
<td>Total cancer deaths</td>
<td>4573 (0.52%)</td>
<td>12554 (0.53%)</td>
</tr>
<tr>
<td>Accident/injury</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homicide</td>
<td>17 (&lt;0.01%)</td>
<td>19 (&lt;0.01%)</td>
</tr>
<tr>
<td>Accident</td>
<td>431 (0.05%)</td>
<td>1282 (0.05%)</td>
</tr>
<tr>
<td>Suicide</td>
<td>18 (&lt;0.01%)</td>
<td>63 (&lt;0.01%)</td>
</tr>
<tr>
<td>Other injury</td>
<td>20 (&lt;0.01%)</td>
<td>36 (&lt;0.01%)</td>
</tr>
<tr>
<td>Total accident/injury deaths</td>
<td>486 (0.06%)</td>
<td>1400 (0.06%)</td>
</tr>
</tbody>
</table>

---

\(^1\) Includes deaths for non-Extension Study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.

\(^2\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

\(^3\) The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

\(^4\) Includes SRC Cohort participants and discovered deaths among non-Extension Study 2010-2025 participants that occurred during Extension Study 2010-2025.
Table 2.6 (continued)

Cause of Death\(^1\) (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>MRC Super Cohort(^2)</th>
<th>SRC Super Cohort(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>44174</td>
<td>117634</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>239.4</td>
<td>241.2</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer's disease</td>
<td>1177 (0.13%)</td>
<td>3631 (0.15%)</td>
</tr>
<tr>
<td>COPD</td>
<td>752 (0.09%)</td>
<td>2055 (0.09%)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>510 (0.06%)</td>
<td>1213 (0.05%)</td>
</tr>
<tr>
<td>Pulmonary fibrosis</td>
<td>199 (0.02%)</td>
<td>506 (0.02%)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>440 (0.05%)</td>
<td>734 (0.03%)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>527 (0.06%)</td>
<td>1084 (0.05%)</td>
</tr>
<tr>
<td>Dementia, other than Alzheimer’s</td>
<td>1258 (0.14%)</td>
<td>3579 (0.15%)</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
<td>49 (0.01%)</td>
<td>239 (0.01%)</td>
</tr>
<tr>
<td>Parkinson’s</td>
<td>219 (0.02%)</td>
<td>773 (0.03%)</td>
</tr>
<tr>
<td>Hepatic cirrhosis</td>
<td>105 (0.01%)</td>
<td>214 (0.01%)</td>
</tr>
<tr>
<td>COVID-19</td>
<td>16 (&lt;0.01%)</td>
<td>31 (&lt;0.01%)</td>
</tr>
<tr>
<td>Other known cause</td>
<td>2000 (0.23%)</td>
<td>6012 (0.25%)</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>196 (0.02%)</td>
<td>2494 (0.11%)</td>
</tr>
<tr>
<td>Total other cause deaths</td>
<td>7448 (0.85%)</td>
<td>22565 (0.95%)</td>
</tr>
</tbody>
</table>

\(^1\) Includes deaths for non-Extension Study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.
\(^2\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.
\(^3\) The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.
Table 2.7

Cause of Death1 (Annualized Percentages): CT and OS Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Number of participants</th>
<th>CT</th>
<th>OS</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>68132</td>
<td>93676</td>
<td>161808</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>245.9</td>
<td>236.9</td>
<td>240.7</td>
</tr>
</tbody>
</table>

Total death
- Adjudicated death
- Centrally adjudicated death
- Locally adjudicated death (final)
- Identified by NDI search
- Not yet adjudicated
- Form 120 death2

Cardiovascular
- Atherosclerotic cardiac
- Definite CHD deaths after 10/99
- Possible CHD deaths after 10/99
- Cerebrovascular
- Pulmonary embolism
- Other cardiovascular
- Unknown cardiovascular

Total cardiovascular deaths

Cancer
- Breast cancer
- Ovarian cancer
- Endometrial cancer
- Colorectal cancer
- Uterus cancer
- Lung cancer
- Pancreas cancer
- Lymphoma (NHL only)
- Leukemia
- Melanoma
- Brain cancer
- Multiple myeloma
- Other cancer
- Unknown cancer site

Total cancer deaths

Accident/injury
- Homicide
- Accident
- Suicide
- Other injury

Total accident/injury deaths

Other
- Alzheimer’s disease
- COPD
- Pneumonia
- Pulmonary fibrosis
- Renal failure
- Sepsis
- Dementia, other than Alzheimer’s
- Amyotrophic lateral sclerosis
- Parkinson’s
- Hepatic cirrhosis
- COVID-19
- Other known cause
- Unknown cause

Total other cause deaths

---

1 Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.
2 Includes SRC Cohort participants and discovered deaths among non-Extension Study 2010-2025 participants that occurred during Extension Study 2010-2025.
Table 2.8
Cause of Death Excluding Discovered Deaths Among Non-Extension Study Participants\(^1\) (Annualized Percentages):
CT and OS Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Number of participants</th>
<th>CT</th>
<th>OS</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean follow-up (months)</td>
<td>207.7</td>
<td>192.3</td>
<td>198.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Death</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudicated death</td>
<td>20126</td>
<td>17597</td>
<td>47723</td>
</tr>
<tr>
<td>(1.71%)</td>
<td>(1.84%)</td>
<td>(1.73%)</td>
<td>(1.78%)</td>
</tr>
<tr>
<td>Centrally adjudicated death</td>
<td>11280</td>
<td>5120</td>
<td>16400</td>
</tr>
<tr>
<td>(0.96%)</td>
<td>(0.34%)</td>
<td>(0.61%)</td>
<td>(0.61%)</td>
</tr>
<tr>
<td>Locally adjudicated death (final)</td>
<td>1 (&lt;0.01%)</td>
<td>5283</td>
<td>5284</td>
</tr>
<tr>
<td>(0.08%)</td>
<td>(0.35%)</td>
<td>(0.20%)</td>
<td>(0.20%)</td>
</tr>
<tr>
<td>Identified by NDI search</td>
<td>7546</td>
<td>15095</td>
<td>22641</td>
</tr>
<tr>
<td>(0.64%)</td>
<td>(1.01%)</td>
<td>(0.84%)</td>
<td>(0.84%)</td>
</tr>
<tr>
<td>Not yet adjudicated</td>
<td>346</td>
<td>67</td>
<td>413</td>
</tr>
<tr>
<td>(&lt;0.01%)</td>
<td>(&lt;0.01%)</td>
<td>(0.02%)</td>
<td>(0.02%)</td>
</tr>
<tr>
<td>Form 120 death(^2)</td>
<td>953</td>
<td>2032</td>
<td>2985</td>
</tr>
<tr>
<td>(0.08%)</td>
<td>(0.14%)</td>
<td>(0.11%)</td>
<td>(0.11%)</td>
</tr>
</tbody>
</table>

| Cardiovascular         |       |       |         |
|                        |       |       |         |
| Atherosclerotic cardiac| 2605  | 3264  | 5869    |
| (0.22%)                | (0.22%) | (0.22%) | (0.22%) |
| Definite CHD deaths after 10/99 | 1178  | 1287  | 2465    |
| (0.10%)                | (0.09%) | (0.09%) | (0.09%) |
| Possible CHD deaths after 10/99 | 1414  | 1945  | 3359    |
| (0.12%)                | (0.13%) | (0.13%) | (0.13%) |
| Cerebrovascular        | 1526  | 1925  | 3451    |
| (0.13%)                | (0.13%) | (0.13%) | (0.13%) |
| Pulmonary embolism     | 134   | 133   | 267     |
| (0.01%)                | (0.01%) | (0.01%) | (0.01%) |
| Other cardiovascular    | 2018  | 2908  | 4926    |
| (0.17%)                | (0.19%) | (0.18%) | (0.18%) |
| Unknown cardiovascular  | 29    | 103   | 132     |
| (<0.01%)               | (<0.01%) | (<0.01%) | (<0.01%) |
| **Total cardiovascular deaths** | 6312  | 8433  | 14745   |
|                       | (0.54%) | (0.56%) | (0.55%) |

| Cancer                 |       |       |         |
| Breast cancer          | 491   | 1043  | 1534    |
| (0.04%)                | (0.07%) | (0.06%) | (0.06%) |
| Ovarian cancer         | 343   | 529   | 872     |
| (0.03%)                | (0.04%) | (0.03%) | (0.03%) |
| Endometrial cancer     | 101   | 123   | 224     |
| (0.01%)                | (0.01%) | (0.01%) | (0.01%) |
| Colorectal cancer      | 475   | 606   | 1081    |
| (0.04%)                | (0.04%) | (0.04%) | (0.04%) |
| Uterus cancer          | 59    | 77    | 136     |
| (0.01%)                | (0.01%) | (0.01%) | (0.01%) |
| Lung cancer            | 1310  | 1629  | 2939    |
| (0.11%)                | (0.11%) | (0.11%) | (0.11%) |
| Pancreas cancer        | 534   | 664   | 1198    |
| (0.05%)                | (0.04%) | (0.04%) | (0.04%) |
| Lymphoma (NHL only)    | 262   | 383   | 645     |
| (0.02%)                | (0.03%) | (0.02%) | (0.02%) |
| Leukemia               | 267   | 341   | 608     |
| (0.02%)                | (0.02%) | (0.02%) | (0.02%) |
| Melanoma               | 79    | 99    | 178     |
| (0.01%)                | (0.01%) | (0.01%) | (0.01%) |
| Brain cancer           | 159   | 184   | 343     |
| (0.01%)                | (0.01%) | (0.01%) | (0.01%) |
| Multiple myeloma       | 184   | 238   | 422     |
| (0.02%)                | (0.02%) | (0.02%) | (0.02%) |
| Other cancer           | 1089  | 1463  | 2552    |
| (0.09%)                | (0.10%) | (0.10%) | (0.10%) |
| Unknown cancer site    | 226   | 320   | 546     |
| (0.02%)                | (0.02%) | (0.02%) | (0.02%) |
| **Total cancer deaths**| 5579  | 7699  | 13278   |
|                       | (0.47%) | (0.51%) | (0.50%) |

| Accident/injury        |       |       |         |
| Homicide               | 15    | 18    | 33      |
| (<0.01%)               | (<0.01%) | (<0.01%) | (<0.01%) |
| Accident               | 498   | 648   | 1146    |
| (0.04%)                | (0.04%) | (0.04%) | (0.04%) |
| Suicide                | 26    | 45    | 71      |
| (<0.01%)               | (<0.01%) | (<0.01%) | (<0.01%) |
| Other injury           | 24    | 30    | 54      |
| (<0.01%)               | (<0.01%) | (<0.01%) | (<0.01%) |
| **Total accident/injury deaths** | 563   | 741   | 1304    |
|                       | (0.05%) | (0.05%) | (0.05%) |

---

\(^1\) Excludes deaths that occurred after a participant’s consent period.

\(^2\) Includes SRC Cohort participants.
### Table 2.8 (continued)

**Cause of Death Excluding Discovered Deaths Among Non-Extension Study Participants**\(^1\) (Annualized Percentages): 

**CT and OS Participants**

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Number of participants</th>
<th>CT</th>
<th>OS</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>68132</td>
<td>93676</td>
<td>161808</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>207.7</td>
<td>192.3</td>
<td>198.8</td>
</tr>
</tbody>
</table>

**Other**

<table>
<thead>
<tr>
<th>Cause</th>
<th>CT</th>
<th>OS</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer's disease</td>
<td>888 (0.08%)</td>
<td>1232 (0.08%)</td>
<td>2120 (0.08%)</td>
</tr>
<tr>
<td>COPD</td>
<td>806 (0.07%)</td>
<td>1021 (0.07%)</td>
<td>1827 (0.07%)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>549 (0.05%)</td>
<td>626 (0.04%)</td>
<td>1175 (0.04%)</td>
</tr>
<tr>
<td>Pulmonary fibrosis</td>
<td>248 (0.02%)</td>
<td>285 (0.02%)</td>
<td>533 (0.02%)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>330 (0.03%)</td>
<td>419 (0.03%)</td>
<td>749 (0.03%)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>492 (0.04%)</td>
<td>574 (0.04%)</td>
<td>1066 (0.04%)</td>
</tr>
<tr>
<td>Dementia, other than Alzheimer’s</td>
<td>912 (0.08%)</td>
<td>1163 (0.08%)</td>
<td>2075 (0.08%)</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
<td>93 (0.01%)</td>
<td>129 (0.01%)</td>
<td>222 (0.01%)</td>
</tr>
<tr>
<td>Parkinson’s</td>
<td>206 (0.02%)</td>
<td>325 (0.02%)</td>
<td>531 (0.02%)</td>
</tr>
<tr>
<td>Hepatic cirrhosis</td>
<td>110 (0.01%)</td>
<td>120 (0.01%)</td>
<td>230 (0.01%)</td>
</tr>
<tr>
<td>COVID-19</td>
<td>22 (&lt;0.01%)</td>
<td>25 (&lt;0.01%)</td>
<td>47 (&lt;0.01%)</td>
</tr>
<tr>
<td>Other known cause</td>
<td>1772 (0.15%)</td>
<td>3043 (0.20%)</td>
<td>4815 (0.18%)</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>898 (0.08%)</td>
<td>1695 (0.11%)</td>
<td>2593 (0.10%)</td>
</tr>
<tr>
<td><strong>Total other cause deaths</strong></td>
<td>7326 (0.62%)</td>
<td>10657 (0.71%)</td>
<td>17983 (0.67%)</td>
</tr>
</tbody>
</table>

---

\(^1\) Excludes deaths that occurred after a participant’s consent period.
## Table 3.1
### Verified Outcomes (Annualized Percentages) by Age at Enrollment for MRC Super Cohort Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Total</th>
<th>Age at Enrollment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>50-54</td>
</tr>
<tr>
<td><strong>Number randomized</strong></td>
<td>44174</td>
<td>6788</td>
</tr>
<tr>
<td><strong>Mean follow-up (months)</strong></td>
<td>185.8</td>
<td>200.7</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD$^2$</td>
<td>3838 (0.56%)</td>
<td>267 (0.24%)</td>
</tr>
<tr>
<td>CHD death$^3$</td>
<td>1771 (0.26%)</td>
<td>80 (0.07%)</td>
</tr>
<tr>
<td>Clinical MI</td>
<td>2558 (0.37%)</td>
<td>201 (0.18%)</td>
</tr>
<tr>
<td>Angina$^4$</td>
<td>1625 (0.47%)</td>
<td>114 (0.20%)</td>
</tr>
<tr>
<td>CABG/PTCA</td>
<td>3111 (0.45%)</td>
<td>260 (0.23%)</td>
</tr>
<tr>
<td>Carotid artery disease</td>
<td>531 (0.08%)</td>
<td>27 (0.02%)</td>
</tr>
<tr>
<td>Congestive heart failure, WHI$^4$</td>
<td>1246 (0.36%)</td>
<td>84 (0.15%)</td>
</tr>
<tr>
<td>Heart failure, UNC$^5$</td>
<td>3231 (0.63%)</td>
<td>202 (0.26%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>3164 (0.46%)</td>
<td>217 (0.19%)</td>
</tr>
<tr>
<td>PAD</td>
<td>710 (0.10%)</td>
<td>48 (0.04%)</td>
</tr>
<tr>
<td>DVT</td>
<td>1379 (0.20%)</td>
<td>129 (0.11%)</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>1132 (0.17%)</td>
<td>121 (0.11%)</td>
</tr>
<tr>
<td>DVT/PE</td>
<td>2017 (0.29%)</td>
<td>195 (0.17%)</td>
</tr>
<tr>
<td>Coronary disease$^6$</td>
<td>7897 (1.15%)</td>
<td>602 (0.53%)</td>
</tr>
<tr>
<td>Aortic aneurysm$^7$</td>
<td>77 (0.04%)</td>
<td>6 (0.02%)</td>
</tr>
<tr>
<td>Valvular heart disease$^7$</td>
<td>550 (0.30%)</td>
<td>39 (0.11%)</td>
</tr>
<tr>
<td><strong>Total cardiovascular disease$^8$</strong></td>
<td>11120 (1.63%)</td>
<td>821 (0.72%)</td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>3042 (0.44%)</td>
<td>475 (0.42%)</td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>2505 (0.37%)</td>
<td>373 (0.33%)</td>
</tr>
<tr>
<td>In-situ breast cancer</td>
<td>595 (0.09%)</td>
<td>109 (0.10%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>289 (0.04%)</td>
<td>30 (0.03%)</td>
</tr>
<tr>
<td>Endometrial cancer$^9$</td>
<td>342 (0.09%)</td>
<td>55 (0.09%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>983 (0.14%)</td>
<td>93 (0.08%)</td>
</tr>
<tr>
<td>Other cancer$^{10}$</td>
<td>4446 (0.65%)</td>
<td>441 (0.39%)</td>
</tr>
<tr>
<td><strong>Total cancer</strong></td>
<td>8409 (1.23%)</td>
<td>1015 (0.89%)</td>
</tr>
<tr>
<td><strong>Fractures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip fracture</td>
<td>1724 (0.25%)</td>
<td>66 (0.06%)</td>
</tr>
<tr>
<td><strong>Deaths</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular deaths</td>
<td>4093 (0.60%)</td>
<td>173 (0.15%)</td>
</tr>
<tr>
<td>Cancer deaths</td>
<td>3361 (0.49%)</td>
<td>279 (0.25%)</td>
</tr>
<tr>
<td>Other known cause</td>
<td>4062 (0.59%)</td>
<td>204 (0.18%)</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>167 (0.02%)</td>
<td>10 (0.01%)</td>
</tr>
<tr>
<td>Not yet adjudicated</td>
<td>413 (0.06%)</td>
<td>26 (0.02%)</td>
</tr>
<tr>
<td>**Total death$^{11}$</td>
<td>19430 (2.21%)</td>
<td>1081 (0.71%)</td>
</tr>
</tbody>
</table>

---

1. The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.
2. “CHD” includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2025.
3. CHD death includes definite and possible CHD death.
4. Angina and CHF are not verified outcomes in the WHI Extension Studies 2005-2025. Reported statistics represent experience during the original program.
5. Coronary disease includes clinical MI, evolving Q-wave MI, CABG/PTCA, Q-wave MI, angina, congestive heart failure, and valvular heart disease.
6. Definite or possible decompensated heart failure adjudicated by UNC.
7. Aortic aneurysm and valvular heart disease are not adjudicated outcomes during the WHI Extension Study 2010-2025.
8. Total CV death does not include aortic aneurysm or valvular heart disease.
9. Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.
10. Only one report of “other cancer” is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.
11. Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.
### Table 3.2
Verified Outcomes (Annualized Percentages) by Race/Ethnicity for MRC Super Cohort Participants

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number randomized</td>
<td>108</td>
<td>526</td>
<td>6525</td>
<td>14025</td>
<td>22278</td>
<td>550</td>
<td>162</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>167.3</td>
<td>179.3</td>
<td>161.5</td>
<td>169.1</td>
<td>203.3</td>
<td>206.9</td>
<td>163.9</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD(^3)</td>
<td>8 (0.53%)</td>
<td>34 (0.43%)</td>
<td>274 (0.31%)</td>
<td>1048 (0.53%)</td>
<td>2407 (0.64%)</td>
<td>50 (0.53%)</td>
<td>17 (0.77%)</td>
</tr>
<tr>
<td>CHD death(^4)</td>
<td>4 (0.27%)</td>
<td>12 (0.15%)</td>
<td>104 (0.12%)</td>
<td>572 (0.29%)</td>
<td>1044 (0.28%)</td>
<td>24 (0.25%)</td>
<td>11 (0.50%)</td>
</tr>
<tr>
<td>Clinical MI</td>
<td>6 (0.40%)</td>
<td>27 (0.34%)</td>
<td>201 (0.23%)</td>
<td>619 (0.31%)</td>
<td>1663 (0.44%)</td>
<td>33 (0.35%)</td>
<td>9 (0.41%)</td>
</tr>
<tr>
<td>Angina(^5)</td>
<td>7 (0.85%)</td>
<td>16 (0.39%)</td>
<td>160 (0.33%)</td>
<td>532 (0.49%)</td>
<td>886 (0.49%)</td>
<td>16 (0.35%)</td>
<td>8 (0.67%)</td>
</tr>
<tr>
<td>CABG/PTCA</td>
<td>7 (0.46%)</td>
<td>23 (0.29%)</td>
<td>298 (0.34%)</td>
<td>742 (0.38%)</td>
<td>1996 (0.53%)</td>
<td>36 (0.38%)</td>
<td>9 (0.41%)</td>
</tr>
<tr>
<td>Carotid artery disease</td>
<td>4 (0.27%)</td>
<td>3 (0.04%)</td>
<td>26 (0.03%)</td>
<td>94 (0.05%)</td>
<td>396 (0.10%)</td>
<td>7 (0.07%)</td>
<td>1 (0.05%)</td>
</tr>
<tr>
<td>Congestive heart failure, WHI(^6)</td>
<td>2 (0.24%)</td>
<td>9 (0.22%)</td>
<td>93 (0.19%)</td>
<td>466 (0.43%)</td>
<td>658 (0.36%)</td>
<td>15 (0.33%)</td>
<td>3 (0.25%)</td>
</tr>
<tr>
<td>Heart failure, UNC(^7)</td>
<td>9 (0.79%)</td>
<td>22 (0.28%)</td>
<td>196 (0.22%)</td>
<td>816 (2.02%)</td>
<td>2128 (0.58%)</td>
<td>49 (0.89%)</td>
<td>11 (1.04%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>7 (0.46%)</td>
<td>22 (0.28%)</td>
<td>247 (0.28%)</td>
<td>905 (0.46%)</td>
<td>1920 (0.51%)</td>
<td>50 (0.53%)</td>
<td>13 (0.59%)</td>
</tr>
<tr>
<td>PAD</td>
<td>1 (0.07%)</td>
<td>7 (0.09%)</td>
<td>40 (0.05%)</td>
<td>248 (0.13%)</td>
<td>401 (0.11%)</td>
<td>10 (0.11%)</td>
<td>3 (0.14%)</td>
</tr>
<tr>
<td>DVT</td>
<td>5 (0.33%)</td>
<td>2 (0.03%)</td>
<td>84 (0.10%)</td>
<td>369 (0.19%)</td>
<td>897 (0.24%)</td>
<td>17 (0.18%)</td>
<td>5 (0.23%)</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>5 (0.33%)</td>
<td>2 (0.03%)</td>
<td>52 (0.06%)</td>
<td>339 (0.17%)</td>
<td>715 (0.19%)</td>
<td>14 (0.15%)</td>
<td>5 (0.23%)</td>
</tr>
<tr>
<td>DVT/PE</td>
<td>8 (0.53%)</td>
<td>3 (0.04%)</td>
<td>114 (0.13%)</td>
<td>579 (0.29%)</td>
<td>1279 (0.34%)</td>
<td>26 (0.27%)</td>
<td>8 (0.36%)</td>
</tr>
<tr>
<td>Coronary disease(^7)</td>
<td>19 (1.26%)</td>
<td>64 (0.81%)</td>
<td>630 (0.72%)</td>
<td>2215 (1.12%)</td>
<td>4836 (1.28%)</td>
<td>102 (1.08%)</td>
<td>31 (1.40%)</td>
</tr>
<tr>
<td>Aortic aneurysm(^8)</td>
<td>0 (0.00%)</td>
<td>2 (0.10%)</td>
<td>5 (0.02%)</td>
<td>19 (0.04%)</td>
<td>48 (0.04%)</td>
<td>3 (0.11%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Valvular heart disease(^8)</td>
<td>0 (0.00%)</td>
<td>4 (0.20%)</td>
<td>53 (0.25%)</td>
<td>71 (0.15%)</td>
<td>412 (0.38%)</td>
<td>9 (0.34%)</td>
<td>1 (0.17%)</td>
</tr>
<tr>
<td>Total cardiovascular disease(^9)</td>
<td>24 (1.59%)</td>
<td>90 (1.15%)</td>
<td>882 (1.00%)</td>
<td>3161 (1.60%)</td>
<td>6764 (1.79%)</td>
<td>157 (1.66%)</td>
<td>42 (1.90%)</td>
</tr>
</tbody>
</table>

---

\(^1\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants from the CT and OS (identified from race/ethnicity collected on Form 2 at baseline. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

\(^2\) Native Hawaiian/Other Pacific Islander MRC Super Cohort participants (n=40) are combined with Asian MRC Super Cohort participants for reporting purposes due to small numbers.

\(^3\) “CHD” includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2025.

\(^4\) “CHD death” includes definite and possible CHD death.

\(^5\) Angina and CHF are not verified outcomes in the WHI Extension Studies 2005-2025. Reported statistics represent experience during the original program.

\(^6\) Definite or possible decompensated heart failure adjudicated by UNC.

\(^7\) “Coronary disease” includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina and congestive heart failure are not collected in the WHI Extension Studies 2005-2025.

\(^8\) Aortic aneurysm and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2025.

\(^9\) Total CVD does not include aortic aneurysm or valvular heart disease.
### Table 3.2 (continued)

**Verified Outcomes (Annualized Percentages) by Race/Ethnicity for MRC Super Cohort Participants**

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>American Indian/ Alaska Native</th>
<th>Asian or Native Hawaiian/ Other Pacific Islander(^2)</th>
<th>Hispanic/ Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/ Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number randomized</strong></td>
<td>108</td>
<td>526</td>
<td>6525</td>
<td>14025</td>
<td>22278</td>
<td>550</td>
<td>162</td>
</tr>
<tr>
<td><strong>Mean follow-up (months)</strong></td>
<td>167.3</td>
<td>179.3</td>
<td>161.5</td>
<td>169.1</td>
<td>203.3</td>
<td>206.9</td>
<td>163.9</td>
</tr>
<tr>
<td><strong>Breast cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>6 (0.40%)</td>
<td>35 (0.45%)</td>
<td>322 (0.37%)</td>
<td>917 (0.46%)</td>
<td>1715 (0.45%)</td>
<td>39 (0.41%)</td>
<td>8 (0.36%)</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>0 (0.00%)</td>
<td>9 (0.11%)</td>
<td>64 (0.07%)</td>
<td>203 (0.10%)</td>
<td>313 (0.08%)</td>
<td>6 (0.06%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td><strong>Ovarian cancer</strong></td>
<td>2 (0.13%)</td>
<td>2 (0.03%)</td>
<td>37 (0.04%)</td>
<td>75 (0.04%)</td>
<td>168 (0.04%)</td>
<td>4 (0.04%)</td>
<td>1 (0.05%)</td>
</tr>
<tr>
<td><strong>Endometrial cancer(^3)</strong></td>
<td>2 (0.26%)</td>
<td>2 (0.04%)</td>
<td>32 (0.07%)</td>
<td>88 (0.10%)</td>
<td>216 (0.09%)</td>
<td>1 (0.02%)</td>
<td>1 (0.08%)</td>
</tr>
<tr>
<td><strong>Colorectal cancer</strong></td>
<td>1 (0.07%)</td>
<td>13 (0.17%)</td>
<td>86 (0.10%)</td>
<td>296 (0.15%)</td>
<td>566 (0.15%)</td>
<td>17 (0.18%)</td>
<td>4 (0.18%)</td>
</tr>
<tr>
<td><strong>Other cancer(^4)</strong></td>
<td>13 (0.86%)</td>
<td>51 (0.65%)</td>
<td>382 (0.44%)</td>
<td>1088 (0.55%)</td>
<td>2848 (0.75%)</td>
<td>52 (0.55%)</td>
<td>12 (0.54%)</td>
</tr>
<tr>
<td><strong>Total cancer</strong></td>
<td>22 (1.46%)</td>
<td>97 (1.23%)</td>
<td>802 (0.91%)</td>
<td>2280 (1.15%)</td>
<td>5077 (1.35%)</td>
<td>106 (1.12%)</td>
<td>25 (1.13%)</td>
</tr>
<tr>
<td><strong>Fractures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip fracture</td>
<td>3 (0.20%)</td>
<td>11 (0.14%)</td>
<td>80 (0.09%)</td>
<td>140 (0.07%)</td>
<td>1465 (0.39%)</td>
<td>21 (0.22%)</td>
<td>4 (0.18%)</td>
</tr>
<tr>
<td><strong>Deaths</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular deaths</td>
<td>6 (0.40%)</td>
<td>25 (0.32%)</td>
<td>258 (0.29%)</td>
<td>1205 (0.61%)</td>
<td>2533 (0.67%)</td>
<td>48 (0.51%)</td>
<td>18 (0.81%)</td>
</tr>
<tr>
<td>Cancer deaths</td>
<td>9 (0.60%)</td>
<td>36 (0.46%)</td>
<td>310 (0.35%)</td>
<td>966 (0.49%)</td>
<td>1988 (0.53%)</td>
<td>38 (0.40%)</td>
<td>14 (0.63%)</td>
</tr>
<tr>
<td>Other known cause</td>
<td>11 (0.73%)</td>
<td>34 (0.43%)</td>
<td>309 (0.35%)</td>
<td>925 (0.47%)</td>
<td>2723 (0.72%)</td>
<td>49 (0.52%)</td>
<td>11 (0.50%)</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>0 (0.00%)</td>
<td>5 (0.06%)</td>
<td>17 (0.02%)</td>
<td>38 (0.02%)</td>
<td>100 (0.03%)</td>
<td>6 (0.06%)</td>
<td>1 (0.05%)</td>
</tr>
<tr>
<td>Not yet adjudicated</td>
<td>1 (0.07%)</td>
<td>2 (0.03%)</td>
<td>25 (0.03%)</td>
<td>115 (0.06%)</td>
<td>266 (0.07%)</td>
<td>4 (0.04%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td><strong>Total death(^5)</strong></td>
<td>47 (2.24%)</td>
<td>200 (1.87%)</td>
<td>1942 (1.43%)</td>
<td>5965 (2.16%)</td>
<td>10976 (2.48%)</td>
<td>233 (2.04%)</td>
<td>67 (2.15%)</td>
</tr>
</tbody>
</table>

\(^1\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants from the CT and OS (identified from race/ethnicity collected on Form 2 at baseline. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

\(^2\) Native Hawaiian/Other Pacific Islander MRC Super Cohort participants (n=40) are combined with Asian MRC Super Cohort participants for reporting purposes due to small numbers.

\(^3\) Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

\(^4\) Only one report of “other cancer” is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

\(^5\) Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.
### Table 3.3

**Verified Outcomes (Annualized Percentages)**\(^1\) by **Age at Diagnosis** for **MRC Super Cohort Participants**\(^2\)

Data as of: March 6, 2021; Events between January 1, 2000 and December 31, 2019

#### Outcomes

<table>
<thead>
<tr>
<th>Number of participants(^3)</th>
<th>Mean follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8898</td>
<td>18159</td>
</tr>
<tr>
<td>32.0</td>
<td>39.0</td>
</tr>
</tbody>
</table>

#### Cancer

<table>
<thead>
<tr>
<th></th>
<th>Age at Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>50-59</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>95 (0.40%)</td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>73 (0.31%)</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>22 (0.09%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>5 (0.02%)</td>
</tr>
<tr>
<td>Endometrial cancer(^4)</td>
<td>3 (0.01%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>10 (0.04%)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>1 (&lt;0.01%)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>18 (0.08%)</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>3 (0.01%)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>10 (0.04%)</td>
</tr>
<tr>
<td>Pancreas cancer</td>
<td>5 (0.02%)</td>
</tr>
<tr>
<td>Total cancer</td>
<td>167 (0.70%)</td>
</tr>
</tbody>
</table>

#### Cardiovascular

<table>
<thead>
<tr>
<th></th>
<th>Age at Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>50-59</td>
</tr>
<tr>
<td>CHD(^5)</td>
<td>35 (0.15%)</td>
</tr>
<tr>
<td>Clinical MI</td>
<td>25 (0.11%)</td>
</tr>
<tr>
<td>CABG/PTCA</td>
<td>48 (0.20%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>26 (0.11%)</td>
</tr>
<tr>
<td>Total cardiovascular(^6)</td>
<td>157 (0.66%)</td>
</tr>
</tbody>
</table>

#### Deaths

| Total death\(^7\)     | 88 (0.37%) | 372 (0.63%) | 907 (0.98%) | 1775 (1.55%) | 3043 (2.72%) | 4017 (5.01%) | 4160 (10.28%) | 3768 (24.20%) |

---

\(^1\) Annualized percentages calculated as the number with an event in the age interval divided by the total person years of all participants with time in the interval.

\(^2\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

\(^3\) Number of participants with any follow-up time in the age interval.

\(^4\) Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

\(^5\) “CHD” includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the OS or in the WHI Extension Study 2005-2010.

\(^6\) Total cardiovascular disease includes CHD, angina, CABG/PTCA, carotid artery disease, WHI CHF, UNC HF, stroke, PVD and CVD death.

\(^7\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

---

Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

“CHD” includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the OS or in the WHI Extension Study 2005-2010.

Total cardiovascular disease includes CHD, angina, CABG/PTCA, carotid artery disease, WHI CHF, UNC HF, stroke, PVD and CVD death. Angina and WHI CHF are not verified outcomes in the WHI Extension Studies 2005-2025.

Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.
Table 3.4
Verified Outcomes (Annualized Percentages) by Age at Enrollment for SRC Super Cohort Participants

Data as of: March 6, 2021; Events through September 30, 2010 and March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes through Extension Study 2005-2010</th>
<th>Total</th>
<th>50-54</th>
<th>55-59</th>
<th>60-69</th>
<th>70-79</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number randomized</td>
<td>117634</td>
<td>14781</td>
<td>22638</td>
<td>53171</td>
<td>27044</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>142.7</td>
<td>154.9</td>
<td>151.9</td>
<td>142.9</td>
<td>128.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiovascular&lt;sup&gt;2&lt;/sup&gt;</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD&lt;sup&gt;3&lt;/sup&gt;</td>
<td>5434</td>
<td>201</td>
<td>489</td>
<td>2362</td>
<td>2382</td>
</tr>
<tr>
<td>CHD death&lt;sup&gt;4&lt;/sup&gt;</td>
<td>1891</td>
<td>49</td>
<td>104</td>
<td>693</td>
<td>1045</td>
</tr>
<tr>
<td>Clinical MI</td>
<td>4044</td>
<td>159</td>
<td>398</td>
<td>1834</td>
<td>1653</td>
</tr>
<tr>
<td>Angina&lt;sup&gt;5&lt;/sup&gt;</td>
<td>3623</td>
<td>139</td>
<td>423</td>
<td>1749</td>
<td>1312</td>
</tr>
<tr>
<td>CABG/PTCA</td>
<td>6113</td>
<td>241</td>
<td>711</td>
<td>3161</td>
<td>2000</td>
</tr>
<tr>
<td>Carotid artery disease</td>
<td>1111</td>
<td>48</td>
<td>117</td>
<td>520</td>
<td>426</td>
</tr>
<tr>
<td>Congestive heart failure, WHI&lt;sup&gt;5&lt;/sup&gt;</td>
<td>2797</td>
<td>78</td>
<td>201</td>
<td>1096</td>
<td>1422</td>
</tr>
<tr>
<td>Stroke</td>
<td>4255</td>
<td>124</td>
<td>319</td>
<td>1856</td>
<td>1956</td>
</tr>
<tr>
<td>PAD</td>
<td>984</td>
<td>24</td>
<td>88</td>
<td>460</td>
<td>412</td>
</tr>
<tr>
<td>Coronary disease&lt;sup&gt;6&lt;/sup&gt;</td>
<td>11771</td>
<td>455</td>
<td>1244</td>
<td>5456</td>
<td>4616</td>
</tr>
<tr>
<td>Total cardiovascular disease</td>
<td>16773</td>
<td>626</td>
<td>1662</td>
<td>7667</td>
<td>6818</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fractures&lt;sup&gt;2&lt;/sup&gt;</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hip fracture</td>
<td>2955</td>
<td>63</td>
<td>186</td>
<td>1108</td>
<td>1598</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes through Extension Study 2010-2025</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number randomized</td>
<td>117634</td>
<td>14781</td>
<td>22638</td>
<td>53171</td>
<td>27044</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>203.7</td>
<td>237.0</td>
<td>230.6</td>
<td>205.2</td>
<td>159.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cancer</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>10866</td>
<td>1482</td>
<td>2349</td>
<td>5029</td>
<td>2006</td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>9145</td>
<td>1199</td>
<td>1969</td>
<td>4252</td>
<td>1725</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>1902</td>
<td>313</td>
<td>418</td>
<td>865</td>
<td>306</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>1052</td>
<td>130</td>
<td>202</td>
<td>501</td>
<td>219</td>
</tr>
<tr>
<td>Endometrial cancer&lt;sup&gt;7&lt;/sup&gt;</td>
<td>1544</td>
<td>183</td>
<td>350</td>
<td>711</td>
<td>300</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>2518</td>
<td>152</td>
<td>351</td>
<td>1245</td>
<td>770</td>
</tr>
<tr>
<td>Other cancer&lt;sup&gt;8&lt;/sup&gt;</td>
<td>14298</td>
<td>1427</td>
<td>2503</td>
<td>7018</td>
<td>3350</td>
</tr>
<tr>
<td>Total cancer</td>
<td>27532</td>
<td>3082</td>
<td>5241</td>
<td>13094</td>
<td>6115</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Deaths</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular deaths</td>
<td>10652</td>
<td>236</td>
<td>678</td>
<td>4515</td>
<td>5223</td>
</tr>
<tr>
<td>Cancer deaths</td>
<td>9917</td>
<td>646</td>
<td>1403</td>
<td>4915</td>
<td>2953</td>
</tr>
<tr>
<td>Other known cause</td>
<td>12632</td>
<td>404</td>
<td>1102</td>
<td>5996</td>
<td>5130</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>2426</td>
<td>117</td>
<td>268</td>
<td>1371</td>
<td>670</td>
</tr>
<tr>
<td>Total death&lt;sup&gt;9&lt;/sup&gt;</td>
<td>52547</td>
<td>1910</td>
<td>4631</td>
<td>23944</td>
<td>22062</td>
</tr>
</tbody>
</table>

---

<sup>1</sup>The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

<sup>2</sup>Cardiovascular diseases and hip fracture are not adjudicated for SRC Super Cohort participants during the WHI Extension Study 2010-2025. Reported statistics represent experience during the original program and the Extension Study 2005-2010.

<sup>3</sup>“CHD” includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Study 2005-2010.

<sup>4</sup>“CHD death” includes definite and possible CHD death.

<sup>5</sup>Angina and CHF are not adjudicated in the WHI Extension Study 2005-2010. Reported statistics represent experience during the original program.

<sup>6</sup>“Coronary disease” includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, and CABG/PTCA; Q-wave MI, angina, and congestive heart failure were not collected in the WHI Extension Study 2005-2010.

<sup>7</sup>Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

<sup>8</sup>Only one report of “other cancer” is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

<sup>9</sup>Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.
## Table 3.5
Verified Outcomes (Annualized Percentages) by Race/Ethnicity for SRC Super Cohort Participants\(^1\)

Data as of: March 6, 2021; Events through September 30, 2010 and March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes through Extension Study 2005-2010</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander(^2)</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number randomized</td>
<td>379</td>
<td>3558</td>
<td>787</td>
<td>142</td>
<td>111050</td>
<td>1119</td>
<td>599</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>115.0</td>
<td>127.6</td>
<td>145.7</td>
<td>137.6</td>
<td>143.4</td>
<td>146.6</td>
<td>106.7</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong>(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD(^4)</td>
<td>21 (0.58%)</td>
<td>89 (0.24%)</td>
<td>27 (0.28%)</td>
<td>3 (0.18%)</td>
<td>5224 (0.39%)</td>
<td>42 (0.31%)</td>
<td>28 (0.53%)</td>
</tr>
<tr>
<td>CHD death(^5)</td>
<td>11 (0.30%)</td>
<td>30 (0.08%)</td>
<td>4 (0.04%)</td>
<td>1 (0.06%)</td>
<td>1812 (0.14%)</td>
<td>13 (0.10%)</td>
<td>20 (0.38%)</td>
</tr>
<tr>
<td>Clinical MI</td>
<td>13 (0.36%)</td>
<td>68 (0.18%)</td>
<td>23 (0.24%)</td>
<td>2 (0.12%)</td>
<td>3889 (0.29%)</td>
<td>31 (0.23%)</td>
<td>18 (0.34%)</td>
</tr>
<tr>
<td>Angina(^6)</td>
<td>19 (0.70%)</td>
<td>54 (0.20%)</td>
<td>28 (0.43%)</td>
<td>2 (0.17%)</td>
<td>3470 (0.39%)</td>
<td>35 (0.38%)</td>
<td>15 (0.37%)</td>
</tr>
<tr>
<td>CABG/PTCA</td>
<td>19 (0.52%)</td>
<td>80 (0.21%)</td>
<td>39 (0.41%)</td>
<td>2 (0.12%)</td>
<td>5906 (0.44%)</td>
<td>47 (0.34%)</td>
<td>20 (0.38%)</td>
</tr>
<tr>
<td>Carotid artery disease</td>
<td>6 (0.17%)</td>
<td>10 (0.03%)</td>
<td>11 (0.12%)</td>
<td>4 (0.25%)</td>
<td>1065 (0.08%)</td>
<td>8 (0.06%)</td>
<td>7 (0.13%)</td>
</tr>
<tr>
<td>Congestive heart failure, WHI(^6)</td>
<td>19 (0.70%)</td>
<td>33 (0.12%)</td>
<td>12 (0.18%)</td>
<td>2 (0.17%)</td>
<td>2684 (0.30%)</td>
<td>23 (0.25%)</td>
<td>24 (0.59%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>19 (0.52%)</td>
<td>98 (0.26%)</td>
<td>19 (0.20%)</td>
<td>6 (0.37%)</td>
<td>4059 (0.31%)</td>
<td>29 (0.21%)</td>
<td>25 (0.47%)</td>
</tr>
<tr>
<td>PAD</td>
<td>5 (0.14%)</td>
<td>9 (0.02%)</td>
<td>3 (0.03%)</td>
<td>3 (0.18%)</td>
<td>949 (0.07%)</td>
<td>13 (0.10%)</td>
<td>2 (0.04%)</td>
</tr>
<tr>
<td>Coronary disease(^7)</td>
<td>52 (1.43%)</td>
<td>177 (0.47%)</td>
<td>71 (0.74%)</td>
<td>7 (0.43%)</td>
<td>11305 (0.85%)</td>
<td>103 (0.75%)</td>
<td>56 (1.05%)</td>
</tr>
<tr>
<td><strong>Total cardiovascular disease</strong></td>
<td>68 (1.87%)</td>
<td>288 (0.76%)</td>
<td>99 (1.04%)</td>
<td>20 (1.23%)</td>
<td>16059 (1.21%)</td>
<td>154 (1.13%)</td>
<td>85 (1.60%)</td>
</tr>
<tr>
<td><strong>Fractures</strong>(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip fracture</td>
<td>4 (0.11%)</td>
<td>28 (0.07%)</td>
<td>15 (0.16%)</td>
<td>0 (0.00%)</td>
<td>2868 (0.22%)</td>
<td>26 (0.19%)</td>
<td>14 (0.26%)</td>
</tr>
</tbody>
</table>

\(^1\) The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

\(^2\) Native Hawaiian/Other Pacific Islander SRC Super Cohort participants (n=79) are combined with Asian SRC Super Cohort participants for reporting purposes due to small numbers.

\(^3\) Cardiovascular diseases and hip fracture are not adjudicated for SRC Super Cohort participants during the WHI Extension Study 2010-2025. Reported statistics represent experience during the original program and the Extension Study 2005-2010.

\(^4\) “CHD” includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Study 2005-2010.

\(^5\) “CHD death” includes definite and possible CHD death.

\(^6\) Angina and CHF are not verified outcomes in the WHI Extension Study 2005-2010. Reported statistics represent experience during the original program.

\(^7\) “Coronary disease” includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, and CABG/PTCA; Q-wave MI, angina and congestive heart failure were not collected in the WHI Extension Study 2005-2010.
### Table 3.5 (continued)
Verified Outcomes (Annualized Percentages) by Race/Ethnicity for SRC Super Cohort Participants

Data as of: March 6, 2021; Events through September 30, 2010 and March 6, 2021

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander</th>
<th>Hispanic Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcomes through Extension Study 2010-2025</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number randomized</td>
<td>379</td>
<td>3558</td>
<td>787</td>
<td>142</td>
<td>111050</td>
<td>1119</td>
<td>599</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>150.9</td>
<td>174.2</td>
<td>207.9</td>
<td>188.0</td>
<td>205.1</td>
<td>208.8</td>
<td>136.1</td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>20 (0.42%)</td>
<td>241 (0.47%)</td>
<td>68 (0.50%)</td>
<td>10 (0.45%)</td>
<td>10410 (0.55%)</td>
<td>82 (0.42%)</td>
<td>35 (0.52%)</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>17 (0.36%)</td>
<td>197 (0.38%)</td>
<td>54 (0.40%)</td>
<td>8 (0.36%)</td>
<td>8768 (0.46%)</td>
<td>73 (0.37%)</td>
<td>28 (0.41%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>4 (0.08%)</td>
<td>47 (0.09%)</td>
<td>15 (0.11%)</td>
<td>2 (0.09%)</td>
<td>1815 (0.10%)</td>
<td>11 (0.06%)</td>
<td>8 (0.12%)</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>3 (0.06%)</td>
<td>14 (0.03%)</td>
<td>3 (0.02%)</td>
<td>1 (0.04%)</td>
<td>1016 (0.05%)</td>
<td>6 (0.03%)</td>
<td>9 (0.13%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>8 (0.17%)</td>
<td>44 (0.09%)</td>
<td>18 (0.13%)</td>
<td>3 (0.13%)</td>
<td>2421 (0.13%)</td>
<td>15 (0.08%)</td>
<td>9 (0.13%)</td>
</tr>
<tr>
<td>Other cancer</td>
<td>31 (0.65%)</td>
<td>231 (0.45%)</td>
<td>66 (0.48%)</td>
<td>14 (0.63%)</td>
<td>13790 (0.73%)</td>
<td>103 (0.53%)</td>
<td>63 (0.93%)</td>
</tr>
<tr>
<td><strong>Total cancer</strong></td>
<td>59 (1.24%)</td>
<td>510 (0.99%)</td>
<td>145 (1.06%)</td>
<td>25 (1.12%)</td>
<td>26478 (1.40%)</td>
<td>204 (1.05%)</td>
<td>111 (1.63%)</td>
</tr>
<tr>
<td><strong>Deaths</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular deaths</td>
<td>31 (0.65%)</td>
<td>180 (0.35%)</td>
<td>47 (0.34%)</td>
<td>10 (0.45%)</td>
<td>10250 (0.54%)</td>
<td>77 (0.40%)</td>
<td>57 (0.84%)</td>
</tr>
<tr>
<td>Cancer deaths</td>
<td>26 (0.55%)</td>
<td>177 (0.34%)</td>
<td>27 (0.20%)</td>
<td>5 (0.22%)</td>
<td>9565 (0.50%)</td>
<td>60 (0.31%)</td>
<td>57 (0.84%)</td>
</tr>
<tr>
<td>Other known cause</td>
<td>50 (1.05%)</td>
<td>169 (0.33%)</td>
<td>80 (0.59%)</td>
<td>5 (0.22%)</td>
<td>12171 (0.64%)</td>
<td>108 (0.55%)</td>
<td>49 (0.72%)</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>5 (0.10%)</td>
<td>32 (0.06%)</td>
<td>12 (0.09%)</td>
<td>3 (0.13%)</td>
<td>2349 (0.12%)</td>
<td>23 (0.12%)</td>
<td>2 (0.03%)</td>
</tr>
<tr>
<td><strong>Total death</strong></td>
<td>187 (2.72%)</td>
<td>1172 (1.59%)</td>
<td>296 (1.78%)</td>
<td>51 (1.75%)</td>
<td>50100 (2.25%)</td>
<td>428 (1.83%)</td>
<td>313 (2.97%)</td>
</tr>
</tbody>
</table>

1 The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

2 Native Hawaiian/Other Pacific Islander SRC Super Cohort participants (n=79) are combined with Asian SRC Super Cohort participants for reporting purposes due to small numbers.

3 Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

4 Only one report of “other cancer” is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

5 Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.
Table 3.6
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>MRC Super Cohort</th>
<th>SRC Super Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>44174</td>
<td>117634</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>185.8</td>
<td>203.7</td>
</tr>
<tr>
<td>Overall cancer</td>
<td>8394 (1.23%)</td>
<td>27504 (1.38%)</td>
</tr>
<tr>
<td>Primary cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>3042 (0.44%)</td>
<td>10866 (0.54%)</td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>2505 (0.37%)</td>
<td>9145 (0.46%)</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>595 (0.09%)</td>
<td>1902 (0.10%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>289 (0.04%)</td>
<td>1052 (0.05%)</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>342 (0.09%)</td>
<td>1544 (0.13%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>983 (0.14%)</td>
<td>2518 (0.13%)</td>
</tr>
<tr>
<td>Other cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accessory sinus</td>
<td>3 (&lt;0.01%)</td>
<td>13 (&lt;0.01%)</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>5 (&lt;0.01%)</td>
<td>12 (&lt;0.01%)</td>
</tr>
<tr>
<td>Anus</td>
<td>32 (&lt;0.01%)</td>
<td>105 (0.01%)</td>
</tr>
<tr>
<td>Appendix</td>
<td>13 (&lt;0.01%)</td>
<td>36 (&lt;0.01%)</td>
</tr>
<tr>
<td>Base of tongue</td>
<td>9 (&lt;0.01%)</td>
<td>26 (&lt;0.01%)</td>
</tr>
<tr>
<td>Biliary tract, parts of (other/ unspecified)</td>
<td>62 (0.01%)</td>
<td>146 (0.01%)</td>
</tr>
<tr>
<td>Bladder</td>
<td>270 (0.04%)</td>
<td>840 (0.04%)</td>
</tr>
<tr>
<td>Bones/joints/articular cartilage (limbs)</td>
<td>2 (&lt;0.01%)</td>
<td>12 (&lt;0.01%)</td>
</tr>
<tr>
<td>Bones/joints/articular cartilage (other)</td>
<td>9 (&lt;0.01%)</td>
<td>21 (&lt;0.01%)</td>
</tr>
<tr>
<td>Brain</td>
<td>72 (0.01%)</td>
<td>323 (0.02%)</td>
</tr>
<tr>
<td>Cervix</td>
<td>45 (0.01%)</td>
<td>89 (&lt;0.01%)</td>
</tr>
<tr>
<td>Central Nervous System (excludes brain)</td>
<td>1 (&lt;0.01%)</td>
<td>4 (&lt;0.01%)</td>
</tr>
<tr>
<td>Connective/subcutaneous/soft tissues</td>
<td>46 (0.01%)</td>
<td>162 (0.01%)</td>
</tr>
<tr>
<td>Endocrine glands, related structures</td>
<td>0 (0.00%)</td>
<td>5 (&lt;0.01%)</td>
</tr>
<tr>
<td>Esophagus</td>
<td>48 (0.01%)</td>
<td>146 (0.01%)</td>
</tr>
<tr>
<td>Eye and adnexa</td>
<td>24 (&lt;0.01%)</td>
<td>59 (&lt;0.01%)</td>
</tr>
<tr>
<td>Floor of Mouth</td>
<td>7 (&lt;0.01%)</td>
<td>11 (&lt;0.01%)</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>47 (0.01%)</td>
<td>103 (0.01%)</td>
</tr>
<tr>
<td>Genital organs</td>
<td>84 (0.01%)</td>
<td>323 (0.02%)</td>
</tr>
<tr>
<td>Gum</td>
<td>8 (&lt;0.01%)</td>
<td>42 (&lt;0.01%)</td>
</tr>
<tr>
<td>Heart</td>
<td>5 (&lt;0.01%)</td>
<td>35 (&lt;0.01%)</td>
</tr>
<tr>
<td>Kidney</td>
<td>212 (0.03%)</td>
<td>582 (0.03%)</td>
</tr>
<tr>
<td>Larynx</td>
<td>21 (&lt;0.01%)</td>
<td>34 (&lt;0.01%)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>279 (0.04%)</td>
<td>940 (0.05%)</td>
</tr>
<tr>
<td>Liver</td>
<td>106 (0.02%)</td>
<td>253 (0.01%)</td>
</tr>
<tr>
<td>Lung</td>
<td>1205 (0.18%)</td>
<td>3205 (0.16%)</td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>1 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
</tr>
<tr>
<td>Lymphoma, Hodgkins</td>
<td>24 (&lt;0.01%)</td>
<td>58 (&lt;0.01%)</td>
</tr>
<tr>
<td>Lymphoma, non-Hodgkins</td>
<td>404 (0.06%)</td>
<td>1535 (0.08%)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>395 (0.06%)</td>
<td>2350 (0.12%)</td>
</tr>
<tr>
<td>Meninges</td>
<td>2 (&lt;0.01%)</td>
<td>6 (&lt;0.01%)</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>216 (0.03%)</td>
<td>464 (0.02%)</td>
</tr>
<tr>
<td>Mycosis fungoides</td>
<td>8 (&lt;0.01%)</td>
<td>21 (&lt;0.01%)</td>
</tr>
<tr>
<td>Nasal cavity mid ear</td>
<td>2 (&lt;0.01%)</td>
<td>19 (&lt;0.01%)</td>
</tr>
<tr>
<td>Oral (mouth)</td>
<td>9 (&lt;0.01%)</td>
<td>36 (&lt;0.01%)</td>
</tr>
<tr>
<td>Other digestive cancer</td>
<td>14 (&lt;0.01%)</td>
<td>50 (&lt;0.01%)</td>
</tr>
<tr>
<td>Other lip</td>
<td>7 (&lt;0.01%)</td>
<td>9 (&lt;0.01%)</td>
</tr>
<tr>
<td>Palate</td>
<td>7 (&lt;0.01%)</td>
<td>27 (&lt;0.01%)</td>
</tr>
</tbody>
</table>

1 The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.
2 The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.
3 Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.
### Table 3.6 (continued)
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Number of participants</th>
<th>MRC Super Cohort</th>
<th>SRC Super Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean follow-up (months)</td>
<td>44174</td>
<td>117634</td>
</tr>
<tr>
<td>Pancreas</td>
<td>360 (0.05%)</td>
<td>1020 (0.05%)</td>
</tr>
<tr>
<td>Parotid gland (Stensen’s duct)</td>
<td>15 (&lt;0.01%)</td>
<td>52 (&lt;0.01%)</td>
</tr>
<tr>
<td>Peripheral nerves and autonomic nervous</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
</tr>
<tr>
<td>Peritoneum</td>
<td>54 (0.01%)</td>
<td>179 (0.01%)</td>
</tr>
<tr>
<td>Pharynx</td>
<td>12 (&lt;0.01%)</td>
<td>19 (&lt;0.01%)</td>
</tr>
<tr>
<td>Pyriform sinus</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
</tr>
<tr>
<td>Renal pelvis</td>
<td>38 (0.01%)</td>
<td>99 (&lt;0.01%)</td>
</tr>
<tr>
<td>Respiratory system, intrathoracic, other</td>
<td>0 (0.00%)</td>
<td>3 (&lt;0.01%)</td>
</tr>
<tr>
<td>Salivary glands, major (other/unspecified)</td>
<td>4 (&lt;0.01%)</td>
<td>15 (&lt;0.01%)</td>
</tr>
<tr>
<td>Small intestine</td>
<td>42 (0.01%)</td>
<td>129 (0.01%)</td>
</tr>
<tr>
<td>Stomach</td>
<td>107 (0.02%)</td>
<td>225 (0.01%)</td>
</tr>
<tr>
<td>Thymus</td>
<td>3 (&lt;0.01%)</td>
<td>11 (&lt;0.01%)</td>
</tr>
<tr>
<td>Thyroid</td>
<td>110 (0.02%)</td>
<td>409 (0.02%)</td>
</tr>
<tr>
<td>Tongue, part of (other/unspecified)</td>
<td>15 (&lt;0.01%)</td>
<td>77 (&lt;0.01%)</td>
</tr>
<tr>
<td>Tonsil</td>
<td>3 (&lt;0.01%)</td>
<td>20 (&lt;0.01%)</td>
</tr>
<tr>
<td>Trachea</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Ureter</td>
<td>20 (&lt;0.01%)</td>
<td>70 (&lt;0.01%)</td>
</tr>
<tr>
<td>Urinary organs (other/unspecified)</td>
<td>13 (&lt;0.01%)</td>
<td>27 (&lt;0.01%)</td>
</tr>
<tr>
<td>Uterus, not otherwise specified</td>
<td>35 (0.01%)</td>
<td>109 (0.01%)</td>
</tr>
<tr>
<td>Other/unknown site of cancer</td>
<td>143 (0.02%)</td>
<td>441 (0.02%)</td>
</tr>
<tr>
<td>Other/unknown cancers reported on death form</td>
<td>102 (0.01%)</td>
<td>403 (0.02%)</td>
</tr>
</tbody>
</table>

---

1. The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.
2. The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.
3. Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.
### Table 3.7
Verified Outcomes (Annualized Percentages)\(^1\) by **Age at Diagnosis** for **CT and OS Participants**

Data as of: March 6, 2021; Events between January 1, 2000 and December 31, 2019 or January 1, 2000 and September 30, 2010

<table>
<thead>
<tr>
<th>Cancer and Death Outcomes between 1/1/2000 and 12/31/2019</th>
<th>Age at Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of participants(^2)</strong></td>
<td>50-59</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>30.9</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>359 (0.49%)</td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>281 (0.38%)</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>80 (0.11%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>26 (0.04%)</td>
</tr>
<tr>
<td>Endometrial cancer(^3)</td>
<td>32 (0.08%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>35 (0.05%)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>6 (0.01%)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>33 (0.04%)</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>18 (0.02%)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>49 (0.07%)</td>
</tr>
<tr>
<td>Pancreas cancer</td>
<td>10 (0.01%)</td>
</tr>
<tr>
<td>Total cancer</td>
<td>644 (0.88%)</td>
</tr>
<tr>
<td><strong>Total death(^4)</strong></td>
<td>221 (0.30%)</td>
</tr>
</tbody>
</table>

| Cardiovascular Outcomes between 1/1/2000 and 9/30/2010 |
|--------------------------------|------------------|
| **Number of participants\(^2\)** | 22435 | 50703 | 75664 | 80683 | 65949 | 40705 | 15580 | 2664 |
| Mean follow-up (months) | 31.1 | 41.6 | 41.9 | 40.6 | 40.8 | 38.3 | 31.0 | 17.6 |
| CHD\(^5\) | 35 (0.06%) | 131 (0.07%) | 307 (0.12%) | 396 (0.14%) | 458 (0.20%) | 379 (0.29%) | 166 (0.41%) | 28 (0.72%) |
| Clinical MI | 25 (0.04%) | 97 (0.06%) | 231 (0.09%) | 298 (0.11%) | 326 (0.15%) | 248 (0.19%) | 95 (0.24%) | 11 (0.28%) |
| CABG/PTCA | 48 (0.08%) | 178 (0.10%) | 395 (0.15%) | 479 (0.18%) | 465 (0.21%) | 288 (0.22%) | 58 (0.14%) | 0 (0.00%) |
| Stroke | 26 (0.04%) | 100 (0.06%) | 191 (0.07%) | 303 (0.11%) | 364 (0.16%) | 315 (0.24%) | 124 (0.31%) | 22 (0.56%) |
| Total cardiovascular\(^6\) | 157 (0.27%) | 493 (0.28%) | 980 (0.37%) | 1252 (0.46%) | 1342 (0.60%) | 999 (0.77%) | 344 (0.86%) | 58 (0.18%) |

---

\(^1\) Annualized percentages calculated as the number with an event in the age interval divided by the total person years of all participants with time in the interval.

\(^2\) Number of participants with any follow-up time in the age interval.

\(^3\) Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

\(^4\) Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.

\(^5\) “CHD” includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the OS or in the WHI Extension Study 2005-2010.

\(^6\) Total cardiovascular disease includes CHD, angina, CABG/PTCA, carotid artery disease, CHF, stroke, PAD and CVD death. Angina and CHF are not verified outcomes in the WHI Extension Study 2005-2010.
### Table 3.8
Verified Primary and Other Cancers (Annualized Percentages): CT and OS Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Table 3.8</th>
<th>Verified Primary and Other Cancers (Annualized Percentages): CT and OS Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT</td>
<td>OS</td>
</tr>
<tr>
<td>Number of participants</td>
<td>68132</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>207.7</td>
</tr>
<tr>
<td>Overall cancer</td>
<td>15387 (1.30%)</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>5806 (0.49%)</td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>4822 (0.41%)</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>1095 (0.09%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>545 (0.05%)</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>798 (0.11%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>1602 (0.14%)</td>
</tr>
<tr>
<td>Accessory sinus</td>
<td>6 (&lt;0.01%)</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>7 (&lt;0.01%)</td>
</tr>
<tr>
<td>Anus</td>
<td>59 (0.01%)</td>
</tr>
<tr>
<td>Appendix</td>
<td>25 (&lt;0.01%)</td>
</tr>
<tr>
<td>Base of tongue</td>
<td>17 (&lt;0.01%)</td>
</tr>
<tr>
<td>Biliary tract, parts of (other/unspecified)</td>
<td>102 (0.01%)</td>
</tr>
<tr>
<td>Bladder</td>
<td>514 (0.04%)</td>
</tr>
<tr>
<td>Bones/joints/articular cartilage (limbs)</td>
<td>7 (&lt;0.01%)</td>
</tr>
<tr>
<td>Bones/joints/articular cartilage (other)</td>
<td>15 (&lt;0.01%)</td>
</tr>
<tr>
<td>Brain</td>
<td>174 (0.01%)</td>
</tr>
<tr>
<td>Cervix</td>
<td>65 (0.01%)</td>
</tr>
<tr>
<td>Central Nervous System (excludes brain)</td>
<td>1 (&lt;0.01%)</td>
</tr>
<tr>
<td>Connective/subcutaneous/soft tissues</td>
<td>97 (0.01%)</td>
</tr>
<tr>
<td>Endocrine glands, related structures</td>
<td>1 (&lt;0.01%)</td>
</tr>
<tr>
<td>Esophagus</td>
<td>88 (0.01%)</td>
</tr>
<tr>
<td>Eye and adnexa</td>
<td>48 (&lt;0.01%)</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>10 (&lt;0.01%)</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>85 (0.01%)</td>
</tr>
<tr>
<td>Genital organs</td>
<td>168 (0.01%)</td>
</tr>
<tr>
<td>Gum</td>
<td>22 (&lt;0.01%)</td>
</tr>
<tr>
<td>Heart</td>
<td>12 (&lt;0.01%)</td>
</tr>
<tr>
<td>Kidney</td>
<td>377 (0.03%)</td>
</tr>
<tr>
<td>Larynx</td>
<td>28 (&lt;0.01%)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>534 (0.05%)</td>
</tr>
<tr>
<td>Liver</td>
<td>152 (0.01%)</td>
</tr>
<tr>
<td>Lung</td>
<td>1903 (0.16%)</td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>2 (&lt;0.01%)</td>
</tr>
<tr>
<td>Lymphoma, Hodgkins</td>
<td>31 (&lt;0.01%)</td>
</tr>
<tr>
<td>Lymphoma, non-Hodgkins</td>
<td>807 (0.07%)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>1175 (0.10%)</td>
</tr>
<tr>
<td>Meninges</td>
<td>3 (&lt;0.01%)</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>302 (0.03%)</td>
</tr>
<tr>
<td>Mycosis fungoides</td>
<td>10 (&lt;0.01%)</td>
</tr>
<tr>
<td>Nasal cavity mid ear</td>
<td>8 (&lt;0.01%)</td>
</tr>
<tr>
<td>Oral (mouth)</td>
<td>24 (&lt;0.01%)</td>
</tr>
<tr>
<td>Other digestive cancer</td>
<td>31 (&lt;0.01%)</td>
</tr>
</tbody>
</table>

1 Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.
Table 3.8 (continued)
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>CT</th>
<th>OS</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>68132</td>
<td>93676</td>
<td>161808</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>207.7</td>
<td>192.3</td>
<td>198.8</td>
</tr>
<tr>
<td>Other lip</td>
<td>7 (&lt;0.01%)</td>
<td>9 (&lt;0.01%)</td>
<td>16 (&lt;0.01%)</td>
</tr>
<tr>
<td>Palate</td>
<td>13 (&lt;0.01%)</td>
<td>21 (&lt;0.01%)</td>
<td>34 (&lt;0.01%)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>612 (0.05%)</td>
<td>768 (0.05%)</td>
<td>1380 (0.05%)</td>
</tr>
<tr>
<td>Parotid gland (Stensen's duct)</td>
<td>27 (&lt;0.01%)</td>
<td>40 (&lt;0.01%)</td>
<td>67 (&lt;0.01%)</td>
</tr>
<tr>
<td>Peripheral nerves and autonomic nervous</td>
<td>1 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
</tr>
<tr>
<td>Peritoneum</td>
<td>95 (0.01%)</td>
<td>138 (0.01%)</td>
<td>233 (0.01%)</td>
</tr>
<tr>
<td>Pharynx</td>
<td>14 (&lt;0.01%)</td>
<td>17 (&lt;0.01%)</td>
<td>31 (&lt;0.01%)</td>
</tr>
<tr>
<td>Pyriform sinus</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
</tr>
<tr>
<td>Renal pelvis</td>
<td>64 (0.01%)</td>
<td>73 (&lt;0.01%)</td>
<td>137 (0.01%)</td>
</tr>
<tr>
<td>Respiratory system, intrathoracic, other</td>
<td>1 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
<td>3 (&lt;0.01%)</td>
</tr>
<tr>
<td>Salivary glands, major (other/unspecified)</td>
<td>6 (&lt;0.01%)</td>
<td>13 (&lt;0.01%)</td>
<td>19 (&lt;0.01%)</td>
</tr>
<tr>
<td>Small intestine</td>
<td>60 (0.01%)</td>
<td>111 (0.01%)</td>
<td>171 (0.01%)</td>
</tr>
<tr>
<td>Stomach</td>
<td>138 (0.01%)</td>
<td>194 (0.01%)</td>
<td>332 (0.01%)</td>
</tr>
<tr>
<td>Thymus</td>
<td>7 (&lt;0.01%)</td>
<td>7 (&lt;0.01%)</td>
<td>14 (&lt;0.01%)</td>
</tr>
<tr>
<td>Thyroid</td>
<td>220 (0.02%)</td>
<td>299 (0.02%)</td>
<td>519 (0.02%)</td>
</tr>
<tr>
<td>Tongue, part of (other/unspecified)</td>
<td>43 (&lt;0.01%)</td>
<td>49 (&lt;0.01%)</td>
<td>92 (&lt;0.01%)</td>
</tr>
<tr>
<td>Tonsil</td>
<td>10 (0.01%)</td>
<td>13 (&lt;0.01%)</td>
<td>23 (&lt;0.01%)</td>
</tr>
<tr>
<td>Trachea</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
</tr>
<tr>
<td>Ureter</td>
<td>45 (&lt;0.01%)</td>
<td>45 (&lt;0.01%)</td>
<td>90 (&lt;0.01%)</td>
</tr>
<tr>
<td>Urinary organs (other/unspecified)</td>
<td>18 (&lt;0.01%)</td>
<td>22 (&lt;0.01%)</td>
<td>40 (&lt;0.01%)</td>
</tr>
<tr>
<td>Uterus, not otherwise specified(^1)</td>
<td>61 (0.01%)</td>
<td>83 (0.01%)</td>
<td>144 (0.01%)</td>
</tr>
<tr>
<td>Other/unknown site of cancer</td>
<td>259 (0.02%)</td>
<td>325 (0.02%)</td>
<td>584 (0.02%)</td>
</tr>
<tr>
<td>Other/unknown cancers reported on death form</td>
<td>169 (0.01%)</td>
<td>336 (0.02%)</td>
<td>505 (0.02%)</td>
</tr>
</tbody>
</table>

\(^1\) Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.
## Table 3.9
Verified Primary and Other Cancers (Annualized Percentages) by Race/Ethnicity for CT and OS Participants
Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander(^1)</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>487</td>
<td>4084</td>
<td>7312</td>
<td>14167</td>
<td>133328</td>
<td>1669</td>
<td>761</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>154.5</td>
<td>174.9</td>
<td>166.5</td>
<td>169.3</td>
<td>204.8</td>
<td>208.2</td>
<td>142.1</td>
</tr>
<tr>
<td>Overall cancer</td>
<td>81 (1.29%)</td>
<td>607 (1.02%)</td>
<td>945 (0.93%)</td>
<td>2299 (1.15%)</td>
<td>31521 (1.39%)</td>
<td>309 (1.07%)</td>
<td>136 (1.14%)</td>
</tr>
<tr>
<td>Primary cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrial cancer(^2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accessory sinus</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>15 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
<td>14 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Anus</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>6 (0.01%)</td>
<td>10 (0.01%)</td>
<td>119 (0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Appendix</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>3 (&lt;0.01%)</td>
<td>4 (&lt;0.01%)</td>
<td>41 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Base of Tongue</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>32 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Biliary tract, parts of (other/unspecified)</td>
<td>1 (0.02%)</td>
<td>2 (&lt;0.01%)</td>
<td>14 (0.01%)</td>
<td>14 (0.01%)</td>
<td>174 (0.01%)</td>
<td>2 (0.01%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Bladder</td>
<td>1 (0.02%)</td>
<td>11 (0.02%)</td>
<td>18 (0.02%)</td>
<td>63 (0.03%)</td>
<td>1004 (0.04%)</td>
<td>12 (0.04%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Bones/joints/articular cartilage (limbs)</td>
<td>1 (0.02%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>12 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Bones/joints/articular cartilage (other)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>26 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Brain</td>
<td>1 (0.02%)</td>
<td>5 (0.01%)</td>
<td>7 (0.01%)</td>
<td>14 (0.01%)</td>
<td>367 (0.02%)</td>
<td>0 (0.00%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Cervix</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>6 (0.01%)</td>
<td>20 (0.01%)</td>
<td>105 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Central Nervous System (excludes brain)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>5 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Connective/subcutaneous/soft tissues</td>
<td>0 (0.00%)</td>
<td>4 (0.01%)</td>
<td>5 (&lt;0.01%)</td>
<td>9 (&lt;0.01%)</td>
<td>186 (0.01%)</td>
<td>3 (0.01%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Endocrine glands, related structures</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>5 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Esophagus</td>
<td>1 (0.02%)</td>
<td>1 (&lt;0.01%)</td>
<td>3 (&lt;0.01%)</td>
<td>9 (&lt;0.01%)</td>
<td>176 (0.01%)</td>
<td>3 (0.01%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Eye and adnexa</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>4 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>77 (&lt;0.01%)</td>
<td>2 (0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
<td>13 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>8 (0.01%)</td>
<td>11 (0.01%)</td>
<td>129 (0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
</tr>
</tbody>
</table>

\(^1\) Native Hawaiian/Other Pacific Islander CT and OS participants (n=119) are combined with Asian CT and OS participants for reporting purposes due to small numbers.

\(^2\) Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.
### Table 3.9 (continued)

**Verified Primary and Other Cancers (Annualized Percentages) by Race/Ethnicity: CT and OS Participants**

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander¹</th>
<th>Hispanic /Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of participants</strong></td>
<td>487</td>
<td>4084</td>
<td>7312</td>
<td>14167</td>
<td>133328</td>
<td>1669</td>
<td>761</td>
</tr>
<tr>
<td><strong>Mean follow-up (months)</strong></td>
<td>154.5</td>
<td>174.9</td>
<td>166.5</td>
<td>169.3</td>
<td>204.8</td>
<td>208.2</td>
<td>142.1</td>
</tr>
<tr>
<td>Genital organs</td>
<td>1 (0.02%)</td>
<td>0 (&lt;0.01%)</td>
<td>17 (0.01%)</td>
<td>363 (0.02%)</td>
<td>3 (0.01%)</td>
<td>1 (0.01%)</td>
<td></td>
</tr>
<tr>
<td>Gum</td>
<td>0 (0.00%)</td>
<td>0 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
<td>45 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td>0 (0.00%)</td>
<td>0 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>40 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>7 (0.11%)</td>
<td>14 (0.02%)</td>
<td>60 (0.03%)</td>
<td>678 (0.03%)</td>
<td>8 (0.03%)</td>
<td>4 (0.04%)</td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td>0 (0.00%)</td>
<td>0 (&lt;0.01%)</td>
<td>6 (&lt;0.01%)</td>
<td>49 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>2 (0.03%)</td>
<td>16 (0.03%)</td>
<td>25 (0.02%)</td>
<td>1095 (0.05%)</td>
<td>13 (0.04%)</td>
<td>6 (0.07%)</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>3 (0.05%)</td>
<td>15 (0.03%)</td>
<td>21 (0.02%)</td>
<td>285 (0.01%)</td>
<td>3 (0.01%)</td>
<td>3 (0.03%)</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>12 (0.19%)</td>
<td>62 (0.10%)</td>
<td>85 (0.08%)</td>
<td>3897 (0.17%)</td>
<td>36 (0.12%)</td>
<td>21 (0.23%)</td>
<td></td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>0 (0.00%)</td>
<td>0 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>3 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Lymphoma, Hodgkins</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>4 (&lt;0.01%)</td>
<td>67 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>1 (0.01%)</td>
<td></td>
</tr>
<tr>
<td>Lymphoma, non-Hodgkins</td>
<td>1 (0.02%)</td>
<td>38 (0.06%)</td>
<td>71 (0.04%)</td>
<td>1750 (0.08%)</td>
<td>7 (0.02%)</td>
<td>8 (0.09%)</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>2 (0.03%)</td>
<td>7 (0.01%)</td>
<td>23 (0.02%)</td>
<td>2682 (0.12%)</td>
<td>18 (0.06%)</td>
<td>4 (0.04%)</td>
<td></td>
</tr>
<tr>
<td>Meninges</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>8 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>2 (0.03%)</td>
<td>3 (0.01%)</td>
<td>83 (0.04%)</td>
<td>555 (0.02%)</td>
<td>8 (0.03%)</td>
<td>3 (0.03%)</td>
<td></td>
</tr>
<tr>
<td>Mycosis fungoides</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>25 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Nasal cavity mid ear</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>21 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Oral (mouth)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>40 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Other digestive cancer</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>58 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>1 (0.01%)</td>
<td></td>
</tr>
<tr>
<td>Other lip</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>15 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Palate</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>33 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>1 (0.02%)</td>
<td>39 (0.07%)</td>
<td>116 (0.06%)</td>
<td>1166 (0.05%)</td>
<td>16 (0.06%)</td>
<td>6 (0.07%)</td>
<td></td>
</tr>
<tr>
<td>Parotid gland (Stensen's duct)</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>56 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Peripheral nerves and autonomic nervous system</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td></td>
</tr>
<tr>
<td>Peritoneum</td>
<td>1 (0.02%)</td>
<td>2 (&lt;0.01%)</td>
<td>8 (0.01%)</td>
<td>205 (0.01%)</td>
<td>2 (0.01%)</td>
<td>1 (0.01%)</td>
<td></td>
</tr>
</tbody>
</table>

¹ Native Hawaiian/Other Pacific Islander CT and OS participants (n=119) are combined with Asian CT and OS participants for reporting purposes due to small numbers.
## Table 3.9 (continued)
**Verified Primary and Other Cancers (Annualized Percentages) by Race/Ethnicity: CT and OS Participants**

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean follow-up (months)</td>
<td>154.5</td>
<td>174.9</td>
<td>166.5</td>
<td>169.3</td>
<td>204.8</td>
<td>208.2</td>
<td>142.1</td>
</tr>
<tr>
<td>Pharynx</td>
<td>0 (0.00%)</td>
<td>0 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>3 (&lt;0.01%)</td>
<td>28 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Pyriform sinus</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>10 (0.01%)</td>
<td>121 (0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Renal Pelvis</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>3 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Respiratory system, intrathoracic, other (other/unspecified)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>19 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Salivary glands, major</td>
<td>0 (0.00%)</td>
<td>3 (0.01%)</td>
<td>0 (0.00%)</td>
<td>13 (0.01%)</td>
<td>149 (0.01%)</td>
<td>2 (0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Stomach</td>
<td>0 (0.00%)</td>
<td>15 (0.03%)</td>
<td>11 (0.01%)</td>
<td>47 (0.02%)</td>
<td>250 (0.01%)</td>
<td>7 (0.02%)</td>
<td>2 (0.02%)</td>
</tr>
<tr>
<td>Thymus</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>12 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0 (0.00%)</td>
<td>8 (0.01%)</td>
<td>14 (0.01%)</td>
<td>37 (0.02%)</td>
<td>457 (0.02%)</td>
<td>3 (0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Tongue, part of (other/unspecified)</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>2 (&lt;0.01%)</td>
<td>85 (&lt;0.01%)</td>
<td>2 (0.01%)</td>
<td>1 (0.01%)</td>
</tr>
<tr>
<td>Tonsil</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>21 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Trachea</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Ureter</td>
<td>1 (0.02%)</td>
<td>3 (0.01%)</td>
<td>2 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>81 (&lt;0.01%)</td>
<td>2 (0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Urinary organs (other/unspecified)</td>
<td>1 (0.02%)</td>
<td>2 (&lt;0.01%)</td>
<td>2 (&lt;0.01%)</td>
<td>4 (&lt;0.01%)</td>
<td>30 (&lt;0.01%)</td>
<td>1 (&lt;0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Uterus, not otherwise specified</td>
<td>1 (0.03%)</td>
<td>4 (0.01%)</td>
<td>5 (0.01%)</td>
<td>16 (0.02%)</td>
<td>117 (0.01%)</td>
<td>1 (0.01%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Other/unknown site of cancer</td>
<td>3 (0.05%)</td>
<td>11 (0.02%)</td>
<td>15 (0.01%)</td>
<td>39 (0.02%)</td>
<td>509 (0.02%)</td>
<td>2 (0.01%)</td>
<td>5 (0.06%)</td>
</tr>
<tr>
<td>Other/unknown cancers reported on death form</td>
<td>5 (0.08%)</td>
<td>8 (0.01%)</td>
<td>13 (0.01%)</td>
<td>39 (0.02%)</td>
<td>434 (0.02%)</td>
<td>2 (0.01%)</td>
<td>4 (0.04%)</td>
</tr>
</tbody>
</table>

1 Native Hawaiian/Other Pacific Islander CT and OS participants (n=119) are combined with Asian CT and OS participants for reporting purposes due to small numbers.
2 Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.
### Table 4.1
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment for MRC Super Cohort Participants\(^1\) Who Did Not Report a Prevalent Condition at Baseline

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total</th>
<th>50-54</th>
<th>55-59</th>
<th>60-69</th>
<th>70-79</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>44174</td>
<td>6788</td>
<td>9352</td>
<td>19418</td>
<td>8616</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>184.4</td>
<td>198.6</td>
<td>199.2</td>
<td>185.5</td>
<td>154.6</td>
</tr>
<tr>
<td>Angina (hospitalized)(^2)</td>
<td>3563 (0.55%)</td>
<td>448 (0.41%)</td>
<td>675 (0.45%)</td>
<td>1720 (0.61%)</td>
<td>720 (0.71%)</td>
</tr>
<tr>
<td>Diabetes (treated)</td>
<td>8161 (1.28%)</td>
<td>1447 (1.35%)</td>
<td>1869 (1.28%)</td>
<td>3691 (1.31%)</td>
<td>1154 (1.11%)</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>1921 (0.49%)</td>
<td>309 (0.51%)</td>
<td>482 (0.52%)</td>
<td>862 (0.50%)</td>
<td>268 (0.43%)</td>
</tr>
<tr>
<td>Osteoarthritis(^3)</td>
<td>14000 (3.29%)</td>
<td>2445 (2.90%)</td>
<td>3284 (3.07%)</td>
<td>6097 (3.42%)</td>
<td>2174 (3.85%)</td>
</tr>
<tr>
<td>Intestinal polyps</td>
<td>10813 (1.71%)</td>
<td>1820 (1.68%)</td>
<td>2577 (1.75%)</td>
<td>4888 (1.76%)</td>
<td>1528 (1.56%)</td>
</tr>
<tr>
<td>Lupus(^3)</td>
<td>811 (0.12%)</td>
<td>132 (0.12%)</td>
<td>181 (0.12%)</td>
<td>370 (0.13%)</td>
<td>128 (0.12%)</td>
</tr>
<tr>
<td>Hypertension treated w/pills</td>
<td>16655 (3.62%)</td>
<td>2750 (3.18%)</td>
<td>3744 (3.35%)</td>
<td>7267 (3.73%)</td>
<td>2894 (4.32%)</td>
</tr>
<tr>
<td>COPD(^4)</td>
<td>2778 (0.81%)</td>
<td>402 (0.68%)</td>
<td>661 (0.84%)</td>
<td>1372 (0.92%)</td>
<td>343 (0.65%)</td>
</tr>
<tr>
<td>Macular degeneration(^5)</td>
<td>5340 (1.08%)</td>
<td>485 (0.57%)</td>
<td>956 (0.83%)</td>
<td>2681 (1.23%)</td>
<td>1218 (1.60%)</td>
</tr>
<tr>
<td>Dementia(^5)</td>
<td>4811 (0.97%)</td>
<td>284 (0.33%)</td>
<td>615 (0.53%)</td>
<td>2459 (1.13%)</td>
<td>1453 (1.91%)</td>
</tr>
<tr>
<td>Parkinson’s disease(^5)</td>
<td>643 (0.13%)</td>
<td>68 (0.08%)</td>
<td>133 (0.12%)</td>
<td>331 (0.15%)</td>
<td>111 (0.15%)</td>
</tr>
</tbody>
</table>

---

\(^1\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

\(^2\) During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

\(^3\) This outcome has not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

\(^4\) Data only collected during the WHI Extension Study 2010-2025.

\(^5\) Data only collected during the WHI Extension Studies 2005-2025.
## Table 4.2

Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for MRC Super Cohort Participants\(^1\) Who Did Not Report a Prevalent Condition at Baseline

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander(^2)</th>
<th>Hispanic/Latina</th>
<th>Race/Ethnicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>108</td>
<td>526</td>
<td>6525</td>
<td>14025</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>166.6</td>
<td>178.0</td>
<td>160.1</td>
<td>167.6</td>
</tr>
<tr>
<td>Angina (hospitalized)(^3)</td>
<td>12 (0.85%)</td>
<td>24 (0.33%)</td>
<td>372 (0.45%)</td>
<td>1033 (0.57%)</td>
</tr>
<tr>
<td>Diabetes (treated)</td>
<td>18 (1.48%)</td>
<td>100 (1.36%)</td>
<td>1184 (1.44%)</td>
<td>2857 (1.62%)</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>2 (0.26%)</td>
<td>13 (0.24%)</td>
<td>292 (0.60%)</td>
<td>434 (0.50%)</td>
</tr>
<tr>
<td>Osteoarthritis(^4)</td>
<td>29 (3.53%)</td>
<td>178 (3.22%)</td>
<td>2118 (3.63%)</td>
<td>3972 (3.39%)</td>
</tr>
<tr>
<td>Intestinal polyps</td>
<td>26 (1.86%)</td>
<td>109 (1.54%)</td>
<td>1347 (1.64%)</td>
<td>3439 (1.90%)</td>
</tr>
<tr>
<td>Lupus(^4)</td>
<td>1 (0.07%)</td>
<td>4 (0.05%)</td>
<td>132 (0.16%)</td>
<td>280 (0.15%)</td>
</tr>
<tr>
<td>Hypertension treated w/pills</td>
<td>49 (5.00%)</td>
<td>196 (3.65%)</td>
<td>2407 (3.65%)</td>
<td>4231 (4.24%)</td>
</tr>
<tr>
<td>COPD(^5)</td>
<td>6 (0.75%)</td>
<td>19 (0.45%)</td>
<td>264 (0.50%)</td>
<td>689 (0.63%)</td>
</tr>
<tr>
<td>Macular degeneration(^6)</td>
<td>11 (0.89%)</td>
<td>42 (0.76%)</td>
<td>560 (0.77%)</td>
<td>932 (0.60%)</td>
</tr>
<tr>
<td>Dementia(^5)</td>
<td>7 (0.57%)</td>
<td>46 (0.84%)</td>
<td>506 (0.69%)</td>
<td>1089 (0.70%)</td>
</tr>
<tr>
<td>Parkinson’s disease(^6)</td>
<td>2 (0.16%)</td>
<td>8 (0.15%)</td>
<td>73 (0.10%)</td>
<td>148 (0.10%)</td>
</tr>
</tbody>
</table>

--

\(^1\) The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

\(^2\) Native Hawaiian/Other Pacific Islander MRC Super Cohort participants (n=40) are combined with Asian MRC Super Cohort participants for reporting purposes due to small numbers.

\(^3\) During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

\(^4\) This outcome has not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

\(^5\) Data only collected during the WHI Extension Study 2010-2025.

\(^6\) Data only collected during the WHI Extension Studies 2005-2025.
### Table 4.3
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment for SRC Super Cohort Participants\(^1\) Who Did Not Report a Prevalent Condition at Baseline

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total</th>
<th>50-54</th>
<th>55-59</th>
<th>60-69</th>
<th>70-79</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of participants</strong></td>
<td>117634</td>
<td>14781</td>
<td>22638</td>
<td>53171</td>
<td>27044</td>
</tr>
<tr>
<td><strong>Mean follow-up (months)</strong></td>
<td>202.0</td>
<td>234.3</td>
<td>228.3</td>
<td>203.7</td>
<td>159.1</td>
</tr>
<tr>
<td><strong>DVT</strong></td>
<td>4528 (0.24%)</td>
<td>413 (0.15%)</td>
<td>775 (0.19%)</td>
<td>2239 (0.26%)</td>
<td>1101 (0.32%)</td>
</tr>
<tr>
<td><strong>Pulmonary embolism(^2)</strong></td>
<td>2816 (0.14%)</td>
<td>278 (0.10%)</td>
<td>528 (0.12%)</td>
<td>1411 (0.16%)</td>
<td>599 (0.17%)</td>
</tr>
<tr>
<td><strong>Angina (hospitalized)(^3)</strong></td>
<td>9370 (0.49%)</td>
<td>849 (0.30%)</td>
<td>1634 (0.39%)</td>
<td>4728 (0.55%)</td>
<td>2159 (0.65%)</td>
</tr>
<tr>
<td><strong>Diabetes (treated)</strong></td>
<td>17724 (0.92%)</td>
<td>2494 (0.88%)</td>
<td>3817 (0.90%)</td>
<td>8348 (0.95%)</td>
<td>3065 (0.88%)</td>
</tr>
<tr>
<td><strong>Hysterectomy</strong></td>
<td>7027 (0.59%)</td>
<td>1123 (0.63%)</td>
<td>1724 (0.63%)</td>
<td>3185 (0.60%)</td>
<td>995 (0.49%)</td>
</tr>
<tr>
<td><strong>Osteoarthritis(^4)</strong></td>
<td>38711 (3.27%)</td>
<td>6049 (2.85%)</td>
<td>8838 (3.06%)</td>
<td>17315 (3.39%)</td>
<td>6509 (3.77%)</td>
</tr>
<tr>
<td><strong>Intestinal polyps</strong></td>
<td>30597 (1.69%)</td>
<td>4843 (1.75%)</td>
<td>7193 (1.77%)</td>
<td>13797 (1.69%)</td>
<td>4764 (1.53%)</td>
</tr>
<tr>
<td><strong>Lupus(^5)</strong></td>
<td>1946 (0.10%)</td>
<td>252 (0.09%)</td>
<td>406 (0.10%)</td>
<td>900 (0.10%)</td>
<td>388 (0.11%)</td>
</tr>
<tr>
<td><strong>Hypertension treated w/pills</strong></td>
<td>46079 (3.12%)</td>
<td>5999 (2.44%)</td>
<td>9499 (2.74%)</td>
<td>21269 (3.26%)</td>
<td>9312 (3.99%)</td>
</tr>
<tr>
<td><strong>COPD(^5)</strong></td>
<td>8082 (0.87%)</td>
<td>1006 (0.76%)</td>
<td>1755 (0.90%)</td>
<td>4217 (1.01%)</td>
<td>1104 (0.67%)</td>
</tr>
<tr>
<td><strong>Macular degeneration(^6)</strong></td>
<td>18671 (1.32%)</td>
<td>1432 (0.70%)</td>
<td>2922 (0.97%)</td>
<td>9648 (1.51%)</td>
<td>4669 (1.87%)</td>
</tr>
<tr>
<td><strong>Dementia(^6)</strong></td>
<td>13647 (0.97%)</td>
<td>604 (0.30%)</td>
<td>1576 (0.52%)</td>
<td>7176 (1.12%)</td>
<td>4291 (1.72%)</td>
</tr>
<tr>
<td><strong>Parkinson’s disease(^6)</strong></td>
<td>2367 (0.17%)</td>
<td>183 (0.09%)</td>
<td>437 (0.14%)</td>
<td>1315 (0.21%)</td>
<td>432 (0.17%)</td>
</tr>
</tbody>
</table>

---

\(^1\) The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

\(^2\) During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2025, pulmonary embolism includes both inpatient and outpatient self-reports.

\(^3\) During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

\(^4\) These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

\(^5\) Data only collected during the WHI Extension Study 2010-2025.

\(^6\) Data only collected during the WHI Extension Studies 2005-2025.
### Table 4.4
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for SRC Super Cohort Participants¹ Who Did Not Report a Prevalent Condition at Baseline

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Race/Ethnicity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>American Indian/Alaska Native</td>
</tr>
<tr>
<td>Number of participants</td>
<td>379</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>149.6 (0.11%)</td>
</tr>
<tr>
<td>DVT</td>
<td>5 (0.11%)</td>
</tr>
<tr>
<td>Pulmonary embolism³</td>
<td>7 (0.15%)</td>
</tr>
<tr>
<td>Angina (hospitalized)⁴</td>
<td>16 (0.37%)</td>
</tr>
<tr>
<td>Diabetes (treated)</td>
<td>65 (1.58%)</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>12 (0.50%)</td>
</tr>
<tr>
<td>Osteoarthritis⁵</td>
<td>97 (3.62%)</td>
</tr>
<tr>
<td>Intestinal polyps</td>
<td>70 (1.60%)</td>
</tr>
<tr>
<td>Lupus⁵</td>
<td>10 (0.22%)</td>
</tr>
<tr>
<td>Hypertension treated w/pills</td>
<td>119 (3.81%)</td>
</tr>
<tr>
<td>COPD⁶</td>
<td>17 (0.59%)</td>
</tr>
<tr>
<td>Macular degeneration⁷</td>
<td>27 (0.62%)</td>
</tr>
<tr>
<td>Dementia⁷</td>
<td>26 (0.59%)</td>
</tr>
<tr>
<td>Parkinson’s disease⁷</td>
<td>2 (0.05%)</td>
</tr>
</tbody>
</table>

¹ The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

² Native Hawaiian/Other Pacific Islander SRC Super Cohort participants (n=79) are combined with Asian SRC Super Cohort participants for reporting purposes due to small numbers.

³ During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2025, pulmonary embolism includes both inpatient and outpatient self-reports.

⁴ During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

⁵ These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

⁶ Data only collected during the WHI Extension Study 2010-2025.

⁷ Data only collected during the WHI Extension Studies 2005-2025.
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total</th>
<th>50-54</th>
<th>Age at Enrollment</th>
<th>55-59</th>
<th>60-69</th>
<th>70-79</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number randomized</td>
<td>68132</td>
<td>9188</td>
<td>14661</td>
<td>31389</td>
<td>12894</td>
<td></td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>206.1</td>
<td>229.3</td>
<td>225.1</td>
<td>206.5</td>
<td>167.3</td>
<td></td>
</tr>
<tr>
<td>Hospitalizations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever</td>
<td>51949</td>
<td>5881</td>
<td>10329</td>
<td>24902</td>
<td>10837</td>
<td>603%</td>
</tr>
<tr>
<td>Two or more</td>
<td>39854</td>
<td>4060</td>
<td>7572</td>
<td>19563</td>
<td>8659</td>
<td>482%</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVT</td>
<td>3052</td>
<td>267</td>
<td>590</td>
<td>1508</td>
<td>687</td>
<td>0.4%</td>
</tr>
<tr>
<td>Pulmonary embolism(^1)</td>
<td>1827</td>
<td>181</td>
<td>359</td>
<td>933</td>
<td>354</td>
<td>0.2%</td>
</tr>
<tr>
<td>Angina (hospitalized)(^2)</td>
<td>6066</td>
<td>625</td>
<td>1143</td>
<td>3085</td>
<td>1213</td>
<td>0.73%</td>
</tr>
<tr>
<td>Diabetes (treated)</td>
<td>12404</td>
<td>1915</td>
<td>2866</td>
<td>5849</td>
<td>1774</td>
<td>1.03%</td>
</tr>
<tr>
<td>Gallbladder disease(^3,4)</td>
<td>5248</td>
<td>746</td>
<td>1195</td>
<td>2463</td>
<td>844</td>
<td>1.05%</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>3800</td>
<td>589</td>
<td>986</td>
<td>1751</td>
<td>474</td>
<td>0.47%</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>7565</td>
<td>744</td>
<td>1457</td>
<td>3662</td>
<td>1702</td>
<td>2.24%</td>
</tr>
<tr>
<td>Osteoporosis(^4)</td>
<td>14697</td>
<td>1451</td>
<td>2635</td>
<td>7142</td>
<td>3469</td>
<td>4.72%</td>
</tr>
<tr>
<td>Osteoarthritis(^5)</td>
<td>23995</td>
<td>3895</td>
<td>5881</td>
<td>10825</td>
<td>3394</td>
<td>3.76%</td>
</tr>
<tr>
<td>Rheumatoid arthritis(^4)</td>
<td>4010</td>
<td>538</td>
<td>866</td>
<td>1822</td>
<td>784</td>
<td>0.84%</td>
</tr>
<tr>
<td>Intestinal polyps</td>
<td>18612</td>
<td>2959</td>
<td>4619</td>
<td>8606</td>
<td>2428</td>
<td>1.53%</td>
</tr>
<tr>
<td>Lupus(^6)</td>
<td>1165</td>
<td>158</td>
<td>277</td>
<td>549</td>
<td>181</td>
<td>0.10%</td>
</tr>
<tr>
<td>Kidney stones(^4,5)</td>
<td>1877</td>
<td>241</td>
<td>379</td>
<td>898</td>
<td>359</td>
<td>0.51%</td>
</tr>
<tr>
<td>Cataracts(^4,5)</td>
<td>21571</td>
<td>1468</td>
<td>3731</td>
<td>11650</td>
<td>4722</td>
<td>9.66%</td>
</tr>
<tr>
<td>Hypertension treated w/pills</td>
<td>27951</td>
<td>3950</td>
<td>6380</td>
<td>12985</td>
<td>4636</td>
<td>4.11%</td>
</tr>
<tr>
<td>COPD(^6)</td>
<td>4970</td>
<td>624</td>
<td>1158</td>
<td>2609</td>
<td>579</td>
<td>0.72%</td>
</tr>
<tr>
<td>Macular degeneration(^7)</td>
<td>10525</td>
<td>822</td>
<td>1846</td>
<td>5570</td>
<td>2287</td>
<td>1.97%</td>
</tr>
<tr>
<td>Dementia(^7)</td>
<td>8256</td>
<td>416</td>
<td>1046</td>
<td>4414</td>
<td>2380</td>
<td>2.05%</td>
</tr>
<tr>
<td>Parkinson’s disease(^2)</td>
<td>1249</td>
<td>106</td>
<td>274</td>
<td>681</td>
<td>188</td>
<td>0.16%</td>
</tr>
</tbody>
</table>

\(^1\) During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2025, pulmonary embolism includes both inpatient and outpatient self-reports.

\(^2\) During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

\(^3\) “Gallbladder disease” includes self-reports of both hospitalized and non-hospitalized events.

\(^4\) Data not collected for the WHI Extension Studies 2005-2025.

\(^5\) These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

\(^6\) Data not collected for the WHI Extension Studies 2005-2025.

\(^7\) Data only collected during the WHI Extension Study 2010-2025.
### Table 4.6
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for CT Participants Who Did Not Report a Prevalent Condition at Baseline

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number randomized</td>
<td>180</td>
<td>1465</td>
<td>3231</td>
<td>6748</td>
<td>55407</td>
<td>821</td>
<td>280</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>166.2</td>
<td>196.7</td>
<td>179.2</td>
<td>185.9</td>
<td>210.7</td>
<td>216.4</td>
<td>156.7</td>
</tr>
<tr>
<td><strong>Hospitalizations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever</td>
<td>124 (4.97%)</td>
<td>879 (3.66%)</td>
<td>1945 (4.03%)</td>
<td>4737 (4.53%)</td>
<td>43432 (4.47%)</td>
<td>641 (4.33%)</td>
<td>191 (5.22%)</td>
</tr>
<tr>
<td>Two or more</td>
<td>99 (3.97%)</td>
<td>544 (2.27%)</td>
<td>1291 (2.67%)</td>
<td>3403 (3.26%)</td>
<td>33875 (3.48%)</td>
<td>507 (3.42%)</td>
<td>135 (3.69%)</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVT</td>
<td>7 (0.30%)</td>
<td>17 (0.07%)</td>
<td>83 (0.18%)</td>
<td>310 (0.30%)</td>
<td>2572 (0.27%)</td>
<td>47 (0.33%)</td>
<td>16 (0.45%)</td>
</tr>
<tr>
<td>Pulmonary embolism^2</td>
<td>6 (0.25%)</td>
<td>6 (0.03%)</td>
<td>35 (0.07%)</td>
<td>173 (0.17%)</td>
<td>1577 (0.16%)</td>
<td>23 (0.16%)</td>
<td>7 (0.19%)</td>
</tr>
<tr>
<td>Angina (hospitalized)^3</td>
<td>12 (0.50%)</td>
<td>61 (0.26%)</td>
<td>211 (0.45%)</td>
<td>588 (0.60%)</td>
<td>5061 (0.54%)</td>
<td>119 (0.87%)</td>
<td>14 (0.41%)</td>
</tr>
<tr>
<td>Diabetes (treated)</td>
<td>31 (1.41%)</td>
<td>305 (1.34%)</td>
<td>682 (1.50%)</td>
<td>1571 (1.67%)</td>
<td>9583 (1.01%)</td>
<td>183 (1.33%)</td>
<td>49 (1.38%)</td>
</tr>
<tr>
<td>Gallbladder disease^4,5</td>
<td>16 (1.48%)</td>
<td>85 (0.82%)</td>
<td>270 (1.41%)</td>
<td>404 (0.85%)</td>
<td>4388 (1.18%)</td>
<td>73 (1.35%)</td>
<td>12 (0.71%)</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>4 (0.35%)</td>
<td>52 (0.33%)</td>
<td>159 (0.58%)</td>
<td>255 (0.56%)</td>
<td>3283 (0.56%)</td>
<td>38 (0.52%)</td>
<td>9 (0.41%)</td>
</tr>
<tr>
<td>Glaucoma^6</td>
<td>20 (1.86%)</td>
<td>148 (1.69%)</td>
<td>381 (1.92%)</td>
<td>964 (2.37%)</td>
<td>5923 (1.70%)</td>
<td>101 (1.96%)</td>
<td>28 (1.78%)</td>
</tr>
<tr>
<td>Osteoporosis^5</td>
<td>34 (3.18%)</td>
<td>374 (3.42%)</td>
<td>727 (3.78%)</td>
<td>879 (2.08%)</td>
<td>12468 (3.68%)</td>
<td>168 (3.38%)</td>
<td>47 (3.07%)</td>
</tr>
<tr>
<td>Osteoarthritis^6</td>
<td>63 (4.05%)</td>
<td>536 (3.07%)</td>
<td>1173 (3.57%)</td>
<td>2105 (3.30%)</td>
<td>19722 (3.25%)</td>
<td>311 (3.50%)</td>
<td>85 (3.57%)</td>
</tr>
<tr>
<td>Rheumatoid arthritis^5</td>
<td>16 (1.31%)</td>
<td>74 (0.68%)</td>
<td>384 (1.63%)</td>
<td>656 (1.33%)</td>
<td>2791 (0.65%)</td>
<td>63 (1.00%)</td>
<td>26 (1.39%)</td>
</tr>
<tr>
<td>Intestinal polyps</td>
<td>43 (1.85%)</td>
<td>367 (1.67%)</td>
<td>752 (1.64%)</td>
<td>1876 (1.93%)</td>
<td>15257 (1.69%)</td>
<td>259 (1.87%)</td>
<td>58 (1.70%)</td>
</tr>
<tr>
<td>Lupus^6</td>
<td>4 (0.17%)</td>
<td>18 (0.08%)</td>
<td>64 (0.14%)</td>
<td>138 (0.14%)</td>
<td>915 (0.10%)</td>
<td>24 (0.17%)</td>
<td>2 (0.06%)</td>
</tr>
<tr>
<td>Kidney stones^5,6</td>
<td>9 (0.99%)</td>
<td>43 (0.55%)</td>
<td>106 (0.61%)</td>
<td>179 (0.48%)</td>
<td>1499 (0.49%)</td>
<td>32 (0.71%)</td>
<td>9 (0.65%)</td>
</tr>
<tr>
<td>Cataracts^5,6</td>
<td>60 (7.03%)</td>
<td>407 (5.84%)</td>
<td>945 (5.68%)</td>
<td>1923 (5.74%)</td>
<td>17860 (6.58%)</td>
<td>300 (7.18%)</td>
<td>76 (6.11%)</td>
</tr>
<tr>
<td>Hypertension treated w/pills</td>
<td>70 (4.26%)</td>
<td>552 (3.33%)</td>
<td>1312 (3.65%)</td>
<td>2219 (4.14%)</td>
<td>23350 (3.23%)</td>
<td>363 (3.57%)</td>
<td>85 (3.50%)</td>
</tr>
<tr>
<td>COPD^7</td>
<td>10 (0.72%)</td>
<td>56 (0.46%)</td>
<td>159 (0.60%)</td>
<td>384 (0.72%)</td>
<td>4266 (0.97%)</td>
<td>83 (1.29%)</td>
<td>12 (0.53%)</td>
</tr>
<tr>
<td>Macular degeneration^6</td>
<td>20 (0.96%)</td>
<td>132 (0.77%)</td>
<td>308 (0.87%)</td>
<td>512 (0.69%)</td>
<td>9407 (1.44%)</td>
<td>122 (1.27%)</td>
<td>24 (0.77%)</td>
</tr>
<tr>
<td>Dementia^8</td>
<td>17 (0.82%)</td>
<td>122 (0.71%)</td>
<td>299 (0.85%)</td>
<td>625 (0.85%)</td>
<td>7042 (1.08%)</td>
<td>122 (1.27%)</td>
<td>29 (0.93%)</td>
</tr>
<tr>
<td>Parkinson’s disease^8</td>
<td>2 (0.10%)</td>
<td>23 (0.13%)</td>
<td>43 (0.12%)</td>
<td>70 (0.10%)</td>
<td>1089 (0.17%)</td>
<td>18 (0.19%)</td>
<td>4 (0.13%)</td>
</tr>
</tbody>
</table>

^1 Native Hawaiian/Other Pacific Islander CT participants (n=66) are combined with Asian CT participants for reporting purposes due to small numbers.

^2 During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2025, pulmonary embolism includes both inpatient and outpatient self-reports.

^3 During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

^4 Gallbladder disease includes self-reports of both hospitalized and non-hospitalized events.

^5 Data not collected for the WHI Extension Studies 2005-2025.

^6 These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

^7 Data only collected during the WHI Extension Study 2010-2025.

^8 Data only collected during the WHI Extension Studies 2005-2025.
### Table 4.7

Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment for OS Participants Who Did Not Report a Prevalent Condition at Baseline

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total</th>
<th>50-54</th>
<th>55-59</th>
<th>60-69</th>
<th>70-79</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number enrolled</td>
<td>93676</td>
<td>12381</td>
<td>17329</td>
<td>41200</td>
<td>22766</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>190.7</td>
<td>218.5</td>
<td>215.3</td>
<td>193.0</td>
<td>152.7</td>
</tr>
<tr>
<td><strong>Hospitalizations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever</td>
<td>67149 (4.51%)</td>
<td>7325 (3.25%)</td>
<td>11492 (3.70%)</td>
<td>30631 (4.62%)</td>
<td>17701 (6.11%)</td>
</tr>
<tr>
<td>Two or more</td>
<td>49647 (3.34%)</td>
<td>4954 (2.20%)</td>
<td>8155 (2.62%)</td>
<td>23213 (3.50%)</td>
<td>13325 (4.60%)</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVT</td>
<td>3270 (0.23%)</td>
<td>323 (0.15%)</td>
<td>538 (0.18%)</td>
<td>1569 (0.25%)</td>
<td>840 (0.30%)</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>2031 (0.14%)</td>
<td>225 (0.10%)</td>
<td>381 (0.12%)</td>
<td>971 (0.15%)</td>
<td>454 (0.16%)</td>
</tr>
<tr>
<td>Angina (hospitalized)</td>
<td>6867 (0.48%)</td>
<td>672 (0.30%)</td>
<td>1166 (0.39%)</td>
<td>3363 (0.54%)</td>
<td>1666 (0.63%)</td>
</tr>
<tr>
<td>Diabetes (treated)</td>
<td>13481 (0.93%)</td>
<td>2026 (0.92%)</td>
<td>2820 (0.93%)</td>
<td>6190 (0.97%)</td>
<td>2445 (0.88%)</td>
</tr>
<tr>
<td>Gallbladder disease</td>
<td>5673 (0.95%)</td>
<td>834 (0.96%)</td>
<td>1148 (0.98%)</td>
<td>2543 (0.99%)</td>
<td>1148 (0.85%)</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>5148 (0.35%)</td>
<td>843 (0.37%)</td>
<td>1220 (0.39%)</td>
<td>2296 (0.35%)</td>
<td>789 (0.27%)</td>
</tr>
<tr>
<td>Glaucosa</td>
<td>8483 (1.87%)</td>
<td>845 (1.33%)</td>
<td>1372 (1.59%)</td>
<td>3899 (1.99%)</td>
<td>2367 (2.19%)</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>20720 (4.75%)</td>
<td>2100 (3.35%)</td>
<td>3378 (4.00%)</td>
<td>9524 (5.07%)</td>
<td>5718 (5.63%)</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>28716 (3.26%)</td>
<td>4599 (2.81%)</td>
<td>6241 (3.05%)</td>
<td>12587 (3.38%)</td>
<td>5289 (3.79%)</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>4588 (0.68%)</td>
<td>636 (0.67%)</td>
<td>883 (0.68%)</td>
<td>1888 (0.65%)</td>
<td>1181 (0.76%)</td>
</tr>
<tr>
<td>Intestinal polyps</td>
<td>22798 (1.69%)</td>
<td>3704 (1.72%)</td>
<td>5151 (1.77%)</td>
<td>10079 (1.69%)</td>
<td>3864 (1.54%)</td>
</tr>
<tr>
<td>Lupus</td>
<td>1592 (0.11%)</td>
<td>226 (0.10%)</td>
<td>310 (0.10%)</td>
<td>721 (0.11%)</td>
<td>335 (0.12%)</td>
</tr>
<tr>
<td>Kidney stones</td>
<td>2317 (0.57%)</td>
<td>292 (0.55%)</td>
<td>433 (0.59%)</td>
<td>994 (0.57%)</td>
<td>598 (0.60%)</td>
</tr>
<tr>
<td>Cataracts</td>
<td>27103 (7.93%)</td>
<td>1726 (3.21%)</td>
<td>4088 (5.63%)</td>
<td>14045 (9.25%)</td>
<td>7244 (11.34%)</td>
</tr>
<tr>
<td>Hypertension treated w/pills</td>
<td>34783 (3.17%)</td>
<td>4799 (2.54%)</td>
<td>6863 (2.78%)</td>
<td>15551 (3.29%)</td>
<td>7570 (4.04%)</td>
</tr>
<tr>
<td>COPD</td>
<td>5890 (0.80%)</td>
<td>784 (0.71%)</td>
<td>1258 (0.84%)</td>
<td>2980 (0.93%)</td>
<td>868 (0.62%)</td>
</tr>
<tr>
<td>Macular degeneration</td>
<td>13486 (1.21%)</td>
<td>1095 (0.65%)</td>
<td>2032 (0.88%)</td>
<td>6759 (1.37%)</td>
<td>3600 (1.72%)</td>
</tr>
<tr>
<td>Dementia</td>
<td>10202 (0.92%)</td>
<td>472 (0.28%)</td>
<td>1145 (0.50%)</td>
<td>5221 (1.06%)</td>
<td>3364 (1.61%)</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>1761 (0.16%)</td>
<td>145 (0.09%)</td>
<td>296 (0.13%)</td>
<td>965 (0.20%)</td>
<td>355 (0.17%)</td>
</tr>
</tbody>
</table>

---

1 During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2025, pulmonary embolism includes both inpatient and outpatient self-reports.

2 During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

3 “Gallbladder disease” includes self-reports of both hospitalized and non-hospitalized events.

4 Data not collected for the WHI Extension Studies 2005-2025.

5 These outcomes have not been self-reported on all versions of Form 33. The annualized percentages are corrected for the different amounts of follow-up.

6 Data only collected during the WHI Extension Study 2010-2025.

7 Data only collected during the WHI Extension Studies 2005-2025.
### Table 4.8

Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for OS Participants Who Did Not Report a Prevalent Condition at Baseline

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>American Indian/Alaska Native</th>
<th>Asian or Native Hawaiian/Other Pacific Islander</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
<th>Other/Not Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number enrolled</td>
<td>307</td>
<td>2619</td>
<td>4081</td>
<td>7419</td>
<td>77921</td>
<td>848</td>
<td>481</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>145.9</td>
<td>159.7</td>
<td>153.8</td>
<td>151.3</td>
<td>197.9</td>
<td>196.9</td>
<td>130.9</td>
</tr>
</tbody>
</table>

#### Hospitalizations

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>DVT</th>
<th>Pulmonary embolism</th>
<th>Angina (hospitalized)</th>
<th>Diabetes (treated)</th>
<th>Gallbladder disease</th>
<th>Lupus</th>
<th>Kidney stones</th>
<th>Cataracts</th>
<th>Hypertension treated w/pills</th>
<th>COPD</th>
<th>Macular degeneration</th>
<th>Dementia</th>
<th>Parkinson’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asian or Native</td>
<td>6 (0.16%)</td>
<td>14 (0.04%)</td>
<td>103 (0.30%)</td>
<td>52 (1.66%)</td>
<td>21 (1.35%)</td>
<td>10 (0.27%)</td>
<td>31 (2.24%)</td>
<td>49 (3.48%)</td>
<td>63 (3.22%)</td>
<td>21 (1.11%)</td>
<td>53 (1.53%)</td>
<td>7 (0.20%)</td>
<td>13 (1.01%)</td>
</tr>
<tr>
<td>Hawaiian/Other Pacific Islander</td>
<td>26 (0.08%)</td>
<td>31 (0.06%)</td>
<td>229 (0.46%)</td>
<td>361 (1.08%)</td>
<td>78 (0.45%)</td>
<td>83 (0.24%)</td>
<td>247 (1.84%)</td>
<td>623 (4.87%)</td>
<td>810 (3.25%)</td>
<td>94 (0.52%)</td>
<td>498 (1.60%)</td>
<td>25 (0.07%)</td>
<td>39 (0.32%)</td>
</tr>
<tr>
<td>Hispanic/Latina</td>
<td>231 (0.26%)</td>
<td>137 (0.15%)</td>
<td>458 (0.53%)</td>
<td>653 (1.32%)</td>
<td>258 (1.14%)</td>
<td>175 (0.33%)</td>
<td>359 (1.83%)</td>
<td>862 (4.53%)</td>
<td>1241 (3.68%)</td>
<td>422 (1.59%)</td>
<td>819 (1.68%)</td>
<td>81 (0.16%)</td>
<td>138 (0.78%)</td>
</tr>
<tr>
<td>Non-Hispanic Black/African American</td>
<td>2898 (0.23%)</td>
<td>1827 (0.14%)</td>
<td>5969 (0.49%)</td>
<td>1323 (1.57%)</td>
<td>365 (0.78%)</td>
<td>183 (0.20%)</td>
<td>955 (2.71%)</td>
<td>1042 (2.84%)</td>
<td>1911 (3.47%)</td>
<td>643 (1.34%)</td>
<td>1608 (1.88%)</td>
<td>144 (0.16%)</td>
<td>254 (0.76%)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>26 (0.20%)</td>
<td>11 (0.08%)</td>
<td>72 (0.55%)</td>
<td>10871 (0.87%)</td>
<td>4871 (0.98%)</td>
<td>4649 (0.36%)</td>
<td>6747 (1.78%)</td>
<td>17848 (4.95%)</td>
<td>24314 (3.23%)</td>
<td>3306 (0.58%)</td>
<td>19520 (1.67%)</td>
<td>1303 (0.10%)</td>
<td>1835 (0.55%)</td>
</tr>
<tr>
<td>More than one Race</td>
<td>6 (0.12%)</td>
<td>5 (0.10%)</td>
<td>20 (0.40%)</td>
<td>152 (1.16%)</td>
<td>47 (0.86%)</td>
<td>33 (0.24%)</td>
<td>94 (2.20%)</td>
<td>189 (4.48%)</td>
<td>273 (3.35%)</td>
<td>57 (0.92%)</td>
<td>204 (1.64%)</td>
<td>22 (0.16%)</td>
<td>14 (0.70%)</td>
</tr>
<tr>
<td>Other/Not Reported</td>
<td>274 (5.22%)</td>
<td>69 (1.41%)</td>
<td>33 (1.26%)</td>
<td>107 (5.13%)</td>
<td>104 (3.23%)</td>
<td>96 (1.97%)</td>
<td>50 (2.23%)</td>
<td>107 (5.13%)</td>
<td>104 (3.23%)</td>
<td>45 (1.54%)</td>
<td>96 (1.97%)</td>
<td>10 (0.20%)</td>
<td>14 (0.70%)</td>
</tr>
</tbody>
</table>

---

1. Native Hawaiian/Other Pacific Islander OS participants (n=53) are combined with Asian OS participants for reporting purposes due to small numbers.
2. During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2025, pulmonary embolism includes both inpatient and outpatient self-reports.
3. During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.
4. Other Pacific Islander includes self-reports of both hospitalized and non-hospitalized events.
6. These outcomes have not been self-reported on all versions of Form 33. The annualized percentages are corrected for the different amounts of follow-up.
7. Data only collected during the WHI Extension Study 2010-2025.
8. Data only collected during the WHI Extension Studies 2005-2025.
### Table 4.9
Self-Reported Fractures (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>MRC Super Cohort</th>
<th>SRC Super Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>44174</td>
<td>117634</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>185.8</td>
<td>203.7</td>
</tr>
<tr>
<td>Elbow</td>
<td>691 (0.10%)</td>
<td>2405 (0.12%)</td>
</tr>
<tr>
<td>Foot</td>
<td>2005 (0.29%)</td>
<td>7435 (0.37%)</td>
</tr>
<tr>
<td>Hand</td>
<td>650 (0.10%)</td>
<td>2085 (0.10%)</td>
</tr>
<tr>
<td>Hip</td>
<td>1908 (0.28%)</td>
<td>6983 (0.35%)</td>
</tr>
<tr>
<td>Knee</td>
<td>1113 (0.16%)</td>
<td>3365 (0.17%)</td>
</tr>
<tr>
<td>Lower arm</td>
<td>3299 (0.48%)</td>
<td>10826 (0.54%)</td>
</tr>
<tr>
<td>Lower leg</td>
<td>2459 (0.36%)</td>
<td>7850 (0.39%)</td>
</tr>
<tr>
<td>Pelvis</td>
<td>871 (0.13%)</td>
<td>3818 (0.19%)</td>
</tr>
<tr>
<td>Tailbone</td>
<td>315 (0.05%)</td>
<td>1261 (0.06%)</td>
</tr>
<tr>
<td>Upper arm</td>
<td>2044 (0.30%)</td>
<td>6613 (0.33%)</td>
</tr>
<tr>
<td>Upper leg</td>
<td>781 (0.11%)</td>
<td>3092 (0.15%)</td>
</tr>
<tr>
<td>Spine</td>
<td>2052 (0.30%)</td>
<td>8773 (0.44%)</td>
</tr>
<tr>
<td>Other</td>
<td>7106 (1.04%)</td>
<td>24934 (1.25%)</td>
</tr>
<tr>
<td>Any fracture</td>
<td>15656 (2.29%)</td>
<td>52525 (2.63%)</td>
</tr>
</tbody>
</table>

1 The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

2 The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.
Table 4.10
Self-Reported Fractures (Annualized Percentages): CT and OS Participants

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>CT</th>
<th>OS</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>68132</td>
<td>93676</td>
<td>161808</td>
</tr>
<tr>
<td>Mean follow-up (months)</td>
<td>207.7</td>
<td>192.3</td>
<td>198.8</td>
</tr>
<tr>
<td>Elbow</td>
<td>1321 (0.11%)</td>
<td>1775 (0.12%)</td>
<td>3096 (0.12%)</td>
</tr>
<tr>
<td>Foot</td>
<td>4124 (0.35%)</td>
<td>5316 (0.35%)</td>
<td>9440 (0.35%)</td>
</tr>
<tr>
<td>Hand</td>
<td>1264 (0.11%)</td>
<td>1471 (0.10%)</td>
<td>2735 (0.10%)</td>
</tr>
<tr>
<td>Hip</td>
<td>3775 (0.32%)</td>
<td>5116 (0.34%)</td>
<td>8891 (0.33%)</td>
</tr>
<tr>
<td>Knee</td>
<td>1905 (0.16%)</td>
<td>2573 (0.17%)</td>
<td>4478 (0.17%)</td>
</tr>
<tr>
<td>Lower arm</td>
<td>6226 (0.53%)</td>
<td>7899 (0.53%)</td>
<td>14125 (0.53%)</td>
</tr>
<tr>
<td>Lower leg</td>
<td>4599 (0.39%)</td>
<td>5710 (0.38%)</td>
<td>10309 (0.38%)</td>
</tr>
<tr>
<td>Pelvis</td>
<td>1888 (0.16%)</td>
<td>2801 (0.19%)</td>
<td>4689 (0.17%)</td>
</tr>
<tr>
<td>Tailbone</td>
<td>646 (0.05%)</td>
<td>930 (0.06%)</td>
<td>1576 (0.06%)</td>
</tr>
<tr>
<td>Upper arm</td>
<td>3921 (0.33%)</td>
<td>4736 (0.32%)</td>
<td>8657 (0.32%)</td>
</tr>
<tr>
<td>Upper leg</td>
<td>1644 (0.14%)</td>
<td>2229 (0.15%)</td>
<td>3873 (0.14%)</td>
</tr>
<tr>
<td>Spine</td>
<td>4502 (0.38%)</td>
<td>6323 (0.42%)</td>
<td>10825 (0.40%)</td>
</tr>
<tr>
<td>Other</td>
<td>13552 (1.15%)</td>
<td>18488 (1.23%)</td>
<td>32040 (1.20%)</td>
</tr>
<tr>
<td>Any fracture</td>
<td>29280 (2.48%)</td>
<td>38901 (2.59%)</td>
<td>68181 (2.54%)</td>
</tr>
</tbody>
</table>
### Table 5.1

Agreement of the Central Adjudications with Self-Reports for Outcomes Reported in Extension Study 2010-2025

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Cardiovascular</th>
<th>Participants with a self-report¹</th>
<th>Closed N (%)</th>
<th>Confirmed N (%)</th>
<th>Denied – related outcome found² N (%)</th>
<th>Denied – unrelated outcome found N (%)</th>
<th>Denied – no outcome found N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical MI</td>
<td>793</td>
<td>692 (87%)</td>
<td>444 (64%)</td>
<td>125 (18%)</td>
<td>3 (0%)</td>
<td>120 (17%)</td>
</tr>
<tr>
<td>CABG</td>
<td>257</td>
<td>228 (89%)</td>
<td>155 (68%)</td>
<td>43 (19%)</td>
<td>0 (0%)</td>
<td>30 (13%)</td>
</tr>
<tr>
<td>PTCA</td>
<td>799</td>
<td>727 (91%)</td>
<td>486 (67%)</td>
<td>104 (14%)</td>
<td>3 (0%)</td>
<td>134 (18%)</td>
</tr>
<tr>
<td>Carotid artery disease</td>
<td>223</td>
<td>201 (90%)</td>
<td>111 (55%)</td>
<td>53 (26%)</td>
<td>0 (0%)</td>
<td>37 (18%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>1612</td>
<td>1386 (86%)</td>
<td>975 (70%)</td>
<td>152 (11%)</td>
<td>1 (0%)</td>
<td>258 (19%)</td>
</tr>
<tr>
<td>PAD</td>
<td>391</td>
<td>310 (79%)</td>
<td>135 (44%)</td>
<td>75 (24%)</td>
<td>2 (1%)</td>
<td>98 (32%)</td>
</tr>
<tr>
<td>DVT</td>
<td>852</td>
<td>708 (83%)</td>
<td>405 (57%)</td>
<td>123 (17%)</td>
<td>6 (1%)</td>
<td>174 (25%)</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>452</td>
<td>406 (90%)</td>
<td>345 (85%)</td>
<td>26 (6%)</td>
<td>3 (1%)</td>
<td>32 (8%)</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>538</td>
<td>480 (89%)</td>
<td>340 (71%)</td>
<td>88 (18%)</td>
<td>0 (0%)</td>
<td>52 (11%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cancers</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>3700</td>
<td>3510 (95%)</td>
<td>3431 (98%)</td>
<td>7 (0%)</td>
<td>1 (0%)</td>
<td>71 (2%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>447</td>
<td>403 (90%)</td>
<td>250 (62%)</td>
<td>103 (26%)</td>
<td>0 (0%)</td>
<td>50 (12%)</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>582</td>
<td>548 (94%)</td>
<td>417 (76%)</td>
<td>102 (19%)</td>
<td>1 (0%)</td>
<td>28 (5%)</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>84</td>
<td>77 (92%)</td>
<td>18 (23%)</td>
<td>23 (30%)</td>
<td>1 (1%)</td>
<td>35 (45%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>1078</td>
<td>987 (92%)</td>
<td>835 (85%)</td>
<td>74 (7%)</td>
<td>4 (0%)</td>
<td>74 (7%)</td>
</tr>
<tr>
<td>Bladder/urinary tract cancer</td>
<td>492</td>
<td>450 (91%)</td>
<td>387 (86%)</td>
<td>28 (6%)</td>
<td>0 (0%)</td>
<td>35 (8%)</td>
</tr>
<tr>
<td>Brain cancer</td>
<td>206</td>
<td>155 (75%)</td>
<td>59 (38%)</td>
<td>20 (13%)</td>
<td>2 (1%)</td>
<td>74 (48%)</td>
</tr>
<tr>
<td>Esophagus cancer</td>
<td>86</td>
<td>75 (87%)</td>
<td>46 (61%)</td>
<td>12 (16%)</td>
<td>1 (1%)</td>
<td>16 (21%)</td>
</tr>
<tr>
<td>Gallbladder/bile duct cancer</td>
<td>106</td>
<td>96 (91%)</td>
<td>37 (39%)</td>
<td>43 (45%)</td>
<td>0 (0%)</td>
<td>16 (17%)</td>
</tr>
<tr>
<td>Kidney cancer</td>
<td>393</td>
<td>353 (90%)</td>
<td>212 (60%)</td>
<td>76 (22%)</td>
<td>2 (1%)</td>
<td>63 (18%)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>401</td>
<td>357 (89%)</td>
<td>269 (75%)</td>
<td>29 (8%)</td>
<td>2 (1%)</td>
<td>57 (16%)</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>365</td>
<td>287 (79%)</td>
<td>64 (22%)</td>
<td>55 (19%)</td>
<td>7 (2%)</td>
<td>161 (56%)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>1578</td>
<td>1378 (87%)</td>
<td>1150 (83%)</td>
<td>66 (5%)</td>
<td>3 (0%)</td>
<td>159 (12%)</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>69</td>
<td>57 (83%)</td>
<td>11 (19%)</td>
<td>33 (58%)</td>
<td>0 (0%)</td>
<td>13 (23%)</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>525</td>
<td>478 (91%)</td>
<td>411 (86%)</td>
<td>39 (8%)</td>
<td>0 (0%)</td>
<td>28 (6%)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>1944</td>
<td>1482 (76%)</td>
<td>1144 (77%)</td>
<td>49 (3%)</td>
<td>0 (0%)</td>
<td>289 (20%)</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>241</td>
<td>212 (88%)</td>
<td>182 (86%)</td>
<td>11 (5%)</td>
<td>3 (1%)</td>
<td>16 (8%)</td>
</tr>
<tr>
<td>Pancreas cancer</td>
<td>496</td>
<td>435 (88%)</td>
<td>362 (83%)</td>
<td>29 (7%)</td>
<td>3 (1%)</td>
<td>41 (9%)</td>
</tr>
<tr>
<td>Stomach cancer</td>
<td>181</td>
<td>158 (87%)</td>
<td>64 (41%)</td>
<td>44 (28%)</td>
<td>0 (0%)</td>
<td>50 (32%)</td>
</tr>
</tbody>
</table>

¹ Excludes duplicates and prior conditions.
² All cardiovascular outcomes are considered related, all cancers are considered related and all fractures are considered related.
³ Percentages between parentheses are relative to “closed.”
Table 5.1 (continued)
Agreement of the Central Adjudications with Self-Reports for Outcomes Reported in Extension Study 2010-2025

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Participants with a self-report</th>
<th>Closed</th>
<th>Confirmed</th>
<th>Denied – related outcome found</th>
<th>Denied – unrelated outcome found</th>
<th>Denied – no outcome found</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Thyroid cancer</td>
<td>189</td>
<td>168</td>
<td>133 (79%)</td>
<td>5 (3%)</td>
<td>30 (18%)</td>
</tr>
<tr>
<td>Other genital organ cancer²</td>
<td>157</td>
<td>132</td>
<td>14 (11%)</td>
<td>95 (72%)</td>
<td>23 (17%)</td>
</tr>
<tr>
<td>Other cancer²</td>
<td>1225</td>
<td>922</td>
<td>422 (46%)</td>
<td>207 (22%)</td>
<td>286 (31%)</td>
</tr>
<tr>
<td><strong>Fractures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip fracture</td>
<td>912</td>
<td>769</td>
<td>658 (86%)</td>
<td>0 (0%)</td>
<td>103 (13%)</td>
</tr>
<tr>
<td>Upper leg fracture⁶</td>
<td>459</td>
<td>395</td>
<td>0 (0%)</td>
<td>179 (45%)</td>
<td>197 (50%)</td>
</tr>
</tbody>
</table>

¹ Excludes duplicates and prior conditions.
² All cardiovascular outcomes are considered related, all cancers are considered related and all fractures are considered related.
³ Percentages between parentheses are relative to “closed.”
⁴ Does not include cancer of the ovary, endometrium, or cervix.
⁵ Any cancer other than those listed above, excluding non-melanoma skin cancer.
⁶ Upper leg fractures are only investigated for possible occurrence of hip fracture.
### Table 5.2

Agreement of the UNC Heart Failure (HF) Adjudications with Self-Reports among MRC Super Cohort Participants¹

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>Potential Case²</th>
<th>Case Eligible for UNC³</th>
<th>Case Processed by UNC³</th>
<th>Case Confirmed⁴</th>
<th>Case Denied</th>
<th>Case Unclassifiable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>(%)</td>
<td>N</td>
<td>(%)</td>
</tr>
<tr>
<td>Overall</td>
<td>8949</td>
<td>8861 (99%)</td>
<td>8660 (98%)</td>
<td>6966 (80%)</td>
<td>1244 (14%)</td>
<td>449 (5%)</td>
</tr>
<tr>
<td>By Self Report</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-reported HF</td>
<td>4641</td>
<td>4592 (99%)</td>
<td>4411 (96%)</td>
<td>3732 (85%)</td>
<td>571 (13%)</td>
<td>108 (2%)</td>
</tr>
<tr>
<td>No HF self-report</td>
<td>4308</td>
<td>4269 (99%)</td>
<td>4249 (100%)</td>
<td>3234 (76%)</td>
<td>673 (16%)</td>
<td>341 (8%)</td>
</tr>
</tbody>
</table>

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

² Includes all self-reported or discovered heart failure cases and a portion of self-reported angina or other heart condition cases with 2 or more essential documents among MRC Super Cohort participants.

³ Cases are eligible if they self-reported HF, or if not, were forwarded by another outcomes committee for possible HF; cases are sent to and processed by UNC when all required records have been received.

⁴ Diagnosis was either definite or probably decompensated heart failure, or chronic stable heart failure.

⁵ Percentages are relative to “Case Eligible for UNC”.

⁶ Percentages are relative to “Case Processed by UNC”.
Table 5.3
Source of Outcomes Confirmed by Central Adjudication for Self-Reported Outcomes in Extension Study 2010-2025

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Source of Outcomes Confirmed by Central Adjudication</th>
<th>Centrally confirmed N</th>
<th>Self-report same outcome N</th>
<th>Self-report related outcome&lt;sup&gt;1&lt;/sup&gt; N</th>
<th>Self-report unrelated outcome&lt;sup&gt;2&lt;/sup&gt; N</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical MI</td>
<td>856</td>
<td>444</td>
<td>239</td>
<td>173</td>
</tr>
<tr>
<td>CABG</td>
<td>176</td>
<td>155</td>
<td>17</td>
<td>4</td>
</tr>
<tr>
<td>PTCA</td>
<td>555</td>
<td>489</td>
<td>51</td>
<td>15</td>
</tr>
<tr>
<td>Carotid artery disease</td>
<td>102</td>
<td>85</td>
<td>11</td>
<td>6</td>
</tr>
<tr>
<td>Stroke</td>
<td>1099</td>
<td>985</td>
<td>18</td>
<td>96</td>
</tr>
<tr>
<td>PAD</td>
<td>207</td>
<td>135</td>
<td>59</td>
<td>13</td>
</tr>
<tr>
<td>DVT</td>
<td>549</td>
<td>415</td>
<td>66</td>
<td>68</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>453</td>
<td>343</td>
<td>54</td>
<td>56</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>550</td>
<td>339</td>
<td>143</td>
<td>68</td>
</tr>
<tr>
<td><strong>Cancers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>3471</td>
<td>3431</td>
<td>24</td>
<td>16</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>275</td>
<td>250</td>
<td>19</td>
<td>6</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>460</td>
<td>417</td>
<td>39</td>
<td>4</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>25</td>
<td>18</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>865</td>
<td>827</td>
<td>27</td>
<td>11</td>
</tr>
<tr>
<td>Bladder/urinary tract cancer&lt;sup&gt;3&lt;/sup&gt;</td>
<td>495</td>
<td>389</td>
<td>99</td>
<td>7</td>
</tr>
<tr>
<td>Brain cancer</td>
<td>59</td>
<td>59</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Esophagus cancer</td>
<td>48</td>
<td>47</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Gallbladder/bile duct cancer</td>
<td>86</td>
<td>37</td>
<td>49</td>
<td>0</td>
</tr>
<tr>
<td>Kidney cancer</td>
<td>224</td>
<td>215</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Leukemia</td>
<td>331</td>
<td>269</td>
<td>49</td>
<td>13</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>77</td>
<td>65</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>1220</td>
<td>1156</td>
<td>37</td>
<td>27</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>18</td>
<td>11</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>581</td>
<td>411</td>
<td>165</td>
<td>5</td>
</tr>
<tr>
<td>Melanoma</td>
<td>1166</td>
<td>1150</td>
<td>14</td>
<td>2</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>210</td>
<td>182</td>
<td>24</td>
<td>4</td>
</tr>
<tr>
<td>Pancreas cancer</td>
<td>382</td>
<td>363</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>Stomach cancer</td>
<td>85</td>
<td>64</td>
<td>17</td>
<td>4</td>
</tr>
<tr>
<td>Thyroid cancer</td>
<td>138</td>
<td>133</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Other genital organ cancer&lt;sup&gt;4&lt;/sup&gt;</td>
<td>169</td>
<td>14</td>
<td>154</td>
<td>1</td>
</tr>
<tr>
<td><strong>Fractures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip fracture</td>
<td>839</td>
<td>654</td>
<td>164</td>
<td>21</td>
</tr>
</tbody>
</table>

<sup>1</sup> All cardiovascular outcomes are considered related, all cancers are considered related and all fractures are considered related.
<sup>2</sup> Includes self-report of hospitalizations.
<sup>3</sup> Cancers of the urinary tract include renal pelvis, ureter and urinary organs (NOS).
<sup>4</sup> Does not include cancers of the ovary, endometrium or cervix; includes cancers of the vulva, vagina, uterus (NOS) and genital organs (NOS).
### Table 6.1

**Consent Status and Participant Characteristics for Long Life Study Participants\(^1\)** by Race/Ethnicity  
Data as of: March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>Total(^2)</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean (SD) or %</td>
<td>N</td>
<td>Mean (SD) or %</td>
<td>N</td>
</tr>
<tr>
<td>Number eligible</td>
<td>14081</td>
<td>2211</td>
<td>5148</td>
<td>6482</td>
<td>184</td>
</tr>
<tr>
<td>Phase 1: Age 72-79</td>
<td>9930</td>
<td>1405</td>
<td>3465</td>
<td>4880</td>
<td>137</td>
</tr>
<tr>
<td>Phase 2: Age 63-72</td>
<td>2651</td>
<td>730</td>
<td>1438</td>
<td>437</td>
<td>34</td>
</tr>
<tr>
<td>Phase 3: Age 64-98</td>
<td>1500</td>
<td>76</td>
<td>245</td>
<td>1165</td>
<td>13</td>
</tr>
<tr>
<td>Consent(^3)</td>
<td>9246</td>
<td>1493</td>
<td>3044</td>
<td>4539</td>
<td>136</td>
</tr>
<tr>
<td>Completed visit 2012-2013(^4)</td>
<td>7875</td>
<td>1277</td>
<td>2483</td>
<td>3978</td>
<td>110</td>
</tr>
<tr>
<td><strong>LLS Participants</strong></td>
<td>7875</td>
<td>1277</td>
<td>2483</td>
<td>3978</td>
<td>110</td>
</tr>
<tr>
<td>Blood draw</td>
<td>7475</td>
<td>1238</td>
<td>2284</td>
<td>3827</td>
<td>101</td>
</tr>
<tr>
<td>Age at visit</td>
<td>7875</td>
<td>1277</td>
<td>2483</td>
<td>3978</td>
<td>110</td>
</tr>
<tr>
<td>63-69</td>
<td>724</td>
<td>236</td>
<td>379</td>
<td>97</td>
<td>9</td>
</tr>
<tr>
<td>70-79</td>
<td>3050</td>
<td>717</td>
<td>1433</td>
<td>829</td>
<td>60</td>
</tr>
<tr>
<td>80-89</td>
<td>3689</td>
<td>305</td>
<td>620</td>
<td>2717</td>
<td>35</td>
</tr>
<tr>
<td>≥90</td>
<td>412</td>
<td>19</td>
<td>51</td>
<td>335</td>
<td>6</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-8 years</td>
<td>112</td>
<td>71</td>
<td>24</td>
<td>17</td>
<td>0</td>
</tr>
<tr>
<td>Some high school</td>
<td>286</td>
<td>76</td>
<td>112</td>
<td>96</td>
<td>1</td>
</tr>
<tr>
<td>High school diploma/GED</td>
<td>1288</td>
<td>199</td>
<td>280</td>
<td>794</td>
<td>10</td>
</tr>
<tr>
<td>School after high school</td>
<td>3041</td>
<td>543</td>
<td>915</td>
<td>1530</td>
<td>46</td>
</tr>
<tr>
<td>College degree or higher</td>
<td>3099</td>
<td>377</td>
<td>1130</td>
<td>1525</td>
<td>53</td>
</tr>
<tr>
<td>Body-mass Index (BMI), kg/m(^2)</td>
<td>7775</td>
<td>1265</td>
<td>2448</td>
<td>3928</td>
<td>107</td>
</tr>
<tr>
<td>Underweight (&lt; 18.5)</td>
<td>112</td>
<td>13</td>
<td>23</td>
<td>72</td>
<td>3</td>
</tr>
<tr>
<td>Normal (18.5 - 24.9)</td>
<td>2378</td>
<td>415</td>
<td>513</td>
<td>1410</td>
<td>31</td>
</tr>
<tr>
<td>Overweight (25.0 - 29.9)</td>
<td>2799</td>
<td>467</td>
<td>868</td>
<td>1419</td>
<td>39</td>
</tr>
<tr>
<td>Obesity I (30.0 - 34.9)</td>
<td>1505</td>
<td>233</td>
<td>577</td>
<td>664</td>
<td>22</td>
</tr>
<tr>
<td>Obesity II (35.0 - 39.9)</td>
<td>633</td>
<td>88</td>
<td>300</td>
<td>240</td>
<td>4</td>
</tr>
<tr>
<td>Extreme Obesity III (≥ 40)</td>
<td>348</td>
<td>49</td>
<td>167</td>
<td>123</td>
<td>8</td>
</tr>
</tbody>
</table>

---

\(^1\) Long Life Study participants are a subset of the Medical Records Cohort (MRC) which includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

\(^2\) Separate columns for American Indian/Alaska Native (n=4), Asian or Native Hawaiian/Other Pacific Islander (n=1) and Other/Not Reported (n=22) race/ethnicities are not displayed due to small numbers, however these participants are included in the Total column.

\(^3\) Percentage is relative to number eligible.

\(^4\) Percentage is relative to consented.
Table 6.1 (continued)
Consent Status and Participant Characteristics for Long Life Study Participants\(^1\) by Race/Ethnicity
Data as of: March 6, 2021

<table>
<thead>
<tr>
<th></th>
<th>Total(^2)</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
<th>More than one Race</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean (SD)</td>
<td>N</td>
<td>Mean (SD)</td>
<td>N</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td></td>
<td>or %</td>
<td></td>
<td>or %</td>
<td>Mean (SD) or %</td>
</tr>
<tr>
<td>&lt;=120</td>
<td>7864</td>
<td>125.9 (14.6)</td>
<td>1276</td>
<td>123.8 (13.7)</td>
<td>2478</td>
</tr>
<tr>
<td></td>
<td>2962</td>
<td>37.7</td>
<td>566</td>
<td>44.4</td>
<td>851</td>
</tr>
<tr>
<td></td>
<td>3796</td>
<td>48.3</td>
<td>564</td>
<td>44.2</td>
<td>1246</td>
</tr>
<tr>
<td>&gt;140</td>
<td>1106</td>
<td>14.1</td>
<td>146</td>
<td>11.4</td>
<td>381</td>
</tr>
<tr>
<td>Diastolic blood pressure, mmHg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;80</td>
<td>7862</td>
<td>72.6 (8.9)</td>
<td>1275</td>
<td>72.2 (8.2)</td>
<td>2479</td>
</tr>
<tr>
<td></td>
<td>6073</td>
<td>77.2</td>
<td>1037</td>
<td>81.3</td>
<td>1807</td>
</tr>
<tr>
<td></td>
<td>1535</td>
<td>19.5</td>
<td>209</td>
<td>16.4</td>
<td>567</td>
</tr>
<tr>
<td>≥90</td>
<td>254</td>
<td>3.2</td>
<td>29</td>
<td>2.3</td>
<td>105</td>
</tr>
<tr>
<td>Grip strength, kg</td>
<td>7274</td>
<td>17.8 (7.0)</td>
<td>1154</td>
<td>18.0 (6.3)</td>
<td>2329</td>
</tr>
<tr>
<td>Repeated chair stands,</td>
<td>6949</td>
<td>0.35 (0.13)</td>
<td>1182</td>
<td>0.37 (0.1)</td>
<td>2178</td>
</tr>
<tr>
<td>Walking pace, m/sec</td>
<td>6911</td>
<td>0.65 (0.29)</td>
<td>1124</td>
<td>0.73 (0.3)</td>
<td>2164</td>
</tr>
<tr>
<td>Look AHEAD SPPB(^3)</td>
<td>7022</td>
<td>1.3 (0.5)</td>
<td>1147</td>
<td>1.4 (0.5)</td>
<td>2238</td>
</tr>
<tr>
<td>EPESE SPPB(^4)</td>
<td>7102</td>
<td>7.9 (2.7)</td>
<td>1159</td>
<td>8.7 (2.6)</td>
<td>2260</td>
</tr>
</tbody>
</table>

1 Long Life Study participants are a subset of the Medical Records Cohort (MRC) which includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.
2 Separate columns for American Indian/Alaska Native (n=4), Asian or Native Hawaiian/Other Pacific Islander (n=1) and Other/Not Reported (n=22) race/ethnicities are not displayed due to small numbers, however these participants are included in the Total column.
3 The Look AHEAD Short Physical Performance Battery (SPPB) ranges from 0 to 3, with higher scores indicating better physical performance.
4 The Established Populations for the Epidemiologic Studies of the Eldery (EPESE) Short Physical Performance Battery (SPPB) ranges from 0 to 12, with higher scores indicating better physical performance.
Table 6.2
Participation and Vital Status: Long Life Study (LLS) Participants

Data as of: March 6, 2021

<table>
<thead>
<tr>
<th>Vital Status/Participation</th>
<th>LLS Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Deceased</td>
<td>2252</td>
</tr>
<tr>
<td>Alive: Current Participation¹</td>
<td>4717</td>
</tr>
<tr>
<td>Alive: Recent Participation²</td>
<td>405</td>
</tr>
<tr>
<td>Stopped Follow-Up³</td>
<td>249</td>
</tr>
<tr>
<td>Lost to Follow-Up⁴</td>
<td>252</td>
</tr>
</tbody>
</table>

¹ Participants who have filled in a Form 33 within the last 15 months.
² Participants who last filled in a Form 33 between 15 and 24 months ago.
³ Participants with codes 5 (no follow-up) or 8 (absolutely no follow-up) on Form 7 or 9.
⁴ Participants not in any of the above categories.
### Table 6.3
Verified Outcomes (Annualized Percentages)
*After Long Life Study (LLS) Visit by Age at Visit for LLS Participants*

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Total</th>
<th>63-69</th>
<th>70-79</th>
<th>80-89</th>
<th>≥ 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number enrolled</td>
<td>7875</td>
<td>723</td>
<td>3052</td>
<td>3688</td>
<td>412</td>
</tr>
<tr>
<td>Mean follow-up (months) after LLS visit</td>
<td>80.7</td>
<td>88.9</td>
<td>86.6</td>
<td>76.1</td>
<td>63.1</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD (^1)</td>
<td>459 (0.87%)</td>
<td>15 (0.28%)</td>
<td>106 (0.48%)</td>
<td>294 (1.26%)</td>
<td>44 (2.03%)</td>
</tr>
<tr>
<td>CHD death (^2)</td>
<td>288 (0.54%)</td>
<td>6 (0.11%)</td>
<td>49 (0.22%)</td>
<td>192 (0.82%)</td>
<td>41 (1.89%)</td>
</tr>
<tr>
<td>Clinical MI</td>
<td>278 (0.53%)</td>
<td>12 (0.22%)</td>
<td>70 (0.32%)</td>
<td>177 (0.76%)</td>
<td>19 (0.88%)</td>
</tr>
<tr>
<td>CABG/PTCA</td>
<td>196 (0.37%)</td>
<td>12 (0.22%)</td>
<td>75 (0.34%)</td>
<td>104 (0.44%)</td>
<td>5 (0.23%)</td>
</tr>
<tr>
<td>Carotid artery disease</td>
<td>25 (0.05%)</td>
<td>1 (0.02%)</td>
<td>9 (0.04%)</td>
<td>14 (0.06%)</td>
<td>1 (0.05%)</td>
</tr>
<tr>
<td>Heart failure, UNC (^3)</td>
<td>513 (0.97%)</td>
<td>12 (0.22%)</td>
<td>110 (0.50%)</td>
<td>339 (1.45%)</td>
<td>52 (2.40%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>455 (0.86%)</td>
<td>19 (0.35%)</td>
<td>124 (0.56%)</td>
<td>272 (1.16%)</td>
<td>40 (1.85%)</td>
</tr>
<tr>
<td>PAD</td>
<td>69 (0.13%)</td>
<td>1 (0.02%)</td>
<td>20 (0.09%)</td>
<td>44 (0.19%)</td>
<td>4 (0.18%)</td>
</tr>
<tr>
<td>DVT</td>
<td>186 (0.35%)</td>
<td>8 (0.15%)</td>
<td>66 (0.30%)</td>
<td>102 (0.44%)</td>
<td>10 (0.46%)</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>153 (0.29%)</td>
<td>8 (0.15%)</td>
<td>57 (0.26%)</td>
<td>80 (0.34%)</td>
<td>8 (0.37%)</td>
</tr>
<tr>
<td>Coronary disease (^4)</td>
<td>738 (1.39%)</td>
<td>25 (0.47%)</td>
<td>185 (0.84%)</td>
<td>463 (1.98%)</td>
<td>65 (3.00%)</td>
</tr>
<tr>
<td>DVT/PE</td>
<td>272 (0.51%)</td>
<td>14 (0.26%)</td>
<td>102 (0.46%)</td>
<td>143 (0.61%)</td>
<td>13 (0.60%)</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>19 (0.04%)</td>
<td>2 (0.04%)</td>
<td>5 (0.02%)</td>
<td>11 (0.05%)</td>
<td>1 (0.05%)</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>171 (0.32%)</td>
<td>4 (0.07%)</td>
<td>40 (0.18%)</td>
<td>110 (0.47%)</td>
<td>17 (0.78%)</td>
</tr>
<tr>
<td><strong>Total cardiovascular disease</strong> (^5)</td>
<td>1170 (2.21%)</td>
<td>41 (0.77%)</td>
<td>308 (1.40%)</td>
<td>705 (3.01%)</td>
<td>116 (5.35%)</td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>199 (0.38%)</td>
<td>21 (0.39%)</td>
<td>110 (0.50%)</td>
<td>66 (0.28%)</td>
<td>2 (0.09%)</td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>176 (0.33%)</td>
<td>16 (0.30%)</td>
<td>98 (0.45%)</td>
<td>59 (0.25%)</td>
<td>3 (0.14%)</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>29 (0.05%)</td>
<td>6 (0.11%)</td>
<td>16 (0.07%)</td>
<td>7 (0.03%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>27 (0.05%)</td>
<td>1 (0.02%)</td>
<td>12 (0.05%)</td>
<td>12 (0.05%)</td>
<td>2 (0.09%)</td>
</tr>
<tr>
<td>Endometrial cancer (^6)</td>
<td>15 (0.03%)</td>
<td>0 (0.00%)</td>
<td>6 (0.03%)</td>
<td>9 (0.04%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>81 (0.15%)</td>
<td>3 (0.06%)</td>
<td>20 (0.09%)</td>
<td>56 (0.24%)</td>
<td>2 (0.09%)</td>
</tr>
<tr>
<td>Other cancer (^7)</td>
<td>460 (0.87%)</td>
<td>24 (0.45%)</td>
<td>170 (0.77%)</td>
<td>247 (1.06%)</td>
<td>19 (0.88%)</td>
</tr>
<tr>
<td><strong>Total cancer</strong></td>
<td>681 (1.29%)</td>
<td>47 (0.88%)</td>
<td>278 (1.26%)</td>
<td>335 (1.43%)</td>
<td>21 (0.97%)</td>
</tr>
<tr>
<td><strong>Fractures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip fracture</td>
<td>307 (0.58%)</td>
<td>6 (0.11%)</td>
<td>40 (0.18%)</td>
<td>222 (0.95%)</td>
<td>39 (1.80%)</td>
</tr>
<tr>
<td><strong>Deaths</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular deaths</td>
<td>806 (1.52%)</td>
<td>14 (0.26%)</td>
<td>130 (0.59%)</td>
<td>532 (2.27%)</td>
<td>130 (6.00%)</td>
</tr>
<tr>
<td>Cancer deaths</td>
<td>399 (0.75%)</td>
<td>16 (0.30%)</td>
<td>121 (0.55%)</td>
<td>242 (1.03%)</td>
<td>20 (0.92%)</td>
</tr>
<tr>
<td>Other known cause</td>
<td>822 (1.55%)</td>
<td>16 (0.30%)</td>
<td>135 (0.61%)</td>
<td>556 (2.38%)</td>
<td>115 (5.31%)</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>47 (0.09%)</td>
<td>2 (0.04%)</td>
<td>6 (0.03%)</td>
<td>29 (0.12%)</td>
<td>10 (0.46%)</td>
</tr>
<tr>
<td>Not yet adjudicated</td>
<td>178 (0.34%)</td>
<td>8 (0.15%)</td>
<td>35 (0.16%)</td>
<td>124 (0.53%)</td>
<td>11 (0.51%)</td>
</tr>
<tr>
<td><strong>Total death</strong></td>
<td>2252 (4.25%)</td>
<td>56 (1.05%)</td>
<td>427 (1.94%)</td>
<td>1483 (6.34%)</td>
<td>286 (13.20%)</td>
</tr>
</tbody>
</table>

\(^1\) CHD includes clinical MI and CHD death.

\(^2\) CHD death includes definite and possible CHD death.

\(^3\) Definite or possible decompensated heart failure adjudicated by UNC.

\(^4\) Coronary disease includes clinical MI, CHD death, UNC heart failure and CABG/PTCA.

\(^5\) Total CVD does not include aortic aneurysm or valvular heart disease.

\(^6\) Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

\(^7\) Only one report of “other cancer” is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.
### Table 6.4
Verified Outcomes (Annualized Percentages)

**After Long Life Study (LLS) Visit by Race/Ethnicity\(^1\) for LLS Participants**

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Hispanic/ Latina</th>
<th>Race/Ethnicity</th>
<th>More than one Race</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-Hispanic</td>
<td>Non-Hispanic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Black/African</td>
<td>White</td>
<td></td>
</tr>
<tr>
<td>Number enrolled</td>
<td>1277</td>
<td>2483</td>
<td>3978</td>
</tr>
<tr>
<td>Mean follow-up (months) after LLS visit</td>
<td>86.8</td>
<td>83.0</td>
<td>77.2</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD(^2)</td>
<td>47 (0.51%)</td>
<td>104 (0.61%)</td>
<td>300 (1.17%)</td>
</tr>
<tr>
<td>CHD death(^3)</td>
<td>26 (0.28%)</td>
<td>59 (0.34%)</td>
<td>198 (0.77%)</td>
</tr>
<tr>
<td>Clinical MI</td>
<td>31 (0.34%)</td>
<td>60 (0.35%)</td>
<td>183 (0.71%)</td>
</tr>
<tr>
<td>CABG/PTCA</td>
<td>22 (0.24%)</td>
<td>48 (0.28%)</td>
<td>125 (0.49%)</td>
</tr>
<tr>
<td>Carotid artery disease</td>
<td>1 (0.01%)</td>
<td>7 (0.04%)</td>
<td>17 (0.07%)</td>
</tr>
<tr>
<td>Heart failure, UNC(^4)</td>
<td>43 (0.47%)</td>
<td>113 (0.66%)</td>
<td>350 (1.37%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>51 (0.55%)</td>
<td>119 (0.69%)</td>
<td>274 (1.07%)</td>
</tr>
<tr>
<td>PAD</td>
<td>6 (0.06%)</td>
<td>25 (0.15%)</td>
<td>37 (0.14%)</td>
</tr>
<tr>
<td>DVT</td>
<td>17 (0.18%)</td>
<td>70 (0.41%)</td>
<td>97 (0.38%)</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>13 (0.14%)</td>
<td>61 (0.36%)</td>
<td>74 (0.29%)</td>
</tr>
<tr>
<td>Coronary disease(^5)</td>
<td>72 (0.78%)</td>
<td>165 (0.96%)</td>
<td>491 (1.92%)</td>
</tr>
<tr>
<td>DVT/PE</td>
<td>25 (0.27%)</td>
<td>110 (0.64%)</td>
<td>132 (0.52%)</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>2 (0.02%)</td>
<td>7 (0.04%)</td>
<td>10 (0.04%)</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>22 (0.24%)</td>
<td>17 (0.10%)</td>
<td>129 (0.50%)</td>
</tr>
<tr>
<td><strong>Total cardiovascular disease(^6)</strong></td>
<td>118 (1.28%)</td>
<td>285 (1.66%)</td>
<td>746 (2.91%)</td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>32 (0.35%)</td>
<td>77 (0.45%)</td>
<td>88 (0.34%)</td>
</tr>
<tr>
<td>Invasive breast cancer</td>
<td>29 (0.31%)</td>
<td>66 (0.38%)</td>
<td>79 (0.31%)</td>
</tr>
<tr>
<td>In situ breast cancer</td>
<td>4 (0.04%)</td>
<td>15 (0.09%)</td>
<td>10 (0.04%)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>3 (0.03%)</td>
<td>7 (0.04%)</td>
<td>17 (0.07%)</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>2 (0.02%)</td>
<td>3 (0.02%)</td>
<td>10 (0.04%)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>7 (0.08%)</td>
<td>19 (0.11%)</td>
<td>54 (0.21%)</td>
</tr>
<tr>
<td>Other cancer</td>
<td>53 (0.57%)</td>
<td>129 (0.75%)</td>
<td>263 (1.03%)</td>
</tr>
<tr>
<td><strong>Total cancer</strong></td>
<td>91 (0.98%)</td>
<td>210 (1.22%)</td>
<td>366 (1.43%)</td>
</tr>
<tr>
<td><strong>Fractures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Fracture</td>
<td>20 (0.22%)</td>
<td>22 (0.13%)</td>
<td>263 (1.03%)</td>
</tr>
<tr>
<td><strong>Deaths</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular deaths</td>
<td>62 (0.67%)</td>
<td>173 (1.01%)</td>
<td>559 (2.18%)</td>
</tr>
<tr>
<td>Cancer deaths</td>
<td>39 (0.42%)</td>
<td>119 (0.69%)</td>
<td>233 (0.91%)</td>
</tr>
<tr>
<td>Other known cause</td>
<td>76 (0.82%)</td>
<td>134 (0.78%)</td>
<td>597 (2.33%)</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>2 (0.02%)</td>
<td>12 (0.07%)</td>
<td>30 (0.12%)</td>
</tr>
<tr>
<td>Not yet adjudicated</td>
<td>10 (0.11%)</td>
<td>49 (0.29%)</td>
<td>117 (0.46%)</td>
</tr>
<tr>
<td><strong>Total death</strong></td>
<td>189 (2.05%)</td>
<td>487 (2.83%)</td>
<td>1536 (6.00%)</td>
</tr>
</tbody>
</table>

---

\(^1\) Long Life Study participants were selected from MRC participants which includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines. Outcome counts for American Indian/Alaska Native (n=4), Asian or Native Hawaiian/Other Pacific Islander (n=1) and Other/Not Reported (n=22) race/ethnicities are not displayed due to small numbers. See Table 6.3 for total counts of adjudicated outcomes.

\(^2\) CHD includes clinical MI and CHD death.

\(^3\) CHD death includes definite and possible CHD death.

\(^4\) Definite or possible decompensated heart failure adjudicated by UNC

\(^5\) Coronary disease includes clinical MI, CHD death, UNC heart failure and CABG/PTCA.

\(^6\) Total CVD does not include aortic aneurysm or valvular heart disease.
Table 6.5
Self-Reported Outcomes (Annualized Percentages) After Long Life Study (LLS) Visit by Age at Visit and Race/Ethnicity\(^1\) for LLS Participants Who Did Not Report a Prevalent Condition at Baseline

Data as of: March 6, 2021; Events through March 6, 2021

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total</th>
<th>63-69</th>
<th>70-79</th>
<th>80-89</th>
<th>≥ 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number enrolled</td>
<td>7875</td>
<td>723</td>
<td>3052</td>
<td>3688</td>
<td>412</td>
</tr>
<tr>
<td>Mean follow-up (months) after LLS visit</td>
<td>78.1</td>
<td>84.8</td>
<td>83.4</td>
<td>74.2</td>
<td>62.1</td>
</tr>
<tr>
<td><strong>Angina (hospitalized)</strong></td>
<td>465 (0.91%)</td>
<td>34 (0.67%)</td>
<td>153 (0.72%)</td>
<td>257 (1.13%)</td>
<td>21 (0.98%)</td>
</tr>
<tr>
<td><strong>Diabetes (treated)</strong></td>
<td>703 (1.37%)</td>
<td>66 (1.29%)</td>
<td>308 (1.45%)</td>
<td>304 (1.33%)</td>
<td>25 (1.17%)</td>
</tr>
<tr>
<td><strong>Hysterectomy</strong></td>
<td>94 (0.18%)</td>
<td>14 (0.27%)</td>
<td>52 (0.25%)</td>
<td>28 (0.12%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td><strong>Osteoarthritis</strong></td>
<td>903 (1.76%)</td>
<td>99 (1.94%)</td>
<td>403 (1.90%)</td>
<td>362 (1.59%)</td>
<td>39 (1.83%)</td>
</tr>
<tr>
<td><strong>Intestinal polyps</strong></td>
<td>503 (0.98%)</td>
<td>99 (1.94%)</td>
<td>280 (1.32%)</td>
<td>120 (0.53%)</td>
<td>4 (0.19%)</td>
</tr>
<tr>
<td><strong>Lupus</strong></td>
<td>37 (0.07%)</td>
<td>4 (0.08%)</td>
<td>19 (0.09%)</td>
<td>13 (0.06%)</td>
<td>1 (0.05%)</td>
</tr>
<tr>
<td><strong>Pills for hypertension</strong></td>
<td>613 (1.20%)</td>
<td>72 (1.41%)</td>
<td>254 (1.20%)</td>
<td>262 (1.15%)</td>
<td>25 (1.17%)</td>
</tr>
<tr>
<td><strong>COPD</strong></td>
<td>793 (1.55%)</td>
<td>68 (1.33%)</td>
<td>299 (1.41%)</td>
<td>399 (1.75%)</td>
<td>27 (1.27%)</td>
</tr>
<tr>
<td><strong>Macular degeneration</strong></td>
<td>1168 (2.28%)</td>
<td>55 (1.08%)</td>
<td>379 (1.79%)</td>
<td>660 (2.89%)</td>
<td>74 (3.47%)</td>
</tr>
<tr>
<td><strong>Dementia</strong></td>
<td>1116 (2.18%)</td>
<td>32 (0.63%)</td>
<td>262 (1.23%)</td>
<td>718 (3.15%)</td>
<td>104 (4.88%)</td>
</tr>
<tr>
<td><strong>Parkinson’s disease</strong></td>
<td>110 (0.21%)</td>
<td>8 (0.16%)</td>
<td>45 (0.21%)</td>
<td>53 (0.23%)</td>
<td>4 (0.19%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Hispanic/Latina</th>
<th>Non-Hispanic Black/African American</th>
<th>Non-Hispanic White</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number enrolled</td>
<td>1277</td>
<td>2483</td>
<td>3978</td>
</tr>
<tr>
<td>Mean follow-up (months) after LLS visit</td>
<td>83.9</td>
<td>80.1</td>
<td>75.1</td>
</tr>
<tr>
<td><strong>Angina (hospitalized)</strong></td>
<td>59 (0.66%)</td>
<td>144 (0.87%)</td>
<td>251 (1.01%)</td>
</tr>
<tr>
<td><strong>Diabetes (treated)</strong></td>
<td>117 (1.31%)</td>
<td>237 (1.43%)</td>
<td>333 (1.34%)</td>
</tr>
<tr>
<td><strong>Hysterectomy</strong></td>
<td>21 (0.24%)</td>
<td>31 (0.19%)</td>
<td>41 (0.16%)</td>
</tr>
<tr>
<td><strong>Osteoarthritis</strong></td>
<td>143 (1.60%)</td>
<td>295 (1.78%)</td>
<td>453 (1.82%)</td>
</tr>
<tr>
<td><strong>Intestinal polyps</strong></td>
<td>120 (1.34%)</td>
<td>207 (1.25%)</td>
<td>172 (0.69%)</td>
</tr>
<tr>
<td><strong>Lupus</strong></td>
<td>8 (0.09%)</td>
<td>12 (0.07%)</td>
<td>17 (0.07%)</td>
</tr>
<tr>
<td><strong>Pills for hypertension</strong></td>
<td>131 (1.47%)</td>
<td>135 (0.81%)</td>
<td>335 (1.35%)</td>
</tr>
<tr>
<td><strong>COPD</strong></td>
<td>114 (1.28%)</td>
<td>251 (1.51%)</td>
<td>420 (1.69%)</td>
</tr>
<tr>
<td><strong>Macular degeneration</strong></td>
<td>167 (1.87%)</td>
<td>274 (1.65%)</td>
<td>708 (2.84%)</td>
</tr>
<tr>
<td><strong>Dementia</strong></td>
<td>135 (1.51%)</td>
<td>243 (1.47%)</td>
<td>720 (2.89%)</td>
</tr>
<tr>
<td><strong>Parkinson’s disease</strong></td>
<td>20 (0.22%)</td>
<td>32 (0.19%)</td>
<td>56 (0.22%)</td>
</tr>
</tbody>
</table>

\(^1\) Long Life Study participants were selected from MRC participants which includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines. Outcome counts for American Indian/Alaska Native (n=4), Asian or Native Hawaiian/Other Pacific Islander (n=1) and Other/Not Reported (n=22) race/ethnicities are not displayed due to small numbers.
**Table 7.1**
Number of Falls per Participant During Extension Study 2010-2025 by Visit Year

Data as of: March 6, 2021; Events between September 30, 2010 and March 6, 2021

<table>
<thead>
<tr>
<th>Number of falls</th>
<th>1 (N=75,553)</th>
<th>2 (N=83,161)</th>
<th>3 (N=80,724)</th>
<th>4 (N=76,931)</th>
<th>5 (N=74,443)</th>
<th>6 (N=68,441)</th>
<th>7 (N=65,622)</th>
<th>8 (N=62,146)</th>
<th>9 (N=59,219)</th>
<th>10 (N=52,833)</th>
<th>11 (N=4,793)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>64.8%</td>
<td>66.2%</td>
<td>65.7%</td>
<td>65.0%</td>
<td>64.3%</td>
<td>64.5%</td>
<td>63.6%</td>
<td>63.5%</td>
<td>62.3%</td>
<td>61.8%</td>
<td>63.4%</td>
</tr>
<tr>
<td>1</td>
<td>20.9%</td>
<td>19.7%</td>
<td>19.7%</td>
<td>20.2%</td>
<td>20.4%</td>
<td>20.2%</td>
<td>20.6%</td>
<td>20.8%</td>
<td>21.0%</td>
<td>21.4%</td>
<td>20.7%</td>
</tr>
<tr>
<td>2</td>
<td>9.5%</td>
<td>9.0%</td>
<td>9.3%</td>
<td>9.4%</td>
<td>9.5%</td>
<td>9.3%</td>
<td>9.6%</td>
<td>9.5%</td>
<td>9.9%</td>
<td>9.8%</td>
<td>9.0%</td>
</tr>
<tr>
<td>≥3</td>
<td>4.9%</td>
<td>5.1%</td>
<td>5.3%</td>
<td>5.4%</td>
<td>5.7%</td>
<td>6.0%</td>
<td>6.2%</td>
<td>6.3%</td>
<td>6.9%</td>
<td>6.9%</td>
<td>7.0%</td>
</tr>
</tbody>
</table>
Figure 7.1

Percent of Participants with Falls During Extension Study 2010-2025 by Visit Year and Age at the Start of Extension Study 2010-2025

Data as of: March 6, 2021; Events between September 30, 2010 and March 6, 2021
Figure 7.2
Age-Adjusted\(^1\) Percent of Participants with Falls During Extension Study 2010-2025
by Visit Year and Race/Ethnicity

Data as of: March 6, 2021; Events between September 30, 2010 and March 6, 2021

\(^1\) Age at the start of Extension Study 2010-2025. Percentages for each race/ethnicity are age-adjusted to the overall age distribution at each time point.
Table 8.1
WHI Manuscript Stages

<table>
<thead>
<tr>
<th>Stage #</th>
<th>Definition</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>12*</td>
<td>Published</td>
<td>2080</td>
</tr>
<tr>
<td>11</td>
<td>In press / accepted by journal</td>
<td>9</td>
</tr>
<tr>
<td>10</td>
<td>Submitted to journal</td>
<td>17</td>
</tr>
<tr>
<td>9</td>
<td>Final manuscript approved by P&amp;P Committee</td>
<td>350</td>
</tr>
<tr>
<td>8</td>
<td>Final manuscript submitted to P&amp;P Committee</td>
<td>35</td>
</tr>
<tr>
<td>7</td>
<td>Draft manuscript</td>
<td>27</td>
</tr>
<tr>
<td>6</td>
<td>Analysis completed</td>
<td>40</td>
</tr>
<tr>
<td>5</td>
<td>Analysis in progress</td>
<td>48</td>
</tr>
<tr>
<td>4</td>
<td>Analysis proposed</td>
<td>7</td>
</tr>
<tr>
<td>2 &amp; 3</td>
<td>Approved proposal</td>
<td>1250</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>3,863</strong></td>
</tr>
</tbody>
</table>

*Only Stage 12 papers published between March 2020 and February 2021 are included in Table 8.2*
### Table 8.2
Publications March 2020 - February 2021

<table>
<thead>
<tr>
<th>MS#</th>
<th>Title</th>
<th>Authors</th>
<th>Focus</th>
<th>Reference</th>
<th>Study #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2422</td>
<td>The Women’s Health Initiative Estrogen-Alone Trial had differential disease and medical expenditure consequences across age groups</td>
<td>Donneyong, Chang, Roth, Guilds, Ankrah, Najafzadeh, Xu, Chlebowski, Margolis, Manson</td>
<td>Gen</td>
<td>Menopause. 2020 Mar 2. doi: 10.1097/GME.0000000000000017. [Epub ahead of print]</td>
<td></td>
</tr>
<tr>
<td>MS#</td>
<td>Title</td>
<td>Authors</td>
<td>Focus</td>
<td>Reference</td>
<td>Study #</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>2850</td>
<td>Heart rate, brain imaging biomarkers and cognitive impairment in older (≥63 Years) women</td>
<td>Haring, Liu, Rapp, Shimbo, Padula, Mozhui, Li, Espeland, Wassertheil-Smoller</td>
<td>CT</td>
<td>Am J Cardiol. 2020 May 26;S0002-9149(20)30540-3. doi: 10.1016/j.amjcard.2020.05.03 0. Online ahead of print</td>
<td>AS39</td>
</tr>
</tbody>
</table>
## Table 8.2
Publications March 2020 - February 2021

<table>
<thead>
<tr>
<th>MS#</th>
<th>Title</th>
<th>Authors</th>
<th>Focus</th>
<th>Reference</th>
<th>Study #</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS#</td>
<td>Title</td>
<td>Authors</td>
<td>Focus</td>
<td>Reference</td>
<td>Study #</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-------</td>
<td>----------------------------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
</tbody>
</table>

Table 8.2
Publications March 2020 - February 2021
<table>
<thead>
<tr>
<th>MS#</th>
<th>Title</th>
<th>Authors</th>
<th>Focus</th>
<th>Reference</th>
<th>Study #</th>
</tr>
</thead>
</table>
| 3449 | Association of prediagnostic frailty, change in frailty status, and mortality after cancer diagnosis in the Women's Health Initiative | Cespedes Feliciano, Hohensee, Rosko, Anderson, Paskett, Zaslavsky, Wallace, Caan | OS    | JAMA Netw Open. 2020 Sep 1;3(9):e2016747. doi: 10.1001/jamane
<p>| 3453 | Association of sedentary time and incident heart failure hospitalization in postmenopausal women | LaMonte, Larson, Manson, Bellettiere, Lewis, Be, Johnson, LaCroix, Klein, Noel, Stefanick, Wactawski-Wende, Eaton | Gen   | Circ Heart Fail. 2020 Nov 24:CIRCHEARTFAILURE12007508. doi: 10.1161/CIRCHEARTFAILURE.120.007508. Online ahead of print. | AS370, W35 |</p>
<table>
<thead>
<tr>
<th>MS#</th>
<th>Title</th>
<th>Authors</th>
<th>Focus</th>
<th>Reference</th>
<th>Study #</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS#</td>
<td>Title</td>
<td>Authors</td>
<td>Focus</td>
<td>Reference</td>
<td>Study #</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>3640</td>
<td>Associations of accelerometer-measured physical activity and physical activity-related cancer incidence in older women: results from the OPACH Study</td>
<td>Parada Jr., McDonald, Bellettiere, Evenson, LaMonte, LaCroix</td>
<td>OS</td>
<td>Br J Cancer. 2020 Mar 5. doi: 10.1038/s41416-020-0753-6. [Epub ahead of print]</td>
<td>AS286</td>
</tr>
<tr>
<td>3652</td>
<td>The severity of vasomotor symptoms and number of menopausal symptoms in postmenopausal women and select clinical health outcomes in the Women's Health Initiative Calcium and Vitamin D randomized clinical trial</td>
<td>Nudy, Jiang, Stefanick, Robbins, Schnatz, Wild, Wactawski-Wende, Shadyab, Manson, LeBlanc</td>
<td>CT</td>
<td>Menopause. 2020 Nov;27(11):1265-1273. doi: 10.1097/GME.0000000000001667.</td>
<td></td>
</tr>
<tr>
<td>MS#</td>
<td>Title</td>
<td>Authors</td>
<td>Focus</td>
<td>Reference</td>
<td>Study #</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>MS#</td>
<td>Title</td>
<td>Authors</td>
<td>Focus</td>
<td>Reference</td>
<td>Study #</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>3861</td>
<td>Short physical performance battery and incident cardiovascular events among older women</td>
<td>Bellettiere, LaMonte, Unkart, Liles, Laddu-Patel, Manson, Banack, Seguin, Chavez, Tinker, Wallace, LaCroix</td>
<td>J Am Heart Assoc. 2020 Jul 14:e016845. doi: 10.1161/JAHA.120.016845. Online ahead of print.</td>
<td>AS286</td>
<td></td>
</tr>
<tr>
<td>MS#</td>
<td>Title</td>
<td>Authors</td>
<td>Focus</td>
<td>Reference</td>
<td>Study #</td>
</tr>
<tr>
<td>-----</td>
<td>-------</td>
<td>---------</td>
<td>-------</td>
<td>-----------</td>
<td>---------</td>
</tr>
</tbody>
</table>
### Table 8.2
**Publications March 2020 - February 2021**

<table>
<thead>
<tr>
<th>MS#</th>
<th>Title</th>
<th>Authors</th>
<th>Focus</th>
<th>Reference</th>
<th>Study #</th>
</tr>
</thead>
<tbody>
<tr>
<td>4173</td>
<td>Subgingival microbiome is associated with alveolar bone loss measured 5-years later in postmenopausal women</td>
<td>LaMonte, Andrews, Hovey, Li, McSkimming, Banack, Sun, Wactawski-Wende</td>
<td>Gen</td>
<td>J Periodontol. 2020 Nov 3. doi: 10.1002/JPER.20-0445. Online ahead of print.</td>
<td>AS382</td>
</tr>
</tbody>
</table>
Table 9.1
WHI COVID-19 Survey Response Rates by Collection Mechanism

<table>
<thead>
<tr>
<th>Total Participants</th>
<th>Forms Received</th>
<th>Percent Received</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contacted</td>
<td>Received</td>
<td></td>
</tr>
<tr>
<td>Form 190 (WHI COVID-19 Survey)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paper¹</td>
<td>26888</td>
<td>19757</td>
</tr>
<tr>
<td>Paper – REDCaP non-responders</td>
<td>20424</td>
<td>16877</td>
</tr>
<tr>
<td>Phone</td>
<td>2899</td>
<td>567</td>
</tr>
<tr>
<td>REDCaP</td>
<td>34398</td>
<td>13072</td>
</tr>
<tr>
<td>Total</td>
<td>64185</td>
<td>50273</td>
</tr>
</tbody>
</table>

¹ The paper mailing included participants who did not respond to the REDCaP email or who did not have a valid email address.
### Table 9.2
Responses to First WHI COVID-19 Survey Overall and by Age at Survey Completion
Data as of: November 1, 2020

<table>
<thead>
<tr>
<th>Current level of well-being</th>
<th>Overall (N=49,695)</th>
<th>Age at WHI COVID-19 Survey</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>70-79 (N=13,317)</td>
<td>80-84 (N=16,083)</td>
<td>85-89 (N=12,160)</td>
<td>≥90 (N=8,135)</td>
<td></td>
</tr>
<tr>
<td>Excellent</td>
<td>4915 10.0</td>
<td>1804 13.6</td>
<td>1757 11.0</td>
<td>866 7.2</td>
<td>488 6.1</td>
<td></td>
</tr>
<tr>
<td>Very Good</td>
<td>19045 38.7</td>
<td>5766 43.5</td>
<td>6406 40.2</td>
<td>4335 36.1</td>
<td>2538 31.9</td>
<td></td>
</tr>
<tr>
<td>Good</td>
<td>18151 36.9</td>
<td>4279 32.3</td>
<td>5796 36.4</td>
<td>4814 40.1</td>
<td>3262 41.0</td>
<td></td>
</tr>
<tr>
<td>Fair</td>
<td>5967 12.1</td>
<td>1253 9.5</td>
<td>1716 10.8</td>
<td>1651 13.8</td>
<td>1347 16.9</td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>901 1.8</td>
<td>138 1.0</td>
<td>232 1.5</td>
<td>271 2.3</td>
<td>260 3.3</td>
<td></td>
</tr>
<tr>
<td>Very Poor</td>
<td>171 0.3</td>
<td>17 0.1</td>
<td>35 0.2</td>
<td>55 0.5</td>
<td>64 0.8</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Living arrangement changed since March 2020 due to pandemic</th>
<th>Overall (N=49,695)</th>
<th>Age at WHI COVID-19 Survey</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>70-79 (N=13,317)</td>
<td>80-84 (N=16,083)</td>
<td>85-89 (N=12,160)</td>
<td>≥90 (N=8,135)</td>
<td></td>
</tr>
<tr>
<td>Moved in with other family or friends</td>
<td>356 13.1</td>
<td>74 12.3</td>
<td>90 12.0</td>
<td>91 12.9</td>
<td>101 15.1</td>
<td></td>
</tr>
<tr>
<td>Family or friends moved in</td>
<td>495 18.2</td>
<td>162 26.9</td>
<td>141 18.9</td>
<td>113 16.1</td>
<td>79 11.8</td>
<td></td>
</tr>
<tr>
<td>Household members moved away</td>
<td>148 5.4</td>
<td>43 7.1</td>
<td>40 5.3</td>
<td>38 5.4</td>
<td>27 4.0</td>
<td></td>
</tr>
<tr>
<td>Moved out of shared housing</td>
<td>62 2.3</td>
<td>17 2.8</td>
<td>13 1.7</td>
<td>15 2.1</td>
<td>17 2.5</td>
<td></td>
</tr>
<tr>
<td>Care provider now comes to help</td>
<td>190 7.0</td>
<td>12 2.0</td>
<td>46 6.1</td>
<td>46 6.5</td>
<td>86 12.9</td>
<td></td>
</tr>
<tr>
<td>Care provider no longer comes to help</td>
<td>92 3.4</td>
<td>8 1.3</td>
<td>21 2.8</td>
<td>19 2.7</td>
<td>44 6.6</td>
<td></td>
</tr>
<tr>
<td>Moved into care facility</td>
<td>233 8.6</td>
<td>12 2.0</td>
<td>47 6.3</td>
<td>62 8.8</td>
<td>112 16.8</td>
<td></td>
</tr>
<tr>
<td>Moved out of care facility</td>
<td>61 2.2</td>
<td>13 2.2</td>
<td>16 2.1</td>
<td>8 1.1</td>
<td>24 3.6</td>
<td></td>
</tr>
<tr>
<td>Other changes to living arrangement</td>
<td>1404 51.6</td>
<td>306 50.7</td>
<td>398 53.2</td>
<td>383 54.5</td>
<td>317 47.5</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of people living in same household with you (including self)</th>
<th>Overall (N=49,695)</th>
<th>Age at WHI COVID-19 Survey</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21065 43.7</td>
<td>4797 36.6</td>
<td>6686 42.6</td>
<td>5753 49.1</td>
<td>3829 49.9</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>18858 39.1</td>
<td>6662 50.8</td>
<td>6756 43.1</td>
<td>3764 32.1</td>
<td>1676 21.8</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2806 5.8</td>
<td>732 5.6</td>
<td>824 5.3</td>
<td>700 6.0</td>
<td>550 7.2</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>911 1.9</td>
<td>238 1.8</td>
<td>293 1.9</td>
<td>241 2.1</td>
<td>139 1.8</td>
<td></td>
</tr>
<tr>
<td>5 or more</td>
<td>1207 2.5</td>
<td>283 2.2</td>
<td>317 2.0</td>
<td>278 2.4</td>
<td>329 4.3</td>
<td></td>
</tr>
<tr>
<td>Not applicable</td>
<td>3340 6.9</td>
<td>401 3.1</td>
<td>814 5.2</td>
<td>977 8.3</td>
<td>1148 15.0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ever exposed to another person diagnosed or suspected of having COVID-19</th>
<th>Overall (N=49,695)</th>
<th>Age at WHI COVID-19 Survey</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No, not that I know of</td>
<td>47137 96.2</td>
<td>12608 95.6</td>
<td>15298 96.3</td>
<td>11584 96.8</td>
<td>7647 96.3</td>
<td></td>
</tr>
<tr>
<td>Yes, someone outside of my home</td>
<td>1495 3.1</td>
<td>482 3.7</td>
<td>486 3.1</td>
<td>305 2.5</td>
<td>222 2.8</td>
<td></td>
</tr>
<tr>
<td>Yes, someone living with me</td>
<td>346 0.7</td>
<td>94 0.7</td>
<td>97 0.6</td>
<td>83 0.7</td>
<td>72 0.9</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tested for COVID-19</th>
<th>Overall (N=49,695)</th>
<th>Age at WHI COVID-19 Survey</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>39453 80.5</td>
<td>10766 81.5</td>
<td>12983 81.7</td>
<td>9660 80.8</td>
<td>6044 76.2</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>9241 18.9</td>
<td>2401 18.2</td>
<td>2841 17.9</td>
<td>2223 18.6</td>
<td>1776 22.4</td>
<td></td>
</tr>
<tr>
<td>Unsure</td>
<td>287 0.6</td>
<td>36 0.3</td>
<td>69 0.4</td>
<td>69 0.6</td>
<td>113 1.4</td>
<td></td>
</tr>
</tbody>
</table>
### Table 9.2 (continued)

Responses to First WHI COVID-19 Survey Overall and by Age at Survey Completion  
Data as of: November 1, 2020

<table>
<thead>
<tr>
<th>Overall</th>
<th>Age at WHI COVID-19 Survey</th>
<th>70-79 (N=13,317)</th>
<th>80-84 (N=16,083)</th>
<th>85-89 (N=12,160)</th>
<th>≥90 (N=8,135)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>If tested, positive result</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>8368</td>
<td>2180</td>
<td>93.2</td>
<td>2585</td>
<td>94.7</td>
</tr>
<tr>
<td>Yes</td>
<td>311</td>
<td>81</td>
<td>3.5</td>
<td>84</td>
<td>3.1</td>
</tr>
<tr>
<td>Unsure</td>
<td>223</td>
<td>78</td>
<td>3.3</td>
<td>62</td>
<td>2.3</td>
</tr>
<tr>
<td>Ever hospitalized for COVID-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>214</td>
<td>64</td>
<td>80.0</td>
<td>50</td>
<td>63.3</td>
</tr>
<tr>
<td>Yes</td>
<td>81</td>
<td>13</td>
<td>16.3</td>
<td>29</td>
<td>36.7</td>
</tr>
<tr>
<td>Unsure</td>
<td>4</td>
<td>3</td>
<td>3.8</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>If hospitalized, number of nights</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 night</td>
<td>1</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>2-3 nights</td>
<td>10</td>
<td>0</td>
<td>0.0</td>
<td>4</td>
<td>13.8</td>
</tr>
<tr>
<td>4-6 nights</td>
<td>29</td>
<td>9</td>
<td>69.1</td>
<td>8</td>
<td>27.6</td>
</tr>
<tr>
<td>7-13 nights</td>
<td>19</td>
<td>3</td>
<td>23.1</td>
<td>6</td>
<td>20.7</td>
</tr>
<tr>
<td>14 or more nights</td>
<td>20</td>
<td>1</td>
<td>7.7</td>
<td>11</td>
<td>37.9</td>
</tr>
<tr>
<td>Unsure</td>
<td>1</td>
<td>1.3</td>
<td>3.8</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>If hospitalized, received treatment in ICU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>9521</td>
<td>2479</td>
<td>19.1</td>
<td>2958</td>
<td>19.1</td>
</tr>
<tr>
<td>Yes</td>
<td>37683</td>
<td>10476</td>
<td>80.7</td>
<td>12466</td>
<td>80.5</td>
</tr>
<tr>
<td>Unsure</td>
<td>252</td>
<td>34</td>
<td>0.3</td>
<td>55</td>
<td>0.4</td>
</tr>
<tr>
<td>Health care appointment cancelled</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>10132</td>
<td>2928</td>
<td>28.6</td>
<td>3342</td>
<td>27.7</td>
</tr>
<tr>
<td>Yes</td>
<td>13735</td>
<td>4015</td>
<td>39.2</td>
<td>4695</td>
<td>38.9</td>
</tr>
<tr>
<td>Health care appointment rescheduled</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>16543</td>
<td>4849</td>
<td>47.4</td>
<td>5488</td>
<td>45.5</td>
</tr>
<tr>
<td>Yes</td>
<td>9355</td>
<td>2365</td>
<td>23.1</td>
<td>3051</td>
<td>25.3</td>
</tr>
<tr>
<td>Health care appointment converted to telephone or online</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>11723</td>
<td>3427</td>
<td>26.2</td>
<td>3732</td>
<td>23.9</td>
</tr>
<tr>
<td>Yes</td>
<td>36377</td>
<td>9798</td>
<td>74.8</td>
<td>11853</td>
<td>75.7</td>
</tr>
<tr>
<td>Some</td>
<td>10549</td>
<td>2939</td>
<td>22.4</td>
<td>3430</td>
<td>21.9</td>
</tr>
<tr>
<td>Much</td>
<td>771</td>
<td>220</td>
<td>1.7</td>
<td>228</td>
<td>1.5</td>
</tr>
<tr>
<td>Unable or very difficult</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>496</td>
<td>136</td>
<td>1.0</td>
<td>146</td>
<td>0.9</td>
</tr>
</tbody>
</table>
### Table 9.2 (continued)

**Responses to First WHI COVID-19 Survey Overall and by Age at Survey Completion**

Data as of: November 1, 2020

<table>
<thead>
<tr>
<th>Overall (N=49,695)</th>
<th>70-79 (N=13,317)</th>
<th>80-84 (N=16,083)</th>
<th>85-89 (N=12,160)</th>
<th>≥90 (N=8,135)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>How do you get prescriptions</strong></td>
<td><strong>N</strong></td>
<td><strong>%</strong></td>
<td><strong>N</strong></td>
<td><strong>%</strong></td>
</tr>
<tr>
<td>Myself at a local pharmacy</td>
<td>19090</td>
<td>50.0</td>
<td>6201</td>
<td>58.7</td>
</tr>
<tr>
<td>Medications delivered</td>
<td>13550</td>
<td>35.5</td>
<td>3583</td>
<td>33.9</td>
</tr>
<tr>
<td>Rely on others to get medications</td>
<td>3159</td>
<td>8.3</td>
<td>342</td>
<td>3.2</td>
</tr>
<tr>
<td>Facility provides medications</td>
<td>1051</td>
<td>2.8</td>
<td>43</td>
<td>0.4</td>
</tr>
<tr>
<td>Other ways of getting medications</td>
<td>1328</td>
<td>3.5</td>
<td>396</td>
<td>3.7</td>
</tr>
</tbody>
</table>

**Way of getting prescription medications changed since March 2020**

<table>
<thead>
<tr>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>3981</td>
<td>9.7</td>
</tr>
</tbody>
</table>

**Difficulties taking medications since the pandemic started**

<table>
<thead>
<tr>
<th>Delays getting prescriptions filled</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1844</td>
<td>37.6</td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>7.6</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No longer have someone to help me take medications</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>328</td>
<td>6.7</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>0.2</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Having difficulty paying for medications</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>778</td>
<td>15.9</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Having other difficulties with taking medications</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1897</td>
<td>38.7</td>
<td></td>
</tr>
<tr>
<td>572</td>
<td>11.0</td>
<td></td>
</tr>
</tbody>
</table>

**How concerned about the COVID-19 pandemic**

<table>
<thead>
<tr>
<th>Not at all concerned</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>3245</td>
<td>6.8</td>
<td></td>
</tr>
<tr>
<td>686</td>
<td>5.2</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Somewhat very concerned</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>20247</td>
<td>42.2</td>
<td></td>
</tr>
<tr>
<td>5281</td>
<td>40.4</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Very concerned</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>24533</td>
<td>51.1</td>
<td></td>
</tr>
<tr>
<td>7115</td>
<td>54.4</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk of getting COVID-19 infection</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>30849</td>
<td>62.1</td>
<td></td>
</tr>
<tr>
<td>9163</td>
<td>68.8</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Family getting COVID-19 infection</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>33448</td>
<td>67.3</td>
<td></td>
</tr>
<tr>
<td>9611</td>
<td>72.2</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Getting healthcare</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>5714</td>
<td>11.5</td>
<td></td>
</tr>
<tr>
<td>1765</td>
<td>13.3</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Getting adequate food</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1375</td>
<td>2.8</td>
<td></td>
</tr>
<tr>
<td>425</td>
<td>3.2</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Getting enough exercise</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>11587</td>
<td>23.3</td>
<td></td>
</tr>
<tr>
<td>3292</td>
<td>24.7</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Getting enough sleep</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>3813</td>
<td>7.7</td>
<td></td>
</tr>
<tr>
<td>1157</td>
<td>8.7</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adequate housing</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>299</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>0.5</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Having enough money</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2380</td>
<td>4.8</td>
<td></td>
</tr>
<tr>
<td>715</td>
<td>5.4</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Personal safety</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>8189</td>
<td>16.5</td>
<td></td>
</tr>
<tr>
<td>2489</td>
<td>18.7</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Health/safety of family/friends</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>29226</td>
<td>58.8</td>
<td></td>
</tr>
<tr>
<td>8090</td>
<td>60.7</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Financial security</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>3795</td>
<td>7.6</td>
<td></td>
</tr>
<tr>
<td>1206</td>
<td>9.1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Financial security of family</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>5168</td>
<td>10.4</td>
<td></td>
</tr>
<tr>
<td>1605</td>
<td>12.1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ability to be with family/friends</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>30533</td>
<td>61.4</td>
<td></td>
</tr>
<tr>
<td>8756</td>
<td>65.8</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nation and economy</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>34561</td>
<td>69.5</td>
<td></td>
</tr>
<tr>
<td>9743</td>
<td>73.2</td>
<td></td>
</tr>
</tbody>
</table>
### Table 9.2 (continued)

Responses to First WHI COVID-19 Survey Overall and by Age at Survey Completion

Data as of: November 1, 2020

<table>
<thead>
<tr>
<th>Overall (N=49,695)</th>
<th>Age at WHI COVID-19 Survey</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>70-79 (N=13,317)</td>
</tr>
<tr>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Since March 2020, steps taken to reduce COVID-19 risk</td>
<td></td>
</tr>
<tr>
<td>Washing hands frequently</td>
<td>45019</td>
</tr>
<tr>
<td>Not touching face</td>
<td>32157</td>
</tr>
<tr>
<td>Disinfecting surfaces frequently</td>
<td>25227</td>
</tr>
<tr>
<td>Physical distancing</td>
<td>44344</td>
</tr>
<tr>
<td>Wearing mask in public</td>
<td>46309</td>
</tr>
<tr>
<td>Wearing gloves in public</td>
<td>9517</td>
</tr>
<tr>
<td>Avoiding in-person activities</td>
<td>36786</td>
</tr>
<tr>
<td>Avoiding or limiting in-person shopping</td>
<td>34828</td>
</tr>
<tr>
<td>Avoiding shaking hands</td>
<td>40159</td>
</tr>
<tr>
<td>Staying home</td>
<td>39210</td>
</tr>
<tr>
<td>How often communicate with others outside your home</td>
<td></td>
</tr>
<tr>
<td>Every day</td>
<td>22819</td>
</tr>
<tr>
<td>Several times per week</td>
<td>16043</td>
</tr>
<tr>
<td>1-2 times per week</td>
<td>5326</td>
</tr>
<tr>
<td>Once per week</td>
<td>1945</td>
</tr>
<tr>
<td>Rarely or never</td>
<td>1607</td>
</tr>
<tr>
<td>Compared to months before outbreak, communication is</td>
<td></td>
</tr>
<tr>
<td>More often than before</td>
<td>7483</td>
</tr>
<tr>
<td>About the same as before</td>
<td>27461</td>
</tr>
<tr>
<td>Less often than before</td>
<td>12791</td>
</tr>
<tr>
<td>How staying in touch with others not living with you</td>
<td></td>
</tr>
<tr>
<td>Speaking in person</td>
<td>18911</td>
</tr>
<tr>
<td>By telephone</td>
<td>46896</td>
</tr>
<tr>
<td>By video calls</td>
<td>16013</td>
</tr>
<tr>
<td>By email</td>
<td>29706</td>
</tr>
<tr>
<td>By social media</td>
<td>15190</td>
</tr>
<tr>
<td>By postal mail</td>
<td>15700</td>
</tr>
<tr>
<td>Other method</td>
<td>3645</td>
</tr>
</tbody>
</table>
Table 9.2 (continued)
Responses to First WHI COVID-19 Survey Overall and by Age at Survey Completion
Data as of: November 1, 2020

<table>
<thead>
<tr>
<th>Overall (N=49,695)</th>
<th>Age at WHI COVID-19 Survey</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>70-79 (N=13,317)</td>
</tr>
<tr>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Over the past month, level of physical activity since COVID-19 pandemic began</td>
<td></td>
</tr>
<tr>
<td>Much less</td>
<td>12568</td>
</tr>
<tr>
<td>Somewhat less</td>
<td>14051</td>
</tr>
<tr>
<td>About the same</td>
<td>18233</td>
</tr>
<tr>
<td>Somewhat more</td>
<td>3226</td>
</tr>
<tr>
<td>Much more</td>
<td>852</td>
</tr>
</tbody>
</table>